Archives

Patient Safety: Fad Diets: Do They Deserve the Hype?

Learning Objectives

 

After completing this application-based continuing education activity, pharmacists will be able to

1. Describe the prevalence of fad diets in society
2. Outline the components of different types of fad diets
3. Explain the effect different fad diets can have on the body
4. Recognize situations in which fad diets present safety concerns for patients

    After completing this application-based continuing education activity, pharmacy technicians will be able to

    1. Describe the prevalence of fad diets in society
    2. Outline the components of different types of fad diets
    3. Explain the effect different fad diets can have on the body
    4. Recognize situations in which fad diets present safety concerns for patients

    Obese individual standing in front of words relating to food.

     

    Release Date: July 15, 2023

    Expiration Date: July 15, 2026

    Course Fee

    Pharmacists: $7

    Pharmacy Technicians: $4

    There is no grant funding for this CE activity

    ACPE UANs

    Pharmacist: 0009-0000-23-022-H05-P

    Pharmacy Technician: 0009-0000-23-022-H05-T

    Session Codes

    Pharmacist:  23YC22-XPK68

    Pharmacy Technician:  23YC22-KPX83

    Accreditation Hours

    2.0 hours of CE

    Accreditation Statements

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-022-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

     

    Disclosure of Discussions of Off-label and Investigational Drug Use

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Faculty

    Abigail R. Johnson, BS
    Senior US FDA Regulatory Affairs/Medical Writing Intern
    Arciel LLC, Stratford, CT

               

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    Ms. Johnson has no financial relationships with ineligibile companies.

     

    ABSTRACT

    In the United States, being overweight or having obesity are two leading causes of health issues, and these rates have increased in recent years. Enter the concept of fad diets. People often turn to diets or tools advertised as promoting quick weight loss without considering the diet’s sustainability and their bodies’ reaction. Fad diets’ one-size-fits-all approach is usually not the cure-all solution people hope it will be. Overall healthy nutrition and lifestyle choices are more beneficial. Due to fad diets’ popularity, it is essential to understand their components and their affect within the body to reduce health risks. This continuing education activity discusses intermittent fasting, ketogenic (“keto”) diets, pay-for-food systems, paleolithic (“paleo”) diets, and the Atkins diet. It identifies patients for whom fad dieting can be dangerous.

    CONTENT

    Content

    INTRODUCTION

    Fad diets have always existed but have been on the rise in recent years due to the explosion of social media in the 21st Century. A fad diet is a popular diet followed to achieve fast results or fix long-term problems associated with eating, specifically weight.1 Fad diets are labeled as fads for a reason. These short-lived trends with wide popularity disregard for the rationale behind or quality of the approach itself.3,4

    People who choose fad diets are often trying to fix ongoing problems including overweight or obesity, inadequate nutrition, sedentary behaviors, and failure to maintain overall healthy habits.2 Individuals who follow fad diets adhere to a mainstream concept of dieting without acknowledging individual health needs and restrictions. Health consequences may arise as a result of adhering to a diet ill-suited to an individual's nutritional needs and ability to sustain the associated effort. In addition, certain diets may influence medication interactions and disease outcomes. For this reason, fad diets can undermine patient safety.

     

    This continuing education activity summarizes popular fad diets to inform pharmacy teams of their benefits and risks. It will allow teams to make recommendations for patients, understand how medications interact with the diets, and help prevent health complications.

     

    The History of Fad Diets

    Fad diets have existed throughout history in different forms. For example, in the 1920s, the Cigarette Diet was popular. Lucky Strike, a cigarette company, promoted the cigarette diet. They claimed that cigarettes would suppress appetite to boost sales using the tagline “Reach for a Lucky instead of a sweet.” Promoters advertised that people would lose weight successfully while following the diet.6 The 1940s saw the rise of the Master Cleanse. This juice cleanse consisted of a meal replacement drink consisting of hot water, lemon juice, maple syrup, and cayenne pepper. Its popularity stemmed from promises of cleansing the body of toxins while providing very few calories. It reached new levels of popularity in 2006, when superstar Beyoncé claimed to lose 20 pounds in two weeks using this method 6 In the 1960s, The Drinking Man’s Diet made an appearance. The recommendation was to consume high-protein and low-carbohydrate foods while drinking as much alcohol as desired. An example meal may have included a large serving of steak, salad or vegetables, and several alcoholic beverages. The Drinking Man’s Diet’s supporters considered alcohol a good carbohydrate and allowed indulgence. This diet was marketed toward the male population.6

     

    People have always been interested in quick fixes for weight loss and appearance without considering how they will feel or how to keep the weight off indefinitely.1 This approach to choosing a diet or making nutrition decisions ignores tactics that sustain weight loss. Fad diets are inherently unsustainable options that often lead to weight regain. These outcomes prove many fad diets are unreliable (if not dangerous).

     

    With the creation and explosion of modern social media in the early 2000s, fad diets surged in popularity. Social media often fosters a community of misinformation regarding fad diet composition, how to follow the specific diet, and the diet’s benefits.5 Much of the information on social media regarding fad diets lacks reputable, verifiable sources. Fad diet promoters use scientific jargon loosely and inappropriately to make information convincing when describing seemingly miraculous diets. However, the information could just be the opinion of an individual or a promotional company sponsorship.5 Unless diet information is published by a credible source, it should be regarded as untrustworthy.

     

    Pause and Ponder: How many times a week do you see diet-related content on social media?

     

    Fad Diet Prevalence

    Approximately 45 million Americans (about 14% of the total population) go on a diet each year.7 Of these diets, 50% are fad diets.7 According to the United States (U.S.) Weight Loss & Diet Control Market, the weight loss industry is one of the most advertised with investors spending $66 billion annually.7 More people than ever are overweight or obese and using diets as a solution. Table 1 summarizes obesity’s prevalence, which is rising each year in the U.S.

     

    Table 1. Obesity Prevalence in the U.S. Population8

    Age (years) % of Population
    Adults aged 20 and up 41.9%
    Adolescents aged 12-19 22.9%
    Children aged 6-11 20.7%
    Children aged 2-5 12.7%

     

    According to the Centers for Disease Control and Prevention (CDC), individuals who are overweight or have obesity are at elevated risk for many health issues. These include elevated cholesterol, stroke, heart disease, hypertension, cancer, type 2 diabetes, mental illness, low quality of life, and mortality, among others.9 While many factors can influence weight, individuals can adapt their diets to meet nutritional needs and make long-term differences to improve health outcomes.

     

    TYPES OF FAD DIETS

    As the definition implies, fad diets’ popularity increases and decreases with current trends. This section discusses some of the most popular current fad diets.

     

    Intermittent Fasting

    Individuals following an intermittent fasting diet alternate eating and fasting (not eating or drinking anything) on a cyclic schedule. This diet focuses more on eating during specific periods of time than restricting meal components. Various intermittent fasting schedules exist, but popular versions include alternate-day and time-restricted fasting.10,11 Alternate-day fasting means fasting every other day, while time-restricted fasting involves eating within set time windows during the day. Individuals should consult a doctor and choose the type of intermittent fasting that best fits their health needs (but most do not). Studies show following intermittent fasting schedules leads to decreased body weight, body mass index (BMI), and waist circumference.11 Studies also show improved blood glucose and triglyceride levels following this diet.10

     

    The body uses ingested calories—specifically carbohydrates, sugars, and nutrients—as fuel.10 If people eat continuously throughout the day, the body uses ingested calories as fuel to perform necessary bodily functions. The body stores unused ingested calories in the form of fat where they become an energy reserve.10,12

     

    When the period between meals lengthens and the body lacks a constant supply of calories for fuel, it turns to the fat reserve to burn fat stored in the body. The theory is that the longer a person goes without eating, the more the body will use its fuel reserve. The more reserve is used, the more fat is burned.10 As more of the reserve is used for energy while intermittent fasting, more weight is lost through fat burn.

     

    Intermittent fasting regulates eating times without restricting foods or food groups. Dieters must make conscious choices to include foods beneficial to health. This includes fruits, vegetables, plant proteins or lean meats, whole grains, superfoods (see Sidebar: Superfoods), and low-fat dairy options.12 Healthy choices also include limiting processed foods and sugars.

     

    Sidebar: Superfoods13

    Superfoods are nutrient-rich and high in important dietary components including antioxidants, vitamins, minerals, fiber, and healthy fats. These help keep the body functioning, reduce disease risk, and improve well-being. Some examples of superfoods are

    • Avocados → These include potassium and healthy fats to lower the risk of heart disease.
    • Chia seeds → These include fiber, protein, antioxidants, vitamins, and minerals. They are also easy to add to recipes.
    • Dark and leafy greens → All greens are good greens, but these are especially nutrient dense, including vitamins A, C, and E. They also contain vitamin K, which promotes bone health.
    • Ginger → This includes vitamin C, magnesium, and potassium. It also helps reduce pain and aid nausea.
    • Salmon → Fish is high in omega-3 fatty acids, which can help reduce heart disease.
    • Yogurt → This includes calcium and protein to help with bone health, cancer prevention, and immune health. It is also a good source of probiotics to support gut health.

     

    Pause and Ponder: Do patients ask about superfoods when discussing dietary information or supplements? Do you know which to recommend?

     

    Pros and Cons

    Like most diets, intermittent fasting has benefits and drawbacks. Following intermittent fasting correctly boosts memory, improves blood pressure, induces fat loss while maintaining muscle mass, helps prevent obesity, improves type 2 diabetes by reducing insulin resistance, and improves tissue health.12,14 Intermittent fasting also regulates the body’s 24-hour cycle to improve physiological functioning and metabolic health. As a result, gastrointestinal (GI) microbiomes, energy levels, and sleep may improve.15

     

    Drawbacks of this diet include issues with long-term maintenance/adherence, leading to regaining weight.10 It is difficult and tiring for individuals to maintain fasting for extended periods. In addition, until the body is accustomed to fasting periods, symptoms such as headaches, nausea, or dizziness may occur. Some individuals may feel an initial decrease in energy levels when starting this diet.10

     

    Keto Diet

    The keto diet, also known as the ketogenic diet, is centered around depriving the body of carbohydrates.16 Researchers originally developed the ketogenic or keto diet in the 1920s as an epilepsy treatment, especially for resistant pediatric cases.17 The rise of effective antiepileptic drugs and treatments decreased use of the ketogenic diet for this purpose. As originally designed, total daily calories were composed of high fat intake (70% to 80%), moderate amounts of protein (10% to 20%), and low carbohydrate intake (5% to 10%).16 An iteration of this diet has gained more traction since the 1990s, as people realized its effectiveness for quick weight loss.16

     

    The keto diet helps with weight loss through the processes of gluconeogenesis and ketogenesis. Under normal circumstances, carbohydrates produce energy for the body.16 When insufficient carbohydrates are available, insulin secretion is reduced and glucose is less available. The body then exploits gluconeogenesis, using lactic acid, glycerol, and amino acids to produce glucose as an energy source.16

     

    If carbohydrate levels drop further, the body enters ketogenesis and secretes ketone bodies as an alternative energy source.16 As insulin secretion levels remain low and ketone bodies are used for energy, fat and glucose storage falls significantly. This can cause other fats to break down, leading to bodily fat loss.16

     

    To remain in ketogenesis, the body needs constant carbohydrate deprivation.16 The longer it is deprived of carbohydrates, the more fat is burned in the ketotic state. This is known as nutritional ketosis and is considered safe, as opposed to the metabolic state of ketoacidosis (an accumulation of ketones that increases the blood’s acidity), which can be life-threatening.16

     

    During ketoacidosis, ketone bodies are produced in large amounts and can acidify the blood pH.16 Acidic blood pH reduces the amount of oxygen blood delivers to cells leading to cell death and life-threatening complications. Insulin keeps the production of ketone bodies at bay, so sometimes people with type 1 diabetes develop ketoacidosis due to decreased insulin production. Taking diabetes-related medication correctly reduces the risk of ketoacidosis in people with diabetes. Following a low carbohydrate diet for a prolonged amount of time can also lead to ketoacidosis.17 To reiterate, ketogenesis is the production of ketone bodies in response to carbohydrate and glucose depletion. Low concentrations of ketone bodies are generally regarded as a safe, as opposed to high concentrations caused by ketoacidosis (which is a medical emergency).16

     

    What to Eat and Avoid

    Given the strong emphasis on high-fat foods, healthy fats comprise the largest part of this diet.16 Foods such as seeds and nuts, coconut, avocados, poultry fat, and plant fats (e.g., olive or coconut oils) are encouraged. In addition, some dairy products—including butter, hard cheese, and yogurt—are allowed, but people on a ketogenic diet should avoid cream, ice cream, and full-fat milk given their natural sugar content.17 Individuals following this diet should consume a moderate amount of protein, ideally meats high in omega-3 fats.16 This includes grass-fed beef, free-range poultry, wild-caught fish, and pork. Nuts, seeds, tofu, and eggs are also acceptable protein sources.17

     

    Adhering to a diet with less than 10% of calories from carbohydrates can be challenging, especially since this diet requires individuals to calculate “net carbs” (See Sidebar: What are “Net Carbs”?).16 Vegetables lacking high starch contents (e.g., cauliflower, broccoli, onions, leafy greens, bell peppers, garlic, mushrooms, cucumber, summer squash) are encouraged. Small portions of fruit are also allowed, and fruits with a lower net carb content (e.g., berries) are preferred. Other acceptable carbohydrates include dark chocolate, herbs, spices, unsweetened tea, coffee, vinegars, and mustards.17

     

     

    Sidebar: What are “Net Carbs”? 17

    The body cannot digest or metabolize some carbohydrates because of their molecular structures. For example, fruits, vegetables, whole grains, and sugar alcohols contain insoluble fibers that are indigestible. Insoluble carbs have no energy value or blood sugar impact, so they are allowed when following the keto diet. The keto diet requires dieters to calculate “net carbs,” the amount of carbohydrates taken in by the body that are digested and metabolized and thus contribute to calories. However, it is important to note that the total calorie level does not change even when “net carbs” are calculated.

     

    Individuals calculate net carbs by subtracting the number of ingestible carbohydrates from the food’s total amount of carbohydrates. For example, food containing 24 total carbohydrates and 21 ingestible carbohydrates equals 3 net carbs. Ingestible carbohydrates can typically be found by subtracting the amount of fiber from the amount of carbohydrates in the food item, but it can be more complicated. A number on online net carb calculators are available to help.

     

    Net carbs are also known as “impact carbs.” Food manufacturers use both terms as marketing strategies, but governing bodies do not regulate use of these phrases.

     

    Foods containing added sugar, whole or refined grains, and flour products are restricted.17 Starchy foods are also not allowed, including some high-starch vegetables such as corn, potatoes, and winter squash. Fruits with a high net carb content and fruit juices are restricted. Most keto programs also advise against alcoholic beverages due to their carbohydrate content and added sweeteners.17

     

    Pros and Cons

    The keto diet may be beneficial for weight loss, as it uses ketone bodies for energy to deplete glucose and fat storage abilities. Decreasing sugar intake lowers the risk of developing diabetes, obesity, and metabolic syndrome.16 Following this diet may reduce cholesterol, blood sugar, and blood pressure, and decrease insulin resistance.17

     

    Diet restrictions may cause short-term adverse effects such as nausea and vomiting, fatigue, headaches, dizziness, and insomnia.16 This is known as the “keto flu.” Symptoms usually resolve once the body adjusts to the diet after a few weeks. Fluids and electrolyte replenishment can help alleviate discomfort during this period.16

     

    Documented long-term adverse effects include increased uric acid levels in the blood, increased risk of kidney stones, and osteoporosis.17 This is due to the diet’s restrictive nature and omission of necessary components to sustain a healthy diet. Nutrient deficiencies can occur as a result of following this diet.17

     

    People struggle to adhere to the ketogenic diet due to strict regulation of fat, protein, and carbohydrates.17 Dieters must carefully monitor their adherence to intake limits and meet target levels. This can be difficult for individuals to maintain long-term and lead to low adherence to the diet.17

     

    Pay-for-Food Systems

    Pay-for-food diets are meal prep services or meal delivery services with pre-portioned ingredients, pre-cooked meals, or meal replacement options. Diets focus on weight loss and are designed for convenience. These options take the guesswork out of planning meals and make it easier to track eating.

     

    Nutrisystem

    The Nutrisystem meal service claims its diets help with weight loss through a high-protein and low glycemic approach.18 Nutrisystem expects users to lose one to two pounds a week by managing blood sugar and controlling hunger to avoid overindulgence. Dietitians design meals to include healthy options and relieve the stress of planning.18

     

    Meals are pre-portioned to fit an individual’s needs and tastes.18 The meals’ composition of lean protein, healthy fat, and smart carbohydrate ingredients is supposed to curb hunger. Protein shakes and bars are options to supplement plans. Nutrisystem claims deprivation is too restrictive and allows for some deviation from the plan or healthy alternatives to “bad foods.” In addition, dieters can track their progress and calories using Nutrisystem’s app. This system promotes prizes and special offers to keep individuals motivated.18

     

    Prices vary by plan type but can range from $9.99 to $15.18 a day. Nutrisystem has plans designed specifically for men, women, partners, and people with diabetes.18

     

    SlimFast

    When SlimFast originated, the system promoted meal replacement shakes to lose weight.19 The company has since expanded to include drink mixes, snacks, and meal replacement bars. The products are grouped into categories such as calorie control, high protein, keto, and intermittent fasting. The website also contains a recipe section for dieters to use in their meal planning.19

     

    SlimFast plans are based on individuals’ goals and preferences, including the Favorite Foods Plan, Keto Plan, High Protein/Low Carb Plan, Original Plan, and Intermittent Fasting.19 Dieters purchase SlimFast products to supplement or replace parts of their current diet. Plans themselves are not priced because individuals buy their own groceries and supplement with SlimFast products associated with the plan of their choice. The company also has an app to use for weight management tracking and a private Facebook group to communicate with other individuals on the diet to offer support or guidance.19 SlimFast claims their plans and products promote and maintain weight loss and encourage people to make better food choices.19

     

    Jenny Craig

    The Jenny Craig company has recently gone out of business after 40 years in the industry. Some experts indicates that one reason has been the availability of weight loss medications and increased competition in this market space. This system emphasized one-on-one coaching mixed with healthy foods to lose weight quickly.20 The company claimed dieters could lose up to 18 pounds in the first four weeks. Coaches designed meal plans to be unrestrictive and included an individual’s favorite foods. Meals focused on low-fat foods with high fiber and protein. This program also emphasized physical activity and occasional intermittent fasting to aid the weight loss process.20

     

    Plans consisted of meals from the program, two snacks, and supplemental grocery items daily to promote weight loss and increase metabolism.20 One snack included Jenny Craig’s Recharge Bar, used when intermittent fasting. The program claimed the Recharge Bar helped dieters lose weight faster, feel less hungry, and maintain fasting. Jenny Craig coaches designed plans and provided guidance for the duration of the program.20

     

    Food was delivered weekly or biweekly. Depending on the type of plan, individuals paid $13.99 to $21.99 per day. Prices were based on the number of meals, membership length, and amount of coaching support included. Promotional offers and meal bundles were available.20

     

    Pros and Cons

    Pay-for-food diets can be intriguing as they promote healthy choices, weight loss, and convenience.18-20  They reduce mental load and stress surrounding dieting by making the choices easier or eliminating the need to choose altogether. Some services also provide support groups or coaches for accountability and guidance. In addition, if dieters can adhere to these plans, meal kits promote portion control and reduce overeating.18-20

     

    A major con associated with these diets and meal kits is adherence. As people lose weight on these diets, they may stop using them, gain weight back, and become discouraged about trying again. This can reverse improved health outcomes.18-20 Another con is cost. Individuals may be discouraged by the prices associated with pay-for-food systems. The cost may not be viable or sustainable options for all individuals.18-20  

     

    Studies have shown these diets to be ineffective. Attrition rates (percentages of people leaving a program) are 30% or greater, and 37% of dieters who complete programs lose less than 5% of their initial body weight.21 Other studies failed to produce significant results for how these pay-for-food diets affect weight loss when compared to educating or counseling individuals on weight.22 High attrition rates and insignificant weight loss results suggest these diets are unsustainable and unreliable.21

     

    Paleo Diet

    The paleo diet goes by many names, including the Paleolithic, caveman, or Stone-Age diet. It consists of (allegedly) eating like humans of the Paleolithic era did, mixed with modern components to supplement the diet. The Paleolithic era occurred from roughly 2.5 million years ago to 1,200 B.C. Diet supporters believe current body function is similar to how it functioned during this era and eating foods available or comparable to this time will improve health.23 Introduced in 2002 by Dr. Loren Cordain, a scientist specializing in nutrition, this diet has surged in popularity in recent years due to weight loss claims.24

     

    Due to disagreements about which foods were available in the Paleolithic era compared with today, many diet plans are dubbed “paleo.” They differ in specific foods allowed. All plans emphasize high protein, healthy fats, low or moderate carbohydrates, low sugar and sodium, and high fiber to meet weight loss goals.23 The term “paleo” will be used to describe this model. The paleo diet consists of consuming mostly lean meats, fruits, vegetables, nuts, seeds, and fish, in line with what researchers believe was consumed during the Paleolithic age.23 It also emphasizes reducing intake of dairy, grains, and carbohydrates.25

     

    Weight loss can occur through several pathways using the paleo diet. 23 Like the keto diet, ingesting fewer carbohydrates forces the body to use fat for fuel. In addition, replacing highly processed foods, added sugars, and large amounts of carbohydrates with healthier options can aid weight loss. Eating more protein and less calorically dense food (i.e., few calories in a large volume of food) also helps curb hunger and leave individuals more satisfied.23

     

    Less calorically dense foods—including vegetables, fruits, low-fat or fat-free dairy, and egg whites—can be eaten in larger quantities. These foods help with weight loss as they allow individuals to eat a larger volume and feel full, without ingesting large numbers of calories.26 This reduces snacking and overall food intake.23

     

    Conversely, calorically dense foods are high in calories and eaten in small amounts. These contribute weight gain as individuals who eat a small volume consume high numbers of calories.27 Examples of calorically dense foods include27

    • Proteins: fish, beans, eggs, cheese, yogurt, fats including nuts, avocados, nut butters
    • Carbohydrates: potatoes, brown rice, whole grains

     

    Overall, the paleo diet works by breaking down the diet into basic components and making healthier choices. Cutting out foods leading to high glucose or carbohydrate storage also aids in eating healthier and inducing weight loss.28

     

    What to Eat and Avoid

    Allowed foods emphasize fresh and healthy choices to remain consistent with foods found in the Paleolithic age.23 This includes lean meats, fish or shellfish, fruit, vegetables, honey, nuts or seeds, and olive or coconut oils. Frozen fruits and vegetables are allowed as they contain the same nutrients as the fresh variety and may be more convenient. Omega-3 fats are important for the body and can be found in fish, grass-fed beef, avocado, olive oil, some nuts (e.g., walnuts, almonds, pistachios), and seeds. Root vegetables such as cassava and sweet potatoes are highly nutritious and are allowed in moderation.23

     

    Restricted foods have little nutritional value or a high glycemic index unsuitable for the paleo diet.23 For example, white potatoes and processed foods are off limits. Other restricted foods include whole or refined grains, cereals, refined sugar, refined vegetable oil, legumes, dairy products, alcohol, coffee, and salt. Canola is a refined vegetable oil and is not allowed. Restricted legumes include peanuts, beans, and lentils.23

     

    This diet emphasizes eating healthy and portioning fats, proteins, and carbohydrates to enhance health.23 Calorie counting and general portion control are deemphasized in this diet. Some plans also allow for “cheat meals” (those consisting of food not beneficial to health) in the early stages of the diet to increase adherence.23

     

    Pros and Cons

    Components of this diet including fiber, potassium, and antioxidants aid bodily functions and reduce disease risk. Reducing the intake of highly processed foods with little nutritional value also helps improve overall health.25 Short-term benefits may include weight loss, improved blood pressure and cholesterol levels, and increased insulin sensitivity.23 One study documented improvements in metabolic levels, specifically glucose control and lipids, in people with diabetes.28

     

    Unfortunately, restricting or excluding foods altogether for long periods of time can lead to nutritional deficiencies and health complications. For example, limiting dairy intake leads to deficiencies of calcium, vitamin D, and B vitamins.23 These deficiencies can increase risk of osteoporosis and bone injuries.24 Dairy-related nutrient deficiencies are not specific to the paleo diet, but can occur due to its food restrictions. Restricting grains in the diet also deprives the body of nutrients, which increases risks of diabetes and heart disease. In addition, increased meat consumption (especially red meat) contributes to saturated fat intake and increases risks of cardiovascular problems and diabetes.23 It may also be difficult for people to adhere to a diet that restricts certain categories of foods.

     

    Atkins Diet

    The Atkins diet promotes low carbohydrate intake while allowing as much protein and fat as desired. Robert C. Atkins, a heart specialist, developed this diet in the 1960s as a method for weight loss and maintenance.30 Although it is a low-carb diet, the Atkins program acknowledges that eating right is always better than eating less.31 This diet is ever evolving to be current with updated nutritional expertise.30

     

    Like the keto diet, Atkins emphasizes low carbohydrate intake of less than 20 g per day to start.30 Unlike the keto diet, consumption of fat and protein is less restricted. Carbohydrates are claimed as the problem without regulating the intake of other food groups. Diet supporters believe the sugars found in carbohydrates cause health issues such as blood sugar imbalances and weight gain.30

     

    Hypothetically, eating fewer carbohydrates lowers dietary sugar leading to greater satiety, increased energy, less stored fat, and higher metabolism.31 When the body lacks glucose and carbohydrates to use as energy, it turns to fat to keep the body functioning through ketogenesis. The more fat a person burns, the more weight they lose.

     

    Fat and protein comprise the remainder of the diet. As carbohydrates are viewed as the source of health issues, intake levels of fat and protein are less restricted. Calorie counting and portion control are unnecessary, besides keeping track of carbohydrate intake to stay below the allowable limit.30

     

    The Atkins diet is split into phases with specific allowable limits of carbohydrates (see Table 2). The diet’s phases adjust to reflect changes in body function and weight. As carbohydrate levels fluctuate in each phase, protein and fat levels change to achieve satiety.

     

     

    Table 2. Atkins Diet Phases31

    Phase Instructions
    Phase 1:

    Induction

    3 regular sized meals or 4-5 small meals, vitamins/supplements, 8 oz. glasses of water, 20 g net carbs per day
    Phase 2:

    Ongoing weight loss

    Can add net carbs in 5 g increments weekly, vitamins/supplements, 8 oz. glasses of water, no more than 40 g a day after adding extra carbs, introduce Atkins food products
    Phase 3:

    Pre-Maintenance

    Maintaining previous stages, can add net carbs in 10 g increments weekly to find the perfect balance until the goal weight is reached, maintain carb intake of goal weight
    Phase 4:

    Maintenance

    Maintaining Phase 3 carb level, reducing fat intake as carb intake increases, managing cravings and weight

     

     

    While phases differ in carbohydrate intake levels, they include similar food groups overall.30 Allowed foods include vegetables, oils, fats, and protein (e.g., eggs, cheese, fish, meat and poultry). Dieters can introduce berries, nuts, seeds, starchy vegetables, and whole grains in the third phase, provided they are still losing weight. Dieters can also eat Atkins’ commercial selection of products during and after phase two. Most fruits, alcohol, baked goods high in sugar, bread, pasta, and nuts are restricted in phase one. Some fruits and grains are added by phase three.30

     

    Pros and Cons

    Benefits of the Atkins diet include weight loss; decreased blood pressure; and lower incidence of heart disease, metabolic syndrome, and diabetes.30 This diet can also improve blood sugar and cholesterol levels. These benefits are attributed to low carbohydrate intake and subsequent weight loss.30

     

    Reducing carbohydrate intake may initially cause symptoms such as headache, weakness, fatigue, and dizziness.30 Unrestricted fat intake can be unhealthy. In addition, using fat as the body’s energy source for too long may lead to ketoacidosis if dieters misuse the plan.29 Nutrient deficiency can also occur on this diet as a result of restrictions.30

     

    Weight loss pursuant to this diet is difficult to maintain due to its deficiencies and restrictive nature. Following the carbohydrate limit for long periods of time is difficult and unsustainable for some people.30 Cardiologists warn this diet puts oxidative stress (disproportionate levels of oxygen reactive species overwhelming the ability of body systems to detoxify them) on organs and can cause serious heart problems or fatal complications.29 Some long-term studies have shown the Atkins diet is no more effective than other fad diets. In addition, these studies show that most people who lost weight while following the Atkins diet regained it.30

     

    IMPLICATIONS FOR PHARMACY TEAM

    Fad dieting can compromise patient safety, and certain patients are at elevated risk for problems. Pharmacy teams are responsible for advising patients about drug-diet interactions and concerns. Table 3 describes conditions and their associated medications that impact the use of fad diets.

     

    Table 3. Implications for Pharmacy Teams10,16,23,30,32-40

    Diet Patient Conditions and Associated Medications That Can Be Contraindications with Diets
    Intermittent Fasting ·       Age younger than 18 years

    ·       Pregnancy or breastfeeding

    ·       Type 1 diabetes

    o   Insulin, blood pressure medication, cholesterol-lowering medication

    ·       History of eating disorder

    Keto ·       Diabetes

    o   Insulin, blood pressure medication, cholesterol-lowering medication

    ·       Hypoglycemia

    o   Glucagon or other forms of glucose

    ·       Pancreatitis

    o   Pain medication

    ·       Liver failure

    ·       Fat metabolism disorders

    o   Cholesterol-lowering medication

    ·       Primary carnitine deficiency

    o   L-carnitine supplements

    ·       Carnitine palmitoyltransferase deficiency

    ·       Carnitine translocase deficiency

    ·       Porphyrias

    o   Hemin

    ·       Pyruvate kinase deficiency

    o   Mitapivat (Pyrukynd), folic acid supplements, iron chelators

    Pay-For-Food Systems ·       Contraindications and associated medication will depend if it is an individually designed plan or the service’s version of intermittent fasting, keto, etc.
    Paleo ·       Cardiovascular related issues

    o   Anticoagulants, ACE inhibitors, cholesterol-lowering medications, diuretics, etc.

    ·       Diabetes

    o   Insulin, blood pressure medication, cholesterol-lowering medication

    ·       Nutrient deficiency disorders

    Atkins ·       Diabetes

    o   Insulin, blood pressure medication, cholesterol-lowering medication

    ·       Taking diuretics

    o   Thiazide, loop, potassium-sparing diuretics or a mix of types

    ·       Severe kidney disease

    o   Blood pressure medication, anemia medication, cholesterol-lowering medication, supplements

    ·       Pregnancy or breastfeeding

     

    Nutritional Myths

    As mentioned, misinformation surrounding diets has always existed, and social media has magnified the problem. Some myths are more harmful than others, but knowing the facts is essential to correctly informing others.32 Examples of nutritional myths that pharmacy teams can debunk for their patients are found in Figure 1.

     

     

    Dieting is not a one-size-fits-all solution. When pharmacy teams advise patients, they must work with patients to consider health factors . Factors to consider include a patient’s medications, lifestyle choices, and known health issues.33 Pharmacy teams should advise individuals that fad diets are not necessary and following a generally healthy diet is usually sufficient to lose weight. They should make healthy swaps and find strategies that work best for them as individuals. For example, they can cut back on processed foods, consume more fruits and vegetables, and be conscious of fat or carbohydrate intake to ensure healthy sources. These choices are effective ways to achieve the long-term goals without employing fad diets that promote quick fixes.33

     

    CONCLUSION

    Fad diets are undeserving of the positive hype they receive. They are short-term solutions that sometimes work for people looking to lose weight or make changes quickly. However, benefits are outweighed by their unsustainability and poor post-diet maintenance planning. Fad dieting also starts a cycle of yoyo dieting (see Sidebar: Yoyo Dieting). The best option for health is to find strategies that work individually and stick with them. Ditch the fad diets and make long-term healthy choices for better, lasting results.33

     

    Sidebar: Yoyo Dieting

    Yoyo dieting, or weight cycling, occurs when people achieve their goal weight through dieting, stop dieting and return to unhealthy habits, gain the weight back, diet again for a period, gain the weight back, and repeat the cycle. Yoyo dieting is not only a conscious choice. Physiological mechanisms related to energy intake and expenditure, genetics affecting weight control processes, and the interaction between genes and the environment also affect the cycle.34

     

    Yoyo dieting lacks substantial or sustainable changes to lifestyle or nutrition to keep weight off and instead focuses on quick fixes.34 These quick fixes ultimately fail when weight is regained, and the cycle continues. Most weight lost is gained back within the first two to three years after dieting ceases. However, if dieters keep weight off for two years, the likelihood of gaining it back decreases.35

     

    Pause and Ponder: Do you think fad diets are helpful or harmful?

    Resources for Pharmacists and Pharmacy Technicians

     

    Pharmacist Post Test (for viewing only)

    Fad Diets: Do They Deserve the Hype?

    Pharmacist Post-test

    After completing this continuing education activity, pharmacists will be able to

    ● Describe the prevalence of fad diets in society
    ● Outline the components of different types of fad diets
    ● Explain the effect different fad diets can have on the body
    ● Recognize the value of the pharmacist/pharmacist technician’s role in understanding this information

    1. Of the 45 million Americans who go on a diet each year, what percentage are fad diets?
    A. 66%
    B. 50%
    C. 14%

    2. What makes fad diets appealing to millions of dieters?
    A. They are a good way to stop the cycle of yoyo dieting
    B. They are considered safe for individuals with health complications
    C. They promote quick weight loss results

    3. Which of the following fad diets mainly focus on low carbohydrate intake?
    A. Keto and Atkins
    B. Keto and intermittent fasting
    C. SlimFast and Atkins

    4. Which types of fad diets claim to improve blood pressure?
    A. Intermittent fasting, pay-for-food diets, and Atkins
    B. Intermittent fasting, keto, paleo, and Atkins
    C. Paleo and Atkins

    5. What causes ketoacidosis?
    A. Prolonged extreme carbohydrate restriction***
    B. Prolonged extremely high carbohydrate intake
    C. Low-level ketone body production

    6. Why should individuals taking cardiovascular-related medications such as ACE inhibitors or cholesterol-lowering drugs avoid the Paleo diet?
    A. Nutrient deficiencies caused by the composition of the diet lead to increased risk of cardiovascular issues.
    B. Reduced grain intake and high meat or fat consumption leads to increased risk of cardiovascular issues.
    C. These medications cause sensitivity to foods included in the Paleo diet.

    7. A patient with type 1 diabetes mentions that she plans to start following the keto diet because she knows that carbohydrates spike her blood sugar. Which of the following is the BEST response?
    A. It is the best way for people with diabetes to lose weight quickly and keep it off long-term
    B. It will be difficult for you to follow long-term, so the Atkins diet is more appropriate
    C. It is not a safe option for you because you are at increased risk of ketoacidosis

    8. Why is it important for pharmacy teams to understand contraindications and health implications of fad diets?
    A. To identify signs of diabetes based on how the body reacts to certain fad diets
    B. To advise patients about drug-diet interactions and how fad diets can impact their health
    C. To direct patients to an appropriate fad diet based on their current medications

    9. What general nutrition information should people follow instead of fad diets?
    A. Cut all dairy, gluten, and fat from the diet and eat only protein and carbohydrates
    B. Decrease fats and carbohydrates in the diet and increase red meat intake
    C. Limit processed foods and make overall healthy choices like eating more superfoods

    10. A patient comes to the pharmacy to pick up medication and you advise him to avoid diets involving fasting and calorie restrictions. His condition and associated medication indicate fasting and restricting calories would be harmful to his health. Which fad diets does this warning pertain to?
    A. Intermittent Fasting, Keto, Atkins
    B. Keto, Paleo, Atkins,
    C. Intermittent Fasting, Paleo, Atkins

    Pharmacy Technician Post Test (for viewing only)

    Fad Diets: Do They Deserve the Hype?

    Pharmacy Technician Post-test

    After completing this continuing education activity, pharmacy technicians will be able to

    ● Describe the prevalence of fad diets in society
    ● Outline the components of different types of fad diets
    ● Explain the effect different fad diets can have on the body
    ● Recognize the value of the pharmacist/pharmacist technician’s role in understanding this information

    1. Of the 45 million Americans who go on a diet each year, what percentage are fad diets?
    A. 66%
    B. 50%
    C. 14%

    2. What makes fad diets appealing to millions of dieters?
    A. They are a good way to stop the cycle of yoyo dieting
    B. They are considered safe for individuals with health complications
    C. They promote quick weight loss results

    3. Which of the following fad diets mainly focus on low carbohydrate intake?
    A. Keto and Atkins
    B. Keto and intermittent fasting
    C. SlimFast and Atkins

    4. Which types of fad diets claim to improve blood pressure?
    A. Intermittent fasting, pay-for-food diets, and Atkins
    B. Intermittent fasting, keto, paleo, and Atkins
    C. Paleo and Atkins

    5. What causes ketoacidosis?
    A. Prolonged extreme carbohydrate restriction
    B. Prolonged extremely high carbohydrate intake
    C. Low-level ketone body production

    6. Why should individuals taking cardiovascular-related medications such as ACE inhibitors or cholesterol-lowering drugs not follow the Paleo diet?
    A. Nutrient deficiencies caused by the composition of the diet lead to increased risk of cardiovascular issues.
    B. Reduced grain intake and high meat or fat consumption leads to increased risk of cardiovascular issues.
    C. These medications cause sensitivity to foods included in the Paleo diet.

    7. A patient with type 1 diabetes mentions that she plans to start following the keto diet because she knows that carbohydrates spike her blood sugar. Which of the following is the BEST response?
    A. It is the best way for people with diabetes to lose weight quickly and keep it off long-term
    B. It will be difficult for you to follow long-term, so the Atkins diet is more appropriate
    C. It is not a safe option for you because you are at increased risk of ketoacidosis

    8. Why is it important for pharmacy teams to understand contraindications and health implications of fad diets?
    A. To identify signs of diabetes based on how the body reacts to certain fad diets
    B. To advise patients about drug-diet interactions and how fad diets can impact their health
    C. To direct patients to an appropriate fad diet based on their current medications

    9. What general nutrition information should people follow instead of fad diets?
    A. Cut all dairy, gluten, and fat from the diet and eat only protein and carbohydrates
    B. Decrease fats and carbohydrates in the diet and increase red meat intake
    C. Limit processed foods and make overall healthy choices like eating more superfoods

    10. You are checking out a customer at the pharmacy counter and notice she is picking up some over-the-counter items along with her prescriptions. Which of the following groups of items would prompt you to refer an individual to the pharmacist?
    A. Metformin (for diabetes), Atkins snack bars, and Dramamine (for dizziness)
    B. Sertraline (for depression), SlimFast shakes, and a bottle of water
    C. Lisinopril (for blood pressure), a gallon of ice cream, and a bottle of soda

    References

    Full List of References

    References

       
      REFERENCES
      1. Wdowik M. The long, strange history of dieting fads. Colorado State University. November 13, 2017. Accessed January 14, 2023. https://source.colostate.edu/the-long-strange-history-of-dieting-fads/
      2. Tahreem A, Rakha A, Rabail R, et al. Fad Diets: Facts and Fiction. Front Nutr. 2022;9:960922. Published 2022 Jul 5. doi:10.3389/fnut.2022.960922
      3. Foxcroft L. Introduction: 'The Price of a Boyish Form'. In: Calories and Corsets: A History of Dieting over Two Thousand Years. Profile Books; 2011:1-8.
      4. British Dietetic Association (BDA). Fad diets: Food fact sheet. September 2021. Accessed January 16, 2023. https://www.bda.uk.com/resource/fad-diets.html
      5. British Dietetic Association (BDA). Fad diets and Instagram – friend or Foe? March 2019. Accessed January 16, 2023. https://www.bda.uk.com/resource/fad-diets-and-instagram-friend-or-foe.html
      6. Gans, K. Fad diets through the decades. U.S. News. December 23, 2019. Accessed January 17, 2023. https://health.usnews.com/health-news/blogs/eat-run/articles/fad-diets
      7. Johnson J. Fad diets are bad diets. American Council on Science and Health. July 2, 2018. Accessed January 20, 2023. https://www.acsh.org/news/2018/07/02/fad-diets-are-bad-diets-13134
      8. Centers for Disease Control and Prevention. Obesity and overweight. Updated January 5, 2023. Accessed January 20, 2023. https://www.cdc.gov/nchs/fastats/obesity-overweight.htm
      9. Centers for Disease Control and Prevention. Health effects of overweight and obesity. Updated September 24, 2022. Accessed January 20, 2023. https://www.cdc.gov/healthyweight/effects/index.html
      10. Johns Hopkins Medicine. Intermittent fasting: What is it, and how does it work? Accessed January 23, 2023. https://www.hopkinsmedicine.org/health/wellness-and-prevention/intermittent-fasting-what-is-it-and-how-does-it-work
      11. Chair SY, Cai H, Cao X, Qin Y, Cheng HY, Ng MT. Intermittent fasting in weight loss and cardiometabolic risk reduction: A randomized controlled trial. J Nurs Res. 2022;30(1):e185. doi:10.1097/jnr.0000000000000469
      12. UC Davis Health. Intermittent fasting: Benefits, how it works, and is it right for you? February 4, 2022. Accessed January 23, 2023. https://health.ucdavis.edu/blog/good-food/intermittent-fasting-benefits-how-it-works-and-is-it-right-for-you/2022/02
      13. Cleveland Clinic. What is a superfood, anyway? November 10, 2021. Accessed January 23, 2023. https://health.clevelandclinic.org/what-is-a-superfood/
      14. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease [published correction appears in N Engl J Med. 2020 Jan 16;382(3):298] [published correction appears in N Engl J Med. 2020 Mar 5;382(10):978]. N Engl J Med. 2019;381(26):2541-2551. doi:10.1056/NEJMra1905136
      15. Patterson RE, Laughlin GA, LaCroix AZ, et al. Intermittent fasting and human metabolic health. J Acad Nutr Diet. 2015;115(8):1203-1212. doi:10.1016/j.jand.2015.02.018
      16. Masood W, Annamaraju P, Uppaluri KR. Ketogenic Diet. In: StatPearls. Treasure Island (FL): StatPearls Publishing; June 11, 2022. Updated June 11, 2022. Accessed January 24, 2023. https://www.ncbi.nlm.nih.gov/books/NBK499830/
      17. Harvard T.H. Chan School of Public Health. Diet Review: Ketogenic diet for weight loss. May 22, 2019. Accessed January 24, 2023. https://www.hsph.harvard.edu/nutritionsource/healthy-weight/diet-reviews/ketogenic-diet/
      18. Nutrisystem. Accessed January 25, 2023. https://www.nutrisystem.com
      19. SlimFast. Accessed March 9, 2023. https://slimfast.com
      20. Jenny Craig. Accessed January 25, 2023. https://www-prd.jennycraig.com/how-it-works
      21. McEvedy SM, Sullivan-Mort G, McLean SA, Pascoe MC, Paxton SJ. Ineffectiveness of commercial weight-loss programs for achieving modest but meaningful weight loss: Systematic review and meta-analysis. J Health Psychol. 2017;22(12):1614-1627. doi:10.1177/1359105317705983
      22. Chaudhry ZW, Doshi RS, Mehta AK, et al. A systematic review of commercial weight loss programmes' effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus. Obes Rev. 2016;17(8):758-769. doi:10.1111/obr.12423
      23. Harvard T.H. Chan School of Public Health. Diet Review: Paleo diet for weight loss. October 28, 2019. Accessed January 26, 2023. https://www.hsph.harvard.edu/nutritionsource/healthy-weight/diet-reviews/paleo-diet/
      24. The Paleo Diet. Accessed January 26, 2023. https://thepaleodiet.com/
      25. UC Davis Health. Paleo diet: What it is and why it's not for everyone. April 27, 2022. Accessed January 26, 2023. https://health.ucdavis.edu/blog/good-food/paleo-diet-what-it-is-and-why-its-not-for-everyone/2022/04
      26. Weight loss: Feel full on fewer calories. Mayo Clinic. March 22, 2022. Accessed January 26, 2023. https://www.mayoclinic.org/healthy-lifestyle/weight-loss/in-depth/weight-loss/art-20044318
      27. Cleveland Clinic. High calorie foods and snack ideas to gain weight. September 15, 2020. Accessed January 26, 2023. https://my.clevelandclinic.org/health/articles/16555-snack-ideas-for-weight-gain
      28. Masharani, U., Sherchan, P., Schloetter, M. et al. Metabolic and physiologic effects from consuming a hunter-gatherer (Paleolithic)-type diet in type 2 diabetes. Eur J Clin Nutr 69, 944–948 (2015). https://doi.org/10.1038/ejcn.2015.39
      29. Parmar RM, Can AS. Dietary Approaches To Obesity Treatment. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 3, 2022. Accessed January 27, 2023. https://www.ncbi.nlm.nih.gov/books/NBK574576/
      30. Atkins diet: What's behind the claims? Mayo Clinic. May 12, 2022. Accessed January 27, 2023. https://www.mayoclinic.org/healthy-lifestyle/weight-loss/in-depth/atkins-diet/art-20048485
      31. Atkins. Accessed January 27, 2023. https://www.atkins.com/how-it-works
      32. Type 1 diabetes. Mayo Clinic. Accessed March 10, 2023. https://www.mayoclinic.org/diseases-conditions/type-1-diabetes/diagnosis-treatment/drc-20353017
      33. American Diabetes Association. Hypoglycemia (low blood glucose). Accessed March 10, 2023. https://diabetes.org/healthy-living/medication-treatments/blood-glucose-testing-and-control/hypoglycemia
      34. Natesan V, Kim SJ. Lipid Metabolism, Disorders and Therapeutic Drugs - Review. Biomol Ther (Seoul). 2021;29(6):596-604. doi:10.4062/biomolther.2021.122
      35. Health Resources & Services Administration. Primary carnitine deficiency. Accessed March 10, 2023. https://newbornscreening.hrsa.gov/conditions/primary-carnitine-deficiency
      36. Porphyria. Mayo Clinic. Accessed March 10, 2023. https://www.mayoclinic.org/diseases-conditions/porphyria/diagnosis-treatment/drc-20356072
      37. Cleveland Clinic. Pyruvate kinase deficiency. Cleveland Clinic. Accessed March 10, 2023. https://my.clevelandclinic.org/health/diseases/23419-pyruvate-kinase-deficiency
      38. American Heart Association. Types of heart medications. Accessed March 10, 2023. https://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heart-attack/cardiac-medications
      39. Cleveland Clinic. Diuretics. Accessed March 10, 2023. https://my.clevelandclinic.org/health/treatments/21826-diuretics
      40. Mayo Clinic. Chronic Kidney Disease. Accessed March 10, 2023. https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/diagnosis-treatment/drc-20354527
      41. Egan S. 10 Nutrition myths experts wish would die. The New York Times. January 19, 2023. Accessed February 3, 2023. https://www.nytimes.com/2023/01/19/well/eat/nutrition-myths.html
      42. Haspel T. Weight-loss diets boil down to one thing, and it's not science jargon. The Washington Post. January 23, 2023. Accessed February 4, 2023. https://www.washingtonpost.com/food/2023/01/23/weight-loss-diets-fasting-keto/
      43. Contreras RE, Schriever SC, Pfluger PT. Physiological and epigenetic features of yoyo dieting and weight control. Front Genet. 2019;10:1015. Published 2019 Dec 11. doi:10.3389/fgene.2019.01015
      44. Johns Hopkins Medicine. Maintaining Weight Loss. August 8, 2021. Accessed February 6, 2023. https://www.hopkinsmedicine.org/health/wellness-and-prevention/maintaining-weight-loss
      45. Centers for Disease Control and Prevention. Weight Loss and Management. March 19, 2021. Accessed February 6, 2023. https://www.cdc.gov/healthyweight/tools/index.html
      46. USDA. Healthy Living and Weight. U.S Department of Agriculture. Accessed February 6, 2023. https://www.nutrition.gov/topics/healthy-living-and-weight

      The revised USP 795 becomes official in November 2023. What’s new?

      Learning Objectives

       

      After completing this application-based continuing education activity, pharmacists and pharmacy technicians will:

      1. Describe recent changes to USP <795>
      2. Identify the designated person’s responsibility
      3. Recognize areas of nonsterile compounding that could be improved

      Image of brown vial with pink liquid splattered around it.

       

      Release Date: July 1, 2023

      Expiration Date: July 1, 2026

      Course Fee

      Pharmacists: $7

      Pharmacy Technicians: $4

      There is no grant funding for this CE activity

      ACPE UANs

      Pharmacist: 0009-0000-23-021-H07-P

      Pharmacy Technician: 0009-0000-23-021-H07-T

      Session Codes

      Pharmacist:  23YC21-MBV42

      Pharmacy Technician:  23YC21-VBM24

      Accreditation Hours

      2.0 hours of CE

      Accreditation Statements

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-021-H07-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

       

      Disclosure of Discussions of Off-label and Investigational Drug Use

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Faculty

      Christina Aglieco
      PharmD Candidate 2025
      UConn School of Pharmacy
      Storrs, CT

      Robin Bogner, PhD
      Professor of Pharmaceutics
      UConn School of Pharmacy
      Storrs, CT

      Laura Nolan, CSPT, CPhT
      Pharmacy Compounding Lab Coordinator
      Instructor Specialist in Sterile and Non-sterile Compounding
      UConn School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Christina Anglieco and Laura Nolan do not have any financial relationships with ineligible companies and therefore have nothing to disclose.

      Robin Bogner acts as a consultant for Biontech.  There is no conflict of interest.

       

      ABSTRACT

      Compounding of drug preparations requires training and knowledge in the science underlying pharmaceutical compounding. Altering the original drug product can change the drug’s stability and clinical efficacy. The United States Pharmacopeia (USP) is an independent non-profit organization of knowledgeable volunteers who set the standards for pharmaceutical compounding to ensure patient safety. State regulating bodies oversee and enforce these standards at compounding pharmacies to ensure compounded preparations are up to quality and purity standards. Since the field of pharmaceutical compounding is constantly changing, USP revises its standards regularly. The USP recently revised General Chapter <795> Pharmaceutical Compounding – Nonsterile Preparations with revisions enforceable on November 1, 2023. To make this transition easier, this continuing education activity outlines the most significant changes made to USP <795>. USP changed General Chapter <795> Pharmaceutical Compounding - Nonsterile preparations to mimic those of USP General Chapter <797> Pharmaceutical Compounding – Sterile Preparations. Overall, the revision elevates nonsterile compounding’s quality and sanitary standards to improve patient safety by reducing common safety errors seen across the United States.

      CONTENT

      Content

      Introduction

      The original “little blue pill” was created in the 1860s and was a popular cure for everything from toothache to tuberculosis.1 Pharmacists compounded “blue mass syrup” and “blue pills” based on their own recipes or on one of several widespread recipes. Its name probably derives from the use of blue dye or blue chalk (used as a buffer) in some formulations. Blue mass’s ingredients varied, as each pharmacist prepared it himself, but they all included elemental mercury. One recipe for blue mass syrup consisted of1

      • 33% mercury (measured by weight)
      • 5% licorice
      • 25% Althaea (a root extract, possibly from hollyhock or marshmallow)
      • 3% glycerol
      • 34% rose honey

       

      Pharmacist-compounders produced blue pills by substituting milk sugar or chalk for the glycerol and rose oil for the rose honey. Each pill contained one grain (64.8 milligrams) of mercury and was prescribed two to three times a day, which today we know causes heavy metal poisoning, since the dose is more than 100 times more than the limit set by the Environmental Protection Agency.1 Products were made without fancy definitions or regard to cleanliness. Times have changed.

       

      Pharmaceutical compounding is the act of manipulating a drug product to create a new drug formulation.2 Pharmacists and pharmacy technicians still compound drug preparations for a specific patient or group of patients when no drug product exists on the market, or as seen more recently, when the drug product is backordered with no therapeutic alternative(s). It is also interesting to note what the United States Pharmacopeia (USP; described below) does NOT consider to be compounding. Preparing a powdered antibiotic bottle with distilled water per manufacturer’s directions is not considered compounding. Splitting tablets and repackaging is also not considered compounding, nor is preparing a single dose for a single patient to be used within four hours. In other words, making one dose of blue mass syrup and giving it directly to a patient is not compounding. (OK, maybe no one makes blue mass syrup anymore, but crushing a tablet and placing it in a liquid for immediate use is still not a compounded preparation.)

       

      Pharmaceutical compounding has two categories: sterile compounding and nonsterile compounding.2

      • Sterile compounding is creating a new drug preparation that must be sterile (completely free of pathologic microorganisms) and includes preparations that are primarily infusions, injections, eye drops, and many irrigations.
      • Nonsterile compounding is creating a new drug product that is not required to be sterile (although these products should be as “clean” as possible) and are mostly used for oral or topical administration. Nonsterile compounding is often employed for pediatric and veterinary preparations where patients need very small or very large doses. Some examples are medicated creams for neuropathic pain, and anesthetic mouthwashes for oral sores and pains.

       

      The USP is an independent non-profit organization of knowledgeable volunteers who set the standards for pharmaceutical compounding to ensure patient safety.3 The USP also distinguishes guidelines for hazardous and non-hazardous compounding. Both sterile and nonsterile compounding can involve manipulation of hazardous drugs. This continuing education activity focuses on non-hazardous nonsterile compounding. More information on hazardous compounding can be found in General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings. Access to the USP Compounding Compendium costs $250.00 for a 12-month membership. There are also various plans for multiple users. Many institutions have a contract with USP. (Readers should check with their designated person or supervisor, as they may already have access to this service.)

       

      The origin of nonsterile pharmaceutical compounding in the U.S. cannot be pinned down to one exact date, but historically, the 1800s saw immense growth in not only population but also in disease states as people traveled and settled to new areas. Between 1840 and 1850, it is estimated that more than 1.5 million persons immigrated to the United States. Backyard herbalists became highly regarded apothecaries seemingly overnight.4

       

      Unfortunately, there were no established compounding standards until 1820 when a small group of physicians raised concerns about the high prevalence of poor-quality medicine across America and the USP was formed. By 1863, during the height of the Civil War, the USP had become the most trusted source for information about medicines.3.

       

      The USP continuously strives to improve the quality of drugs, including compounded preparations. Today we know that the quality of a compounded preparation depends as much on handwashing, gloving and cleaning, as checking the pH of the product itself. These steps are necessary to safeguard the preparation that a pharmacist or pharmacy technician compounds, and ultimately, safeguard the patient.

       

      The USP sets standards for pharmaceutical compounding but has no regulatory authority, so it does not enforce the standards it sets. Each state is responsible for regulating pharmaceutical compounding, but the Food and Drug Administration (FDA) is also authorized to regulate all aspects of drugs, including compounding. Both state regulating bodies and the FDA can inspect compounding in pharmacies and take legal action and can amass fines if compounders do not uphold USP standards. However, this action only applies to states that write USP standards into their laws. Depending on the situation’s severity, legal action could result in a loss of license for the pharmacy or pharmacist.

       

      The USP sets standards for sterile and nonsterile compounding through General Chapter <797> and General Chapter <795>, respectively. (Here’s a PRO TIP: chapters numbered from 1 to 1000 are enforceable by state and federal agencies). More recently, the FDA has been inspecting compounding pharmacies to ensure they meet General Chapter <797> standards, but it is only a matter of time before these agencies turn their attention to General Chapter <795>.

       

      In November 2022, the USP published a revised General Chapter <795> Pharmaceutical Compounding – Nonsterile Preparations. Going forward, we will call these standards the newly revised standards. This revision now includes a designated person (the individual assigned to be accountable and responsible for the compounding facility’s operation, performance, and personnel) requirement to mimic General Chapter <797>. With the implementation of a designated person for nonsterile compounding under proposed General Chapter <795>, when the facility is not up to code, State boards of Pharmacy and the FDA hold the designated person responsible, creating a risk of loss of license. The revised standards will be official in November 2023. Major changes include

      • garbing
      • cleaning
      • training
      • beyond-use dating and
      • a designated person requirement

       

      The focus here is on how to implement the major changes made to the currently enforceable General Chapter <795>, which was revised and reissued in 2020. Going forward, we will call these standards the current standards. Once readers are familiar with this summary of the major changes in the newly revised standards, they are encouraged to review the full text of the proposed chapter <795> to address additional minor changes.

       

      So, to repeat, the standards that were revised and reissued in 2020 and are currently enforceable will be called the current standards. The revision that will be adopted in November 2023 will be called the newly revised standards.

       

      Garbing

      The newly revised standards put greater emphasis on garbing procedures for nonsterile compounding than the current standards do. Pharmacy personnel who compound sterile preparations are well acquainted with garbing, however, garbing is a foreign concept to many who prepare nonsterile preparations. Think back to the past. How often did you go to the back of the store, push some items on the counter aside, and start mixing a magic mouthwash? You probably made it wearing a shirt and tie or more formal dress, while possibly wearing a lab coat, unless it was a really hot day. You might even have washed your hands if you just came back from lunch. Conversely, many hospital pharmacies mix magic mouthwash in so much garb, that you might think that it is a toxic preparation. The SIDEBAR explores this topic in greater detail.

       

       

      TECH TALK SIDE BAR5

      Have you noticed that many pharmacists and pharmacy technicians no longer wear white lab coats? Physicians began to wear white coats in the late 1800s as doctors started to recognize the color white’s effectiveness. It is easier to see dirt and soil that prompts the wearer to launder it, and frequent laundering helps reduce pathogens. Soon all medical professionals adopted the practice. White coats were worn not only to protect one’s clothing, but they were seen as a sign of prestige and respect.

       

      Today, white coats are rarely used, because according to Dennis Miller, “White coats cause white coat syndrome” (hypertension) and they “increase the distance between the pharmacist and the customer.” Few states regulate pharmacy technician attire. Many institutions and most large retail chains require pharmacy technicians to wear uniform “scrubs.” Restricting white coats to professional staff may reduce some customer confusion, but in certain situations, scrubs might imply the wearer is a nurse or other hospital professional, which is also confusing. One of this CE’s authors says, “I can’t even tell you how many patients and families would ask if I was a nurse.”

       

      Recently, some hospitals have banned pharmacy technicians from wearing scrubs, forcing them to wear civilian clothing. Unfortunately, that makes technicians look like pharmacists again. Of course, some pharmacists like to wear scrubs to work; are they secretly wishing they were technicians? Doubtful. Business attire has certainly gone downhill lately. So, if we can’t wear a white coat and we can’t wear scrubs, what are we to wear?

       

      THE ANSWER (which is required by law in many states): A name tag that indicates your position!

       

       

      The current standards state that personnel involved in compounding should garb “as needed for personal protection and to prevent contamination” of the compounded nonsterile product (CNSP) prior to preparation.6 For example, compounding staff don two pairs of gloves for personal protection when preparing cytotoxic CNSPs for their own safety. More information on hazardous compounding can be found in General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings. The current standards also state compounding personnel are responsible for maintaining good hand hygiene and wearing appropriate clothing to prevent contamination of the CNSP.6 These statements give compounding personnel some latitude when they make decisions. For example, currently, some compounders don gloves to make magic mouthwash, while many others prepare it with ungloved hands in their practice. Nonsterile gloves will become mandatory on November first.

       

      The newly revised standards now specify hand washing and garbing procedures and provide guidance on personnel who should NOT prepare a CNSP. Compounding personnel are to remove all “garments that cannot be easily cleaned” before entering the designated compounding area. So compounding personnel must now remove personal outer garments (such as jackets, sweaters, hats, and scarves), hand and wrist jewelry, anything that might hinder the use of gloves, and headphones must be removed before compounding something as simple as magic mouthwash. Compounding personnel must wash their hands for at least 30 seconds and dry with one-time use paper towels before compounding as well. After handwashing, personnel must don nonsterile gloves and inspect the gloves for holes, rips, or tears. Compounding personnel should wipe or replace gloves in between different preparations and must remove these gloves before leaving the designated compounding area.6 These proposed standards are analogous to the procedures required for sterile compounding. In fact, the format of and definitions within the revised <795> aligns with the revised <797> for sterile products much more closely than in the past.

       

      The current standards still require personnel to be in good health and fit for compounding, but the revisions are considerably more specific. Personnel who have new tattoos, oozing sores, open wounds, conjunctivitis, rashes, or active respiratory infections are not considered fit to compound due to risk of contamination of the CNSP. The newly revised standards hold the designated person responsible for deciding if personnel are fit for compounding or not.6

       

      Cleaning the Designated Compounding Area

      Do I need to create an area for compounding? Yes. The newly revised standards describe a designated compounding area in detail. Some readers are thinking, “My pharmacy is small. Can I use the area for tasks other than compounding?” The designated compounding area is a space with a marked perimeter that is required to be clean, orderly, sanitary, well-lit, and have low foot traffic, and no other activities can occur in this space simultaneously. You may perform other duties there if there is no compounding going on as long as someone cleans the area before compounding again. The newly revised standards suggest the designated compounding area be uncarpeted for easier cleaning, which in one of this CE’s author’s opinion should be changed to a must, since carpets tend to harbor dust and dander, and can be very difficult to clean. (Have you ever dropped and broken a bottle on the carpet in your pharmacy? It’s not pretty.)

       

      The compounding area must be used in a manner that prevents cross contamination of CNSPs from other areas of the pharmacy. For compounding to be completed in the most efficient manner possible, all equipment in the designated compounding area must be arranged in a way that prevents errors. Last, the facility’s standard operating procedures (SOPs) must always include this information and be available to staff.

       

      The current standards simply state that compounding equipment “shall be clean, properly maintained and used appropriately.”6 This statement allowed compounding personnel to decide on their own standard of clean when preparing a CNSP and their own definition of when or if they should clean. The newly revised guidelines strengthen the minimum requirements for cleaning the designated CNSP compounding area. The USP dedicates an entire section to cleaning procedures, representing a major change in the standards. The new standards indicate that personnel must clean the perimeters—walls and ceilings—when visibly soiled, after spills, and when surface contamination occurs.6 Readers will see that visible soil, spills, and surface contamination form a frequent theme in the newly revised standards!

       

      The new standards also establish a routine cleaning schedule. The section, “Cleaning and Sanitizing” states pharmacy personnel must clean work surfaces at the beginning and end of each shift at a minimum, between each CNSP, and again if spills or surface contamination occurs. The standards add that personnel must clean floors daily on days when compounding occurs, and again if spills or surface contamination occurs.6. Personnel must clean storage shelves every three months, after spills, and when surface contamination occurs. Personnel qualified to clean can be defined as any staff member who has been properly trained and observed in a facilities cleaning procedures. That means that pharmacy staff can train housekeeping staff to complete the cleaning.

       

      Personnel need to clean and sanitize, and if two separate products are used—one to clean and one to sanitize—cleaning is done first, followed by sanitizing second. Selecting appropriate cleaning products requires careful attention. They should be (1) compatible, (2) effective, and (3) leave minimal residue. Finally, daily documentation is essential on days when compounding occurs.6 An old adage applies here: cleaning is not truly done unless it is documented. High tech organizations commonly complete this documentation using an online platform integrated with other daily documentation requirements such as daily temperature monitoring, but a simple sign off sheet is also acceptable. A best practice is to include any cleaning and its documentation into the compounder’s daily workflow, so it is not forgotten. Daily and or weekly task charts can be created to include all activities that need to be performed.

       

      PAUSE AND PONDER: How were you originally trained to compound? Were you told to watch how it was done and then you were on your own?

       

      Training

      Another major area of change is the training of compounding personnel. The current standards state that compounders must be “proficient in compounding” and suggest that compounders should pursue knowledge by attending seminars or studying literature related to compounding. It also states that compounders must be conversant on General Chapter <795> and familiar with General Chapter <797>. With standards this vague, and no required number of CE credits on this subject, how often do you think compounding personnel previously searched for compounding topics? Also, the current standards simply require at a minimum compounding personnel to be trained and capable of the compounding duties assigned to them, and for someone to document the training. Compounding duties include verifying critical processes like weighing and mixing that occur frequently during compounding.

       

      The newly revised standards will require a more structured training program for compounding personnel. All compounding personnel must complete this training program initially before being allowed to compound and every 12 months thereafter. The newly revised standards require compounding personnel to repeat compounding procedures “independently while under the supervision of the designated person or assigned trainer for completion of the training program.”6 The organization’s designated person will be responsible for designing the training program, which must include

      • the required training, meaning a detailed description of the training
      • the frequency of training, and
      • the process used to evaluate competency.

       

      Table 1 lists the training program’s required topics. It is interesting to note that pharmacists who do not compound but complete in-process checks, verification, or dispensing also must complete the CNSP training program before completing checks, verification, or dispensing. A training program may include an online portion of reading or videos teaching concepts with quizzes to evaluate understanding, and a physical portion to evaluate measuring, mixing, and overall compounding. The designated person or assigned trainers can train personnel, and of course, they must document the completion of the training program.6

       

      Table 1. Proposed General Chapter <795> Required Topics for Training6

      Training programs must teach compounding personnel the following:
      ·       cleaning and sanitizing
      ·       documentation such as Master Formulation Records and Compounding Records
      ·       hand hygiene and garbing
      ·       handling and transporting CNSPs and their components
      ·       measuring and mixing
      ·       proper use of compounding equipment and devices
      ·       understanding General Chapter <795>
      ·       understanding safety data sheets
      ·       understanding procedures to complete compounding duties

       

      It is important to note this table only lists the minimum requirements, additional requirements may be necessary according to each facility’s needs.

       

      The Designated Person

      The necessity to designate a person who has oversight and full responsibility for compounding practices now in General Chapter <800> is included in proposed General Chapter <795> and <797>. The current standards again broadly describe the requirements. The chapter states that compounding personnel are responsible for adhering to the general principles of compounding outlined in the current standards. It specifies several responsibilities, which include training, selecting ingredients for compounding, labeling, and cleaning. However, since the compounding process may include many people, the ultimate accountability is unclear.

       

      To clarify accountability, the proposed General Chapter <795> requires each organization to designate one or more persons to be responsible and accountable for nonsterile compounding. The designated person’s responsibilities include ensuring the organization develops written formal quality control and quality assurance procedures and reviews them annually. The designated person must monitor and observe compounding, identify areas of error, and take corrective action if needed. The designated person has several other responsibilities. These include6

       

      • establishing, documenting, and monitoring SOPs within the CNSP compounding area to include component handling and storage
      • ensuring that all staff members follow all SOPs
      • reviewing complaints
      • determining if potential issues are likely with CNSPs
      • selecting components to be used in compounding

       

      Beyond Use Dates

      The final major difference is the establishment of beyond-use dates (BUD) for CNSPs. The current standards hold compounders responsible for establishing BUDs based on their observation of the drug during compounding. Compounders (not a designated person) are held responsible for noticing signs of instability and using their education and experience to assign a BUD to the final preparation.6 The current standards also recommend assigning BUDs based on three categories: non-aqueous, water-containing oral, or water-containing topical. The new guidelines are based on the activity of water (aw) in each product.

       

      Table 2 compares the current and proposed BUD recommendations.6

       

       

      Table 2. A Comparison of BUD Requirements6,7       

      Description Minimum BUD requirement
      Current USP <795> Proposed USP <795>
      Aqueous non-preserved 14 days in refrigerator 14 days in refrigerator

       

      Aqueous preserved 14 days in refrigerator 35 days controlled room temp or refrigerator
      Aqueous topical

      (Cream, lotion, shampoo, nasal spray, gel, rinse, foam, etc.)

      30 days 35 days if preserved

      14 days if non-preserved

      See activity of water chart

      Nonaqueous oral

      (Oil or powder filled capsule, glycol or oil based oral solution, compressed tablet, powder for inhalation, troche, lollipop, etc.)

      6 months 90 days
      Nonaqueous

      (Medicated stick, ointment, suppository, etc.)

      6 months 180 days (6 months)

       

      Proposed General Chapter <795> determines BUDs based on a preparation’s water activity (aw, see SIDEBAR), which is more clearly defined as aqueous and non-aqueous by the following distinction:

       

      • CNSPs with an aw ≥0.6, considered aqueous dosage forms
      • CNSPs with an aw <0.6, considered non-aqueous dosage forms

       

       

      SIDEBAR: Activity of Water7-10

      The water in a preparation can “participate in chemical, biochemical, or physicochemical reactions.” However, it is not the water content (such as % water in the CNSP), but rather the activity of water that determines the water’s availability to participate in degradation reactions and allow microbial growth. Therefore, compounders must determine a BUD by considering the preparation’s water activity and not the preparation’s water content.

       

      Water activity is roughly equivalent to relative humidity, except that relative humidity is expressed in terms of percent and water activity is expressed as a fraction. So, a water activity of 0.6 is roughly equivalent to 60% relative humidity. If the dosage form with a water activity of 0.6 were to be sealed in a package, any surrounding space would eventually have a relative humidity of 60%. Compounders can measure water activity for a specific preparation by the procedures outlined in General Chapter <922> Water Activity. However, the proposed General Chapter <795> provides an easy classification system (see Table 3).

       

      The aw cut-off of 0.6 established in USP comes from various studies showing no microbial growth of any kind in foods below this value. Although the water activity determination was constructed using food, it is also the basis of USP <1112> Water Activity Determination and is the foundation for the BUD rationale in the proposed <795>. A product with an aw greater than or equal to 0.6 has been shown to have increased bacterial, fungal, and other microbial growth. However, in products with an aw below the threshold of 0.6, no microbial growth was found.

       

       

      The newly revised standards recommend adding antimicrobial agents to any CNSP with an aw at or exceeding 0.6 when assigning a BUD of 35 days. Even components as simple as ascorbic acid can help extend the BUD. As always, careful research must be done to determine suitable preservatives for each product and if an extended BUD date is assigned, the preparation must be tested for antimicrobial effectiveness. Consider one formula for magic mouthwash, which might have an aw of 0.73 and contains no preservatives. With no USP monograph, one would refer to Table 3 to determine that the BUD should be limited to 14 days when stored in the refrigerator. We are sure that pharmacists compounding blue mass syrup could have cared less about the activity of water in their concoctions. We wonder if they would have viewed mercury as a preservative.

       

      Compounders can assign non-aqueous dosage forms with an aw less than 0.6 a maximum BUD of 90 days for an oral liquid and 180 days for alternative routes.

       

      While the newly revised standards provide strong guidance on determining a CNSP’s BUD, compounders should only use its tables if no other stability information is available. The designated person is responsible for searching for stability information for each CNSP and determining if a CNSP can have a BUD beyond that specified in Table 2. If the designated person finds an extended BUD appropriate, compounding staff must test it for antimicrobial effectiveness. However, if compounding staff is following a United States Pharmacopeia- National Formulary (USP-NF) monograph for CNSP preparations, the BUD must not exceed that which is indicated in the monograph. Last, the CNSP’s components should drive the overall expiration date, which is not a change from the current standards.

       

      Table 3. Proposed General Chapter <795> classification of commonly compounded dosage forms as non-aqueous or aqueous partial list.

      Nonaqueous Dosage Forms aw <0.6

       

      Aqueous Dosage Forms aw ≥0.6

       

      -       ­Animal treat, oil based

      -       Capsule: oil filled or powder filled

      -       Oral solution: glycol based or oil based.

      -       Glycol based gel

      -       Stick or lip balm

      -       Tablet compressed or triturate

      -       Sorbitol based lollipop

      -       Ointment: hydrophilic petrolatum polyethylene and mineral oil based

      -       Oral suspension: fixed oil

      -       Powder for inhalation

      -       Suppository: polyethylene glycol base or fatty acid base

      -       Troche or lozenge: gelatin based or glycol based

      -       Animal treat

      -       Foam

      -       Shampoo

      -       Cream: oil in water emulsion, emollient cream, petrolatum, and mineral oil gel: alcohol free aqueous or hydroxypropyl methylcellulose gel

      -       Lotion

      -       Nasal spray

      -       Rinse

      -       Oral solution: water based, low sucrose syrup vehicle

      -       Oral suspension

       

       

      CONCLUSION

      Compounders face many of the same challenges today as they did in the 1800s. They were faced with a limited drug list, similar to a closed formulary in today’s world. They searched for alternative therapies, and they did, as we still do, face many drug shortages. The main difference is that we have advanced knowledge to make better products to keep patients safer.

       

      The time has come to designate your area, designate your person, and train your staff, including pharmacists who may not actually be compounding! Keep the designated area clear for compounding use only, if possible, and remove any unnecessary items before entering. Set up a cleaning routine for the entire space, including floors, walls, and shelving, and incorporate the routine into the daily workflow so it is never forgotten. Train your staff well to the new standards and reevaluate every 12 months. Look into the literature to determine the best BUD for each CNSP and when information is not available, use USP guidance for assigning a BUD date. Choose a designated person wisely, as they need to be responsible and organized with taking responsibility and accountability for all nonsterile compounding occurring in the facility.

       

      Remember, improvements in non-sterile compounding standards will make for higher quality and safer compounded non-sterile products for our patients and are enforceable come November 1, 2023.

      Pharmacist Post Test (for viewing only)

      After completing this continuing education activity, pharmacists and pharmacy technicians will be able to

      1. Describe recent changes to USP <795>
      2. Identify the designated person’s responsibilities
      3. Recognize areas of nonsterile compounding that could be improved

      1. The USP made major revisions to General Chapter <795> in the newly revised standards. What topics are affected?
      a. Cleaning, training, purchasing, designated person, and verification processes.
      b. Garbing, training, sanitizing, designated person, purchasing.
      c. Garbing, cleaning, training, designated person, and BUDs.

      2. When will the proposed General Chapter <795> become enforceable?
      a. It is already enforceable
      b. July 1, 2023
      c. November 1, 2023

      3. Which of the following conditions would make compounding personnel unfit for compounding at the discretion of the designated person?
      a. Recent placement of a temporary (water-removable) tattoo
      b. Cough, runny nose, and upper respiratory congestion
      c. All of the above.

      4. Who must create and enforce a new training program under the newly revised standards?
      a. Only staff who will perform compounding
      b. All personnel involved in compounding verification and dispensing
      c. The designated person or the designated person’s designee

      5. How often must the training program and reevaluation of competency be completed?
      a. Once prior to compounding, and then every 12 months
      b. Once after November 1, 2023, and then biannually
      c. Once only, since compounding never changes

      6. Sally is about to enter the compounding area. She is wearing makeup, a set of bangle bracelets, and sterile gloves. Which item is not allowed when compounding a CNSP?
      a. Makeup
      b. Wrist jewelry
      c. Gloves

      7. Which of the following must the designated person complete personally (that is, not train or delegate to others)?
      a. Cleaning the compounding area twice daily
      b. Identifying BUDs for all compounded products
      c. Ensuring staff follow all operating procedures

      8. The FDA visits your pharmacy after several patients develop infections related to a CNSP compounded in your facility. They find that the BUD was incorrect and the product was contaminated. Who will ultimately “take the fall” for this issue?
      a. The designated person.
      b. The entire pharmacy department.
      c. The compounder who prepared the CNSP.

      9. Which of the following CNSP properties now restricts the maximum BUD?
      a. Activity of water
      b. Time till it reaches the patient
      c. Duration of treatment

      10. Your supervisor tells you it’s time to improve your organization’s compounding. You need to find the best area for compounding. Which of the following is the best option for a designated compounding area?
      a. The farthest corner of the pharmacy provided that customers cannot see it and housekeeping staff indicates it is clean
      b. A carpeted section of the pharmacy next to the employee refrigerator that has easily cleanable countertops and shelving.
      c. A well-lit, uncarpeted area with easily cleanable countertops that is segregated from countertop space used for daily activities

      Pharmacy Technician Post Test (for viewing only)

      After completing this continuing education activity, pharmacists and pharmacy technicians will be able to

      1. Describe recent changes to USP <795>
      2. Identify the designated person’s responsibilities
      3. Recognize areas of nonsterile compounding that could be improved

      1. The USP made major revisions to General Chapter <795> in the newly revised standards. What topics are affected?
      a. Cleaning, training, purchasing, designated person, and verification processes.
      b. Garbing, training, sanitizing, designated person, purchasing.
      c. Garbing, cleaning, training, designated person, and BUDs.

      2. When will the proposed General Chapter <795> become enforceable?
      a. It is already enforceable
      b. July 1, 2023
      c. November 1, 2023

      3. Which of the following conditions would make compounding personnel unfit for compounding at the discretion of the designated person?
      a. Recent placement of a temporary (water-removable) tattoo
      b. Cough, runny nose, and upper respiratory congestion
      c. All of the above.

      4. Who must create and enforce a new training program under the newly revised standards?
      a. Only staff who will perform compounding
      b. All personnel involved in compounding verification and dispensing
      c. The designated person or the designated person’s designee

      5. How often must the training program and reevaluation of competency be completed?
      a. Once prior to compounding, and then every 12 months
      b. Once after November 1, 2023, and then biannually
      c. Once only, since compounding never changes

      6. Sally is about to enter the compounding area. She is wearing makeup, a set of bangle bracelets, and sterile gloves. Which item is not allowed when compounding a CNSP?
      a. Makeup
      b. Wrist jewelry
      c. Gloves

      7. Which of the following must the designated person complete personally (that is, not train or delegate to others)?
      a. Cleaning the compounding area twice daily
      b. Identifying BUDs for all compounded products
      c. Ensuring staff follow all operating procedures

      8. The FDA visits your pharmacy after several patients develop infections related to a CNSP compounded in your facility. They find that the BUD was incorrect and the product was contaminated. Who will ultimately “take the fall” for this issue?
      a. The designated person.
      b. The entire pharmacy department.
      c. The compounder who prepared the CNSP.

      9. Which of the following CNSP properties now restricts the maximum BUD?
      a. Activity of water
      b. Time till it reaches the patient
      c. Duration of treatment

      10. Your supervisor tells you it’s time to improve your organization’s compounding. You need to find the best area for compounding. Which of the following is the best option for a designated compounding area?
      a. The farthest corner of the pharmacy provided that customers cannot see it and housekeeping staff indicates it is clean
      b. A carpeted section of the pharmacy next to the employee refrigerator that has easily cleanable countertops and shelving.
      c. A well-lit, uncarpeted area with easily cleanable countertops that is segregated from countertop space used for daily activities

      References

      Full List of References

      References

      1. Massae Pilularum—pill masses, Henriette’s Herbal Homepage. Accessed June 2, 2023. https://www.henriettes-herb.com/eclectic/kings/massae-pilu.html
      2. Watson, C.J., Whitledge, J.D., Siani, A.M. et al. Pharmaceutical Compounding: a History, Regulatory Overview, and Systematic Review of Compounding Errors. J. Med. Toxicol. 17, 197–217 (2021). https://doi.org/10.1007/s13181-020-00814-3
      3. USP Timeline. www.usp.org. Accessed March 21, 2023. https://www.usp.org/200-anniversary/usp-timeline#:~:text=1820&text=Concerned%20about%20the%20dangers%20of
      4. Sprowls, Joseph Barnett, Lewis W. Dittert, and Rufus Ashley Lyman. Sprowls' American Pharmacy: An Introduction to Pharmaceutical Techniques and Dosage Forms. Lippincott Williams & Wilkins, 1974. page 3.
      5. Miller D. Are those white coats really necessary? Accessed June 3, 2023. https://www.drugtopics.com/view/dear-pharmacists-are-those-white-coats-really-necessary
      6. USP. Pharmaceutical Compounding - Nonsterile Preparations <795>. In: USP-NF. Rockville, MD: USP; May 1, 2020.

      DOI: https://doi.org/10.31003/USPNF_M99595_05_01

      1. USP. Pharmaceutical Compounding - Nonsterile Preparations <795>. In: USP-NF. Rockville, MD: USP; November 1, 2023.

      DOI: https://doi.org/10.31003/USPNF_M99595_06_01

      1. USP. Applications of Water Activity Determination to Non-sterile Pharmaceutical Dosage Products <1112>. In: USP-NF. Rockville, MD: USP; 2013

      DOI: https://doi.org/10.31003/USPNF_M402_01_01

      1. USP. Water Activity <922>. In: USP-NF. Rockville, MD: USP; May 1, 2021.

      DOI: https://doi.org/10.31003/USPNF_M12475_02_01

       

      1. Sikorski ZE. Fennema's food chemistry (fifth edition) edited by SrinivasanDamodaranKirk L.parkin CRC press, Boca Raton, Florida, 2017. 1107 pp. ISBN 9781482208122. J Food Biochem. 2018;42(2):e12483-n/a. doi: 10.1111/jfbc.12483.

       

      Patient Safety: Social Media Sensation: Semaglutide

      Learning Objectives

       

      After completing this application-based continuing education activity, pharmacists will be able to

      ·       Recall the mechanism of action and dosing schedule of GLP-1 receptor agonists
      ·       Classify adverse reactions most commonly associated with GLP-1 receptor agonists
      ·       Discuss GLP-1 receptor agonists indications for use

      After completing this application-based continuing education activity, pharmacy technicians will be able to

      ·       Identify the different formulations of GLP-1 receptor agonists
      ·       Classify storage requirements for GLP-1 receptor agonists
      ·       Review GLP-1 receptor agonists indications for use

      Cartoon person scratching head while looking at a scale

       

      Release Date: June 17, 2023

      Expiration Date: June 17, 2026

      Course Fee

      Pharmacists: $5

      Pharmacy Technicians: $2

      There is no grant funding for this CE activity

      ACPE UANs

      Pharmacist: 0009-0000-23-020-H05-P

      Pharmacy Technician: 0009-0000-23-020-H05-T

      Session Codes

      Pharmacist:  23YC20-XFT68

      Pharmacy Technician:  23YC20-TXF84

      Accreditation Hours

      1.5 hours of CE

      Accreditation Statements

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-020-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

       

      Disclosure of Discussions of Off-label and Investigational Drug Use

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Faculty

      Jennifer Kuivinen, RPh, CIP
      Pharmacist
      Meijer Pharmacy
      Petoskey, MI

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Jennifer Kuivinen does not have any financial relationships with ineligible companies and therefore has nothing to disclose.

       

      ABSTRACT

      Recently, it’s a rare day when the national news outlets and social media platforms don’t discuss medication-assisted weight loss. Semaglutide has become a social media sensation for its ability to help people–even people who do not have diabetes (its approved indication) lose weight. With celebrities reporting significant weight loss with off-label use of glucagon-like peptide-1 (GLP-1) receptor agonists, pharmacy teams are fielding questions and juggling prescriptions to deal with drug shortages. This continuing education activity provides basic facts about using GLP-1 receptor agonists for weight loss.

      CONTENT

      Content

      INTRODUCTION

      Lifestyle modifications have been the mainstay of weight management for years. We’ve all heard the advice: Exercise more, eat less, limit fried foods and sugary drinks, and the weight should slowly disappear. As the weight comes off, you might have some setbacks but just keep tracking your foods and your success is right around the corner.

       

      If only it was that easy!

       

      Scroll any social media platform today and search the term, “#ozempicweightloss” and a plethora of joyful testimonials appear. Some videos have reports of people losing 17 pounds in 3 months or 64 pounds in a year with no cravings for food. “I can eat whatever I want!!” cried a satisfied user. It is as if the golden ticket has been found in all the candy bars ever produced and everyone is going to the candy factory!

       

      Although the recent media emphasis has been on semaglutide, and the Ozempic product primarily, other glucagon-like peptide-1 (GLP-1) receptor agonists have also been associated with weight loss to varying degrees. This continuing education activity’s primary focus is to clarify misinformation, highlight specific GLP-1s’ risks and benefits when used for weight loss, and answer frequently asked questions.

       

      WHAT ARE GLP-1 RECEPTOR AGONISTS?

       

      Major breakthroughs in the physiology of the pancreas occurred in the early 1900s.1 At that time, physiologists thought the nervous system had exclusive control of all bodily functions. That idea changed when two scientists, William Bayliss and Ernest Starling, discovered a chemical compound they named secretin. Released from intestinal mucosa, secretin stimulated the pancreas.2 Shortly after the discovery of the hormone insulin in 1921, research being conducted at the time primarily stimulated the pancreas to produce insulin by administering glucose via the intravenous route. However, when glucose was administered orally (allowing nutrients to travel to gastrointestinal areas), insulin levels improved substantially. This observation was known as the incretin effect. As a result, two insulinotropic hormones were later identified as incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) discovered in 1971 and glucagon-like peptide-1 (GLP-1) discovered in 1985.1,2

       

      Analyzing the venom of the Gila monster (Heloderma suspectum) in 1990, endocrinologist Dr. John Eng discovered a peptide that stimulated insulin release from the pancreas.3 Named exendin-4, this peptide was similar in structure and function to GLP-1 found in humans. One problem with GLP-1 was that when it is released into the body, dipeptidyl peptidase-4 (DPP-4). quickly inactivated it. Researchers then developed the DPP-4 inhibitors to allow GLP-1 to remain active for a longer period of time. However, synthetically producing GLP-1 receptor agonists (GLP-1RA) directly has extended the peptide’s life. Initial development resulted in twice daily and then daily administration (half-life of 13 hours) of GLP-1RAs. However, when researchers combined semaglutide with a free fatty acid side chain that was tightly bound to albumin, its half-life was increased substantially. The resultant half-life of 165 hours led to an advantageous injection administration schedule for semaglutide: once weekly.3,4,5

       

      Mechanism of Action

      As a class of medications, all GLP-1RAs share common mechanisms of action in the treatment of diabetes: stimulate the pancreas to secrete insulin, suppress the action of glucagon, and decrease gastric emptying.4 Scientists previously studied the effects of GLP-1 and noticed that the protein, when injected in rats, decreased appetite quickly.5 Once clinicians began using GLP-1RAs to treat diabetes in humans, they also observed weight loss due to decreased appetite, increased feelings of fullness, and reduced caloric consumption.4

       

      Researchers determined that the brain contained GLP-1 receptors. Weight loss was due to GLP-1RAs ability to travel to these receptors and influence specific areas of the hypothalamus that are key to controlling appetite, calorie consumption, satiety, and body weight.4 Among GLP-1RAs, semaglutide and liraglutide stimulate the highest amount of weight loss success.

       

       

      Comparison of GLP-1 drugs

       

       

      Table 1. GLP-1RAs for Weight Loss

      Medication Dosing Counseling points Supplies needed for injection
      Semaglutide (Wegovy) Adult and pediatric patients aged 12 and older, starting dosage at 0.25 mg injected subcutaneously once weekly.

       

      Weeks 1-4: 0.25 mg

      Weeks 5-8: 0.5 mg

      Weeks 9-12: 1 mg

      Weeks 13-16: 1.7 mg

      Weeks 17 & forward: 2.4 mg maintenance dose once weekly.

       

      If adverse reactions occur during the upward titration period, consider delaying increase in dosage for four weeks.

       

      Consider discontinuing the drug if patients do not lose at least 5% of baseline body weight within 3 months

      1 alcohol swab or soap and water

       

      1 gauze pad or cotton ball

       

      1 sharps disposable container for used Wegovy pens

      Liraglutide

      (Saxenda)

      Adults and pediatric patients aged 12 and older, starting dosage at 0.6 mg injected subcutaneously once daily. (NOTE: This is a DAILY dose)

       

      Week 1: 0.6 mg

      Week 2: 1.2 mg

      Week 3: 1.8 mg

      Week 4: 2.4 mg

      Week 5 & forward: 3 mg maintenance dose daily.

       

       

       

       

       

       

       

       

       

      If adverse reactions occur during upward titration period, consider delaying dose increase for approximately one additional week.

       

      Patients can continue on maximally tolerated dose if goal weight loss achieved on that dose.

       

      Soap and water

       

      Pen needle: 8 mm

      (Novofine or NovoTwist)

       

      1 sharps disposable container for pen and needles

       

       

      Adverse Drug Reactions and Boxed Warning

      GLP-1 agonists all have similar and common gastrointestinal adverse effects (nausea [~15–30%], vomiting [~10-15%], diarrhea [~5-10%], abdominal pain, constipation).6,7,8 Patients can use some strategies to possibly mitigate these adverse effects6,7,8:

      • Increasing the GLP-1 agonist dose slowly
      • Staying hydrated and increasing fiber
      • Avoiding high-fat foods and alcohol
      • Stopping eating when full (and eating only when hungry)
      • Spacing meals appropriately
      • Using short-term proton pump inhibitors or H2 blockers if needed

      Patients may also experience headache, fatigue, dyspepsia (gastrointestinal upset), dizziness, abdominal distension, eructation  (burping), hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.7 Clinicians should evaluate patients for gallbladder disease if cholelithiasis (gallstones) or cholecystitis (an inflamed gall bladder) is suspected.

       

       

      Reports of patients experiencing hair loss have surfaced recently from news and social media. Listed as an adverse reaction for Wegovy, but not for Ozempic, the Wegovy dose is much higher for treatment of weight loss.9 Some clinicians think that the rapid loss of weight triggers the body to conserve calories consumed for essential functions.9 Since patients eat less while taking the medications, their diet may consist of lower amounts of protein and minerals important for hair growth. Clinicians have seen hair growth resume once the body reaches a plateau in weight loss, therefore the loss of hair is not permanent.9

      These drugs also share a boxed warning for risks of pancreatitis and medullary thyroid carcinoma (cancer in the thyroid gland in its medulla, the calcitonin-producing area), which is rare.6 Patients with a personal history of pancreatitis or a personal or family history of medullary thyroid carcinoma must avoid these drugs.6

      These drugs also required an FDA approved Medication Guide whenever GLP-1RAs are dispensed. Pharmacy technicians can be very helpful to pharmacists if they check the patient’s bag and make sure that the Medication Guide is in it.

       

      Recent Shortages of GLP-1 Receptor Agonists

       

      The sensation of weight loss success for some has caused serious problems for other patients who have diabetes and are struggling to find medication at local pharmacies. Staff in community-based pharmacy practice are well aware of the semaglutide shortages that have occurred in the past year. Pharmacists and technicians should be able to explain the current drug shortages, adverse reactions, and FDA approved or off-label use to patients and other healthcare providers.

       

      Ozempic face”

       

      As social media and now news media have reported the success of dramatic weight loss, some users bemoan weight loss woes associated with use of GLP-1 agonists. The term, “Ozempic face,” introduced by a dermatologist in New York, describes the typical female patient who has lost a significant amount of weight on semaglutide but now needs (or wants) dermal fillers for her sagging facial structures.10 Patients complain about sagging skin and a gaunt appearance, two problems that follow the loss of facial fat after any harsh weight loss.

       

      Facial fat loss is common when patients lose weight, and when the weight loss is significant, patients will look older. Skin wrinkles and loosens—hallmarks of aging. Similar to weight loss from old-fashioned dieting, fat loss while taking GLP-1 agonists affects the entire body (not just the face). But patients on GLP-1 agonists for cosmetic weight loss fail to understand that they can’t just lose weight where they’d like to lose weight. The facial fat loss is distressing to them.10 Pharmacy teams need to know that “Ozempic face” is a slang term, and GLP-1 agonists don’t specifically target the face.11

       

       

      Weight Loss Blockbuster or Fad

       

      Over the past two years, celebrities and social media influencers have posted successful weight loss stories while using semaglutide and as a result, catapulted its popularity as a weight loss miracle.12 Questions remain as to how long the weight loss effect will last and if patients will gain the weight back once stopping the treatment. Novo Nordisk, semaglutide’s manufacturer, indicates weight loss can be sustained with long-term use. However, the data collected is limited by a time span of two to three years. Since people who pay out-of-pocket for semaglutide will pay around $1200 per month and some insurance companies may not cover the medication, pharmacists should counsel patients that once the medication is discontinued, weight gain is likely to occur and the weight gain might exceed the original amount lost.12

       

       

      FDA APPROVED AND OFF-LABEL USE

      In December of 2017, the FDA approved semaglutide (Ozempic) for the treatment of diabetes. As significant weight loss was observed, the Semaglutide Treatment Effect in People with obesity (STEP) studies produced promising weight loss data.13 As a result, the FDA approved semaglutide for an additional indication, weight loss, in June 2021 under the brand name Wegovy.

       

       

      Diabetes

      In patients with type 2 diabetes mellitus (T2DM), semaglutide is used in combination with diet and exercise to reduce blood sugar levels.14 In patients with T2DM who additionally have established cardiovascular disease, liraglutide and semaglutide are indicated to help lessen the risk of major cardiovascular incidents. Dulaglutide, liraglutide, and semaglutide also have beneficial effects on chronic and diabetic kidney disease.6 Patients who have a history of pancreatitis should avoid any member of the GLP-1RA class and they are not to be used as treatment for patients who have type 1 diabetes.

       

      Dosing semaglutide for the treatment of diabetes requires a period of time for dosage escalation to minimize adverse effects. The FDA has approved both subcutaneous and oral semaglutide (Rybelsus) dosage forms, but only the injectable version is approved for weight loss. Subcutaneously, semaglutide is initially dosed at 0.25 mg once weekly, and after four weeks the patient should increase to 0.5 mg weekly for four weeks. Doses of 1 mg and 2 mg are optional if glycemic control has not been achieved, however the 1 mg dose should also be used for a minimum of four weeks before increasing to the maximum 2 mg strength.6 Dosed on the same day of the week, injections can be dosed at any time of the day with or without regard to meals. Patients sometimes miss or forget their scheduled dosing day. If this occurs, patients should inject the dose within 5 days of the missed dose.6

       

      Patients who have diabetes and currently use metformin, sulfonylureas, thiazolidinediones, or insulin can use semaglutide in combination.  However, patients can administer semaglutide and insulin injections at the same time and in the same areas of the body, but not close together; they must never mix them together in the same syringe.14 Hypoglycemic episodes are possible when using a sulfonylurea and/or insulin with semaglutide. Pharmacists therefore should remind patients of the signs and symptoms of hypoglycemia when these drugs are used together. Prescribers may need to adjust the dose of insulin and/or a sulfonylurea when starting semaglutide.6

       

      Obesity and Weight Management

      Affecting 70% of American adults, obesity and being overweight contribute to a variety of complications and have reduced quality of life.15 Debilitating and expensive disease states associated with obesity include: T2DM, cardiovascular disease, osteoarthritis, sleep apnea and cancer.13,15 Since obesity has roughly tripled worldwide from 1975 to 2016, investigating the reasons for the rise in prevalence and finding solutions is of utmost importance to prevent and treat obesity.16

       

      The access and ease of inexpensive prepared high caloric foods, limited physical activity, and sedentary life styles are factors that have contributed to the rise of obesity.17 As mentioned, treatment typically has concentrated around the modification of these lifestyle habits.18 Although the weight reduction is usually moderate in magnitude, it is recovered over time (yes, that means that people gain the weight back!).13

       

      Anti-obesity medications have been added to lifestyle modifications. Discouraged by adverse drug reactions, contraindications, cost, and moderate weight loss results with weight that is regained over time, many patients and prescribers are hesitant to consider these treatment options.16

       

      Maintaining weight loss has proved equally difficult due to the regulatory centers in the brain that control appetite. Increased hunger and abnormal satiety signals controlled by neuroendocrine pathways have been discovered in the hypothalamus.16 Researchers have also identified levels of hormones that regulate weight in the hypothalamus. These hormones (leptin, ghrelin, peptide YY, and GIP) play a role in counteracting weight loss after dieting and lead to regain of weight.17, 16

       

      Once semaglutide was approved for the treatment of diabetes, clinical trials focused on weight loss. The STEP trials were phase 3 studies implemented to evaluate the safety and efficacy of semaglutide 2.4 mg subcutaneously once weekly injections for 68 weeks. Patients enrolled in the studies were adults with obesity or overweight, a mean age of 46.2 to 55.3 years, mean BMI of 35.7 to 38.5 kg/m², and were mostly female (mean: 74.1% to 81.0%) for five of the trials.13All studies included lifestyle interventions at varied intensities.13, 18 In one of the larger studies that compared semaglutide with placebo, semaglutide was associated with a 12.4% loss of body weight.15As a result of the  ≥ 5% in weight loss exhibited in the studies, the FDA approved semaglutide for chronic weight management.18,15 The approval came in June of 2021, and the manufacturer marketed semaglutide as Wegovy.

       

      The STEP 8 trial compared once-weekly semaglutide to once-daily liraglutide and enrolled 338 adult patients with 126 receiving semaglutide 2.4 mg, and 127 participants receiving liraglutide 3 mg. Participants were overweight or obese, without diabetes, had a mean BMI of 37.5, and most had 0-2 comorbidities with dyslipidemia and hypertension being the most frequent.19, 18 The primary results at 68 weeks reported an estimated mean change in body weight at -15.8% with semaglutide, and -6.8% with liraglutide.19 Based on data from this STEP study, the researchers concluded semaglutide is far superior to liraglutide when used for weight loss and had significantly improved cardiometabolic risk factors.19, 18

       

      The most frequent adverse side effects reported in the STEP studies were gastrointestinal disorders. Most gastrointestinal side effects were considered mild or moderate in severity and usually were most prominent during the dose titration phase.19 In the STEP 8 study, semaglutide (84.1%) reported a higher occurrence of gastrointestinal events than liraglutide (82.7%).19  Other side effects reported were hypoglycemia, acute pancreatitis, gallbladder disorders that generally resulted in cholelithiasis (gall stones), malignant neoplasms (cancer), change in pulse and injection site reactions.18, 19

       

      SIDEBAR: Alcohol use disorder potential

      As patient use of semaglutide has expanded over the past several years, a side effect has emerged that is surprising many clinicians. Patients have reported an abrupt loss in the desire to drink alcohol, almost to the point of repulsion for some patients. GLP-1RAs are known to decrease the desire, enjoyment, and consumption of fatty foods in humans, but observations that patients began to decrease alcohol consumption was unexpected. Although studies to date have observed a reduction of alcohol in rats, mice, and monkeys when receiving GLP-1RAs, reliable researchers avoid extrapolating results from animal studies directly to humans, especially since humans tend to consume more alcohol than animals.20 Since several patients have reported decreased intake of alcohol and data from animal models reflect these results, researchers are starting to investigate GLP-1RAs effect on patients who have alcohol use disorder (AUD).

       

      Existing studies on GLP-1RAs effect on AUD in humans are minimal. A recent study published from Denmark compared the use of a different GLP-1RA, exenatide 2 mg versus placebo in patients with AUD. Researchers were looking to determine if exenatide reduced the amount of heavy drinking days. At the same time, functional MRI brain scans were also completed during the study that focused on areas involved in addiction and reward centers of the brain. Administered once weekly to 127 patients along with cognitive behavior therapy for 26 weeks, exenatide failed to show a decrease in heavy drinking days.21  However, in a subgroup of obese patients (BMI > 30 kg/m2) heavy drinking days and total alcohol intake was reduced.21 Brain scans revealed weakened alcohol cue reactivity and lower dopamine transporter availability for those patients in the exenatide group.21

       

      Ongoing phase two clinical trials are studying the effects of semaglutide on patients with AUD.22 Since semaglutide usage and availability have increased with approved indications for diabetes and obesity, researchers are continuing to investigate this drug class for potential promising new therapies.

       

      Product information

      When used for chronic weight management, semaglutide (Wegovy) is approved in addition to a reduced calorie diet and increased physical activity.7, 15 Semaglutide is indicated for patients who meet one of the following criteria: BMI of 30 kg/m² or greater, or patients who have a BMI of 27 kg/m² with at least one comorbid weight related condition (cancer, cardiac disease, diabetes, dyslipidemia, obstructive sleep apnea).7, 15 Available in a prefilled pen that contains one dose, semaglutide is a clear and colorless liquid that can be injected into the upper arm, lower stomach or upper thigh.7 Semaglutide should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C).7 If the pen has been frozen, exposed to light, or heat above 86°F (30°C), the pen should be discarded. The pen remains stable and active for 28 days once removed from refrigeration. Each pen contains the exact dose to be delivered with the needle located inside each pen, therefore each pen should be disposed of in a sharps container.7

       

       

      Drug shortages, alternatives for therapy

      Shortly after marketing Wegovy, the facility hired by Novo Nordisk to fill syringes was cited by the FDA for issues with current good manufacturing processes.23, 24 As a result, deliveries and manufacturing of Wegovy was halted in December of 2021.24 At the same time, staggering demand for the drug was reported by the manufacturer mainly due to news and social media platforms announcing the success of several celebrity weight loss stories. As a result of the Wegovy shortage, prescribers started to write for Ozempic off label in an effort to treat obesity and therefore depleted the supplies of Ozempic.24 At the end of 2022 and early 2023, Novo Nordisk announced that supply issue resolution for Wegovy was on the horizon and that production of the drug was being increased. Due to residual and increasing demand though, some supply issues might continue sporadically but over time distribution centers and pharmacies should receive more drug product in the months ahead.25

       

      CONCLUSION

      Probably the first drug to be considered a social media sensation, semaglutide’s entrance into the realm of prescription weight loss treatments has been filled with anticipation, fame, demand, intrigue, and acceptance. Lifestyle management will continue to play a role in losing and maintaining weight loss, with or without a GLP-1RA used in treatment for weight management. Long term use of semaglutide seems to be necessary to maintain a healthy weight but more research is necessary. Gastrointestinal side effects are seen as the most prevalent adverse effect, leading some patients to discontinue the drug. As availability of semaglutide increases due to resolution of the issues that halted production, price, and lack of coverage by insurance plans continues to be problematic for some patients. This is an area where pharmacy technicians can help by looking for coupons or patient assistance programs.

       

      Researchers continue to investigate the various effects seen as a result of usage of semaglutide. Investigators are hopeful of finding new treatments for patients that are struggling with alcohol use disorder and addictive behaviors. GLP-1RAs will continue to be in the headlines for years to come. Pharmacists and technicians hold the golden ticket of information by helping patients and providers understand this unique class of medication’s history, mechanism of action, dosing, side effects, storage requirements, pricing and potential treatments being investigated.

       

       

      Pharmacist Post Test (for viewing only)

      Pharmacist Post-test

      After completing this continuing education activity, technicians will be able to
      • Recall the mechanism of action and dosing schedule of GLP-1 receptor agonists
      • Classify adverse reactions most commonly associated with GLP-1 receptor agonists
      • Discuss FDA approved and off-label therapeutic uses of GLP-1 receptor agonists

      1. What are the GLP-1RAs’ common mechanisms of action in the treatment of diabetes?
      A. Stimulate central glucose receptors to secrete insulin, suppress the action of glucagon, and decrease gastric emptying
      B. Stimulate the pancreas to secrete insulin, suppress the action of glucagon, and decrease gastric emptying
      C. Suppress the pancreas so insulin secretion decreases, increase the action of glucagon, and speed gastric emptying

      2. Why do patients who take GLP-1RAs eat less?
      A. GLP-1RAs influence specific areas of the hypothalamus that are key to controlling appetite
      B. GLP-1RAs influence specific areas of the medulla that are key to controlling appetite
      C. GLP-1RAs influence specific areas of the GI tract that are key to controlling appetite

      3. Which of the following is a common adverse reaction associated with GLP-1RAs?
      A. Vasovagal reaction
      B. Blurred vision
      C. Gastrointestinal upset

      4. Joey is a 44 year-old-man who comes to the pharmacy and says that he is experiencing flatulence and burping ever since he started his GLP-1RA. Which of the following do you
      suggest as a way to mitigate this adverse effect?

      A. Reschedule the dose to take it right before bedtime
      B. Recommend a probiotic with Lactobacillus
      C. Avoid high fat foods and alcoholic beverages

      5. Which of the following GLP-1RAs are approved by the Food and Drug Administration for weight loss?
      A. Semaglutide and liraglutide
      B. Dulaglutide and semaglutide
      C. Only semaglutide

      6. Which of the following would be considered an off-label use of a GLP-1RA?
      A. Weight loss in patients with T2DM, used in combination with diet and exercise to reduce blood sugar levels
      B. Weight loss in patients who need to lose 10 pounds quickly to fit into Marilyn Monroe’s size 12 dress
      C. Weight loss in patients who have a BMI greater than 27 kg/m² with at least one weight-related comorbid condition

      Pharmacy Technician Post Test (for viewing only)

      Social Media Sensation: Semaglutide

      After completing this continuing education activity, technicians will be able to
      • Identify the different formulations of GLP-1 receptor agonists
      • Classify storage requirements for GLP-1 receptor agonists
      • Review GLP-1 receptor agonists indications for use

      1. Which of the following GLP-RA is injected once daily?
      A. Semaglutide, (Ozempic)
      B. Semaglutide, (Wegovy)
      C. Liraglutide, (Saxenda)

      2. A patient presents a prescription for Wegovy 0.5 mg. Checking the refrigerator, the place for Wegovy is empty. You notice Saxenda is in stock and you have Ozempic 0.5 mg and 1 mg in stock. What is your best response?
      A. We have Ozempic 1 mg pens in stock and I can have the pharmacist check and fill today
      B. We have Ozempic 0.5 mg in stock but we need a new prescription for Ozempic from your prescriber
      C. We have Saxenda in stock, we can have that ready later today

      3. Semaglutide should be discarded when exposed to which of the following conditions?
      A. Exposed to light or the pen was frozen
      B. Refrigeration between 36-46 °F
      C. Room temperature for up to 28 days

      4. Sharon calls the pharmacy and informs you that she has used her GLP-1RA pen this morning but wants to know how she should dispose of the pen. What is the correct response?
      A. At a drug take-back event
      B. In a sharps container
      C. In the trash

      5. Semaglutide is approved for weight loss in patients who have a BMI of what level?
      A. BMI between 27-30 kg/m² with two comorbid conditions
      B. BMI less than 25 kg/m² who has depression
      C. BMI greater than 30 kg/m² alone or 27 kg/m² with one comorbid condition

      6. Which of the following would be considered an off-label use of a GLP-1RA?
      A. Weight loss in patients with T2DM, used in combination with diet and exercise to reduce blood sugar levels
      B. Weight loss in patients who need to lose 10 pounds quickly to fit into Marilyn Monroe’s size 12 dress
      C. Weight loss in patients who have a BMI greater than 27 kg/m² with at least one weight-related comorbid condition

      References

      Full List of References

      REFERENCES

      1. Creutzfeldt, W. The [pre-] history of the incretin concept. Regulatory Peptides. 2005;128:87-91.
      2. Holst JJ, Gasbjerg LS, Rosenkilde MM. The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology. 2021;162(7). doi:10.1210/endocr/bqab065
      3. Exendin-4: From lizard to laboratory...and beyond. National Institute on Aging. July 11, 2012. Accessed April 3, 2023. https://www.nia.nih.gov/news/exendin-4-lizard-laboratory-and-beyond
      4. Nauck M, Quast D, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism. 2021; 46. https://doi.org/10.1016/j.molmet.2020.101102
      5. Blakeslee, S. A Protein Tells Eaters To Stop. The New York Times Jan 4, 1996 Section A, Page 1.
      6. OZEMPIC (semaglutide) injection, for subcutaneous use. Novo Nordisk. October 2022. Accessed March 22, 2023. https://www.ozempic.com/prescribing-information.html
      7. WEGOVY (semaglutide) injection, for subcutaneous use. Novo Nordisk. June 2021. Accessed March 22, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
      8. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-19. doi:10.1080/00325481.2021.2002616
      9. Sullivan K, Some people taking weight loss drugs say they're experiencing hair loss. April 22, 2023. Accessed April 27, 2023. https://www.nbcnews.com/health/health-news/weight-loss-drugs-and-hair-loss-rcna79798
      10. Johnson A. ‘Ozempic Face’ Explained: Why It Happens And How To Fix It. February 1, 2023. Accessed February 22, 2023. https://www.forbes.com/sites/ariannajohnson/2023/02/01/ozempic-face-explained-why-it-happens-and-how-to-fix-it/
      11. Speckhard Pasque L. Let’s stop using the term “Ozempic face.” February 10, 2023. Accessed March 22, 2023. https://mcpress.mayoclinic.org/women-health/lets-stop-using-the-term-ozempic-face/
      12. Constantino, A. People taking obesity drugs Ozempic and Wegovy gain weight once they stop medication. March 29, 2023.  Accessed April 3, 2023. https://www.cnbc.com/2023/03/29/people-taking-obesity-drugs-ozempic-and-wegovy-gain-weight-once-they-stop-medication.html
      13. Kushner R, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the step trials 1 to 5. Obesity. 2020; (6):1050-1061. doi: 10.1002/oby.22794
      14. Drug Trial Snapshot: Ozempic. US Food & Drug Administration. Published August 20, 2020. Accessed April 12, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic
      15. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. U.S. Food and Drug Administration. Published June 4, 2021. Accessed April 18, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
      16. Obesity and overweight. World Health Organization. Published June 9, 2021. Accessed April 18, 2023. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
      17. Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Advances in Therapy. 2021;38(6):2821-2839. doi:10.1007/s12325-021-01710-0
      18. Alabduljabbar K, Al-Najim W, le Roux CW. The impact once-weekly semaglutide 2.4 mg will have on clinical practice: a focus on the STEP trials. Nutrients. 2022;14(11):2217. Published 2022 May 26. Assessed April 20, 2023. doi:10.3390/nu14112217
      19. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA.2022;327(2):138–150. doi:10.1001/jama.2021.23619
      20. Blum D, Some people on Ozempic lose the desire to drink. Scientists are asking why. February 24, 2023. Accessed May1, 2023. https://www.nytimes.com/2023/02/24/well/eat/ozempic-side-effects-alcohol.html#:~:text=Side%20Effects%3A%20Diabetes%20treatments%20like,can%20also%20take%20a%20toll.
      21. Klausen MK, Jensen ME, Moller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022. 7(19). doi: 10.1172/jci.insight.159863.
      22. Hendershot C, Semaglutide for alcohol use disorder. NIH Clinical Trials.gov. Indentifier:NCT05520775
      23. Wegovy® supply update, investor conference call. Novo Nordisk. Dec 2021. Accessed: April 25, 2023. https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2021/conference-call-supply-update-20Dec2021.pdf
      24. Goodman B, As the market for new weight loss drugs soars, people with diabetes pay the price. December 28, 2022. Accessed April 25, 2023. https://www.cnn.com/2022/12/28/health/weight-loss-diabetes-drug-shortages/index.html
      25. Lovelace Jr B, Supply of weight loss drug Wegovy expected to improve in next few months, company says. February 1, 2023. Accessed April 25, 2023. https://www.nbcnews.com/health/health-news/supply-weight-loss-drug-wegovy-expected-improve-months-company-says-rcna68572

       

       

      The Gall of it All: Gallbladder Disease

      Learning Objectives

        After completing this application-based continuing education activity, pharmacists will be able to
      1. DESCRIBE the functions of the gallbladder and how it aids digestion
      2. RECOGNIZE gallbladder disease based on various presentations
      3. EXPLAIN gallstone prevalence, risk factors, and pathogenesis
      4. DISCUSS treatment approaches for gallbladder disease and post-cholecystectomy management
      After completing this application-based continuing education activity, pharmacy technicians will be able to:
      1. DESCRIBE the functions of the gallbladder and how it aids digestion
      2.EXPLAIN gallstone prevalence, risk factors, and pathogenesis
      3. LIST over-the-counter medications used by patients with gallbladder disease and post-cholecystectomy
      4. IDENTIFY when to refer patients with questions about gallbladder disease to a pharmacist

      Cartoon image of gallbladder filled with stones

      Release Date:

      Release Date:  June 15, 2023

      Expiration Date: June 15, 2026

      Course Fee

      FREE

      There is no funding for this CPE activity.

      ACPE UANs

      Pharmacist: 0009-0000-23-019-H01-P

      Pharmacy Technician: 0009-0000-23-019-H01-T

      Session Codes

      Pharmacist:  23YC19-ABC92

      Pharmacy Technician:  23YC19-BCA36

      Accreditation Hours

      2.0 hours of CE

      Accreditation Statements

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-019-H01-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

       

      Disclosure of Discussions of Off-label and Investigational Drug Use

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Faculty

      Sara L. Tolliday, PharmD
      Pharmacy Team Lead
      Wentworth-Douglass Hospital
      Outpatient Pharmacy
      Dover, NH


       

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Dr. Tolliday has no financial relationships with ineligible companies.

      ABSTRACT

      The gallbladder—a member of the biliary system—is responsible for bile secretion into the digestive tract. It was more useful centuries ago when the human diet was largely carnivorous and high in fat, its role in digestion today is less essential. This makes removal of the organ to treat gallbladder disease (GBD) quite commonplace. Although surgery is first line GBD treatment, pharmacy teams should remain involved in care for patients with this condition. Pharmacy involvement is especially important post-gallbladder removal. This continuing education activity describes the function of the gallbladder, risk factors for and pathogenesis of GBD, treatment approaches for GBD, and how to optimize care for patients with the disease and post-gallbladder removal.

      CONTENT

      Content

      INTRODUCTION

      Gallbladder disease (GBD; see Sidebar: Types of Gallbladder Disease) is the most common surgical emergency, responsible for 600,000 surgeries per year in the United States.1 Cholelithiasis, or gallstones, is one of the most common and costly gastrointestinal diseases, affecting more than 20 million Americans annually.2 An estimated 115 of every 100,000 of the world’s population will undergo gallbladder removal surgery every year.3

      GBD is influenced by genetic and environmental factors, diet, physical activity, and nutrition. The healthcare team should encourage patients to incorporate healthy habits into their lifestyles to reduce the risk of GBD. This continuing education activity will discuss GBD pathology, risk factors, treatment, considerations post-cholecystectomy, and the pharmacy team’s role.

       

      GALLBLADDER DISEASE

      The Gallbladder

      The gallbladder is the small pear-shaped organ located in the right upper quadrant (RUQ) of the abdomen beneath the liver. It is part of the biliary system, which is a series of ducts in the liver, gallbladder, and pancreas that drain into the small intestine.4 The gallbladder acts as a storage pouch for up to 50 mL of bile, also known as “gall.”5 Gall became a synonym for bile in the Middle Ages and also meant “embittered spirit.”5 In the late 19th century, gall was used to describe a person having boldness or insolence.4

      Bile is a yellowish-brown alkaline surfactant (substance that decreases surface tension) continuously produced by the liver.1,2 It is composed of cholesterol, bilirubin, water, bile salts, phospholipids, and ions. The common bile duct carries bile from the liver to the gallbladder. Fatty foods and proteins released from the stomach into the small intestine stimulate the gallbladder to empty bile into the duodenum via the sphincter of Oddi, which facilitates digestion. Bile salts emulsify lipids in the intestines allowing absorption of dietary fats such as cholesterol and fat-soluble vitamins. Unused bile salts return to the gallbladder through the distal ileum and portal circulation.1,2

      The gallbladder was probably more valuable centuries ago.5 Primitive humans were carnivorous hunters; meals were large, few, and far between.5 The gallbladder would have been crucial for digestion of large, high fat meals. The organ wasn’t considered nonessential until the late 1600s, after two Italian doctors discovered that animals could thrive without it.1 This discovery was forgotten until a German physician successfully performed the first cholecystectomy (surgical removal of the gallbladder) in a human in 1878.1,6 Figure 1 describes a brief history of the gallbladder, gallstones, and cholecystectomy beginning in the 15th century.

      Today, the gallbladder assists in digestion of fat-soluble vitamins, proving important even for vegetarians.5 People can still live a healthy life after gallbladder removal; however, the risk of hepatic problems increases due to impaired fat digestion.5

       

      Timeline of gall bladder surgical history from the 1400's to 1992

      Sidebar: Types of Gallbladder Disease2,8

      • Biliary dyskinesia: gallbladder motility disorder caused by scarring or spasm of sphincter of Oddi, the valve that controls the flow of biliary and pancreatic secretions into the duodenum
      • Cholangitis: inflammation of the biliary system
      • Cholecystitis: inflammation of the gallbladder
      • Choledocholithiasis: common bile duct stones
      • Cholelithiasis: gallstones
      • Gallbladder empyma: severe acute cholecystitis, a surgical emergency
      • Gallbladder pancreatitis: inflammation of the pancreas caused by pancreatic duct obstruction by a gallstone
      • Gallbladder perforation: a hole in the gallbladder wall
        • Acute: generalized biliary peritonitis
        • Subacute: acute plus pericholecystic abscess
        • Chronic: cholecystoenteric fistula
      • Gallbladder polyps: overgrowths or lesions in the gallbladder wall

      This continuing education activity will focus on gallstones and their complications, which may include cholecystitis, choledocholithiasis, and cholangitis. Cholecystectomy (gallbladder removal) is the treatment mainstay for gallstones and pharmacist intervention is most valuable post-cholecystectomy.

       

      Gallstones and Acute Cholecystitis

      The most common gallbladder disease is gallstones.7 Gallstones commonly form from imbalances in bile constituents and biliary sludge (solids precipitated from bile) caused by slowed gallbladder motility or altered hepatic cholesterol metabolism. Hardened cholesterol or bilirubin become saturated in bile and crystalize, like rock candy, and can lodge in the common bile duct.7 Gallbladder hypomotility leads to delayed emptying, resulting in the formation of biliary sludge and consequently, gallstones.7

      Bilirubin is a substance found in bile resulting from red blood cell breakdown in the liver. It is normally eliminated through the feces. Gallstones caused by bilirubin, or “pigment stones”, are rare and only account for approximately 10% of all gallstones.8 Pigment stones are commonly seen in individuals with blood disorders, such as sickle-cell anemia.8 Approximately 75% of gallstones in Western countries contain cholesterol as their major component.9

      The presence of stones in the gallbladder is called cholelithiasis. Most patients with gallstones are asymptomatic and may not have any attributable symptoms during their lifetime.8 Asymptomatic cholelithiasis does not require treatment as the risk of symptom development is only about 10% at five years.8

      Cholelithiasis becomes acute cholecystitis when gallstones block the cystic duct, causing the gallbladder to become inflamed and patients to become symptomatic. Biliary pain—also known as biliary colic—is the most common symptom of cholecystitis. Epigastric (upper-middle abdomen) pain lasting from 30 minutes to several hours radiates around or through the back and may be accompanied by heartburn, bloating, nausea, and/or vomiting. The sharp, stabbing pain generally follows food intake and peaks after the first hour. It is characteristically steady and is severe enough to interfere with activities of daily living. The pain is not relieved with a bowel movement. Women often describe biliary pain as being worse than childbirth.2,8

      Cholecystitis pain from an acute episode usually subsides over one to five hours as the stone dislodges.3,10 The likelihood that patients experience repeated symptomatic episodes from their gallstones is approximately 38% to 50% annually.8 More than 90% of patients presenting with a single episode of biliary colic have recurrent pain within 10 years.13

      Ultrasound is the best test for diagnosing gallstones and finds most patients with an average of two to 20 stones. The record-setting number of stones was found in England in 1987; a female patient had 23,530 stones removed.5 Computerized tomography (CT) can also be used for diagnosis, but it is less accurate than other imaging methods, detecting approximately 75% of gallstones.2 Providers can also diagnose by the presence of Murphy’s sign, or pain upon inhalation when the inflamed gallbladder meets the examiner’s hand.8 Other diagnostic markers include elevated liver function tests, white cell count, erythrocyte sedimentation rate, and C-reactive protein.8 Patients presenting with acute cholecystitis may have experienced several bouts of biliary colic before diagnosis.

      Acute cholecystitis diagnosis typically requires admission for pain management and intravenous (IV) fluid rehydration. Nonsteroidal anti-inflammatory drugs (NSAIDS) like ketorolac, diclofenac or indomethacin combat inflammation and promote speedy recovery.8 NSAIDS are generally preferred to narcotic analgesics as they are equally effective with fewer adverse effects.2 A study of 324 patients given IV ketorolac or meperidine showed both drugs offered similar pain relief but patients in the NSAID group reported fewer adverse effects.2 Patients receive broad-spectrum antibiotics (e.g., ciprofloxacin, cefuroxime) to prevent or treat bacterial infection.8

      Failure to properly treat cholecystitis can lead to severe inflammation, gangrene, sepsis, and life-threatening gallbladder perforation. Cholecystitis can also lead to gallstone pancreatitis if stones in the sphincter of Oddi are not cleared and block the pancreatic duct.2

      Chronic Cholecystitis

      Repeated episodes of cholecystitis or chronic irritation from gallstones can lead to chronic cholecystitis.11 Chronic cholecystitis more often presents with cholelithiasis (calculous) but can also exist without gallstones (acalculous). Symptomatic patients usually present with dull RUQ pain that radiates around the waist to the middle back. Most patients are afebrile.11

      While acute cholecystitis symptoms are sharp and abrupt, chronic cholecystitis symptoms usually develop and worsen over weeks to months.11 Lab values normally elevated in acute disease may not be in chronic disease and therefore cannot be used in diagnosis. Ultrasound of the RUQ is the best diagnostic tool to evaluate the gallbladder for wall thickening and inflammation. Elective cholecystectomy is the preferred treatment for chronic cholecystitis. Patients who are not eligible for or who prefer not to undergo surgery should be closely monitored. A low-fat diet and other lifestyle modifications can help reduce symptom frequency.11

      Pharmacists should recognize the differences between presentations of acute versus chronic cholecystitis and refer patients to the nearest emergency department if symptoms are severe.

      Choledocholithiasis and Cholangitis

      Choledocholithiasis, or common duct stones, are gallstones that have migrated from the gallbladder to the common bile duct via the cystic duct. Approximately 8% to 16% of patients with symptomatic gallstones will also have common bile duct stones.8 Common duct stones can be asymptomatic or may lead to complications such as gallstone pancreatitis or acute cholangitis. Cholangitis is inflammation of the biliary system that causes fever, jaundice, and abdominal pain (Charcot triad).8 Charcot triad becomes Reynolds pentad when hypotension and altered mental state are also present.8 These symptoms develop due to bile stasis and bacterial infection in the biliary tract.

      Cholangitis is most commonly caused by gram-negative (Escherichia coli [25% to 50%], Klebsiella spp. [15% to 20%], Enterobacter spp. [5% to 10%]) intestinal bacteria, and less often by gram-positive bacteria (Enterococcus spp. [10% to 20%]).8 Patients require prompt treatment with IV antibiotics such as a broad-spectrum cephalosporin or ciprofloxacin.8 Pharmaceutical intervention should be followed by stone removal to prevent septicemia (systemic blood infection), which can be fatal.  Most clinicians recommend that common bile duct stones be removed once discovered, even when asymptomatic.8

      Risk Factors

      Several genetic and environmental factors contribute to gallstone development. Patients with first-degree relatives with history of cholelithiasis are at a three times higher risk of gallstones.8 Approximately 60% of patients with acute cholecystitis are female, but the illness is generally more severe in males.2 Women experience a higher prevalence because of estrogen’s effects on cholesterol metabolism.12 Estrogen increases cholesterol synthesis and decreases bile acid production.12 Progesterone in pregnancy decreases gallbladder contractility leading to stasis, making gallstones 10 to 15 times more common in women who have been pregnant.8,12 Women with history of biliary colic, gallstones, and the like should be aware of how hormones may affect their risk for recurrence. This is valuable information for pharmacists to consider and an appropriate place to intervene and educate.

      European and American populations are more likely to develop gallstones, and Black people of African descent are least likely. Prevalence is highest in Native American populations, with 60% incidence in the Pima Indian populace of southern Arizona.8 Table 1 summarizes risk factors for GBD.2,8,13

       

      Table 1. Risk Factors for Developing Gallbladder Disease2,8,14-16
      Demographics

      ·       Ethnicity (American Indians, Chilean and Mexican Hispanics)

      ·       Family history

      ·       Female gender (10:1 female:male)

      ·       Older age

       

      Diet

      ·       High fat, calorie, and refined carbohydrate intake

      ·       Low fiber and unsaturated fat intake

      ·       Total parenteral nutrition

       

      Lifestyle

      ·       Pregnancy and multiple pregnancies

      ·       Persistent fasting or very low-calorie diet

      ·       Rapid weight loss (i.e., bariatric surgery)

      ·       Sedentary

       

      Medications

      ·       Estrogen therapy or oral contraceptives

      ·       Some hypoglycemic medications (GLP-1RAs)

      ·       Chronic use of gastric acid suppressants (H2RAs, PPIs)

      ·       Ketamine abuse

       

      Heath Conditions & Other Factors

      ·       Alcoholic liver cirrhosis

      ·       Dyslipidemia (elevated triglycerides and low HDL)

      ·       Gallbladder motor dysfunction

      ·       Gastrointestinal surgery

      ·       Metabolic syndrome, gallbladder, or intestinal stasis

      ·       Short bowel syndrome

      ·       Type 2 diabetes mellitus

       

      GLP-1RAs, glucagon-like peptide 1 receptor agonists; H2RAs, histamine-2-receptor antagonists; HDL, high-density lipoprotein; PPIs, proton-pump inhibitors.

       

      Glucagon-like peptide 1 (GLP1) receptor agonists (GLP-1RAs) are notable for their glucose control and cardiovascular risk reduction for patients with type 2 diabetes mellitus and more recently, for weight loss. Their link to GBD is controversial as GLP1 inhibits gallbladder motility and delays gallbladder emptying.14 A recent systematic review and meta-analysis of 76 randomized clinical trials shows an association between GLP-1RA use and elevated GBD risk. The risk for gallbladder or biliary diseases were more prominent with higher doses, longer duration, and when used for weight loss.14 Clinicians should discuss the benefits of using these hypoglycemics for type 2 diabetes or weight loss and whether they outweigh the risk for GBD. Pharmacists can educate patients initiating GLP-1RAs about their benefits, risks, and implications with past medical history of or additional risk factors for GBD. Multiple GLP-1RAs are available in varying doses and pharmacists should continue to counsel patients as doses are increased over time.

      Chronic use of gastric acid suppressants may cause cholelithiasis.15 These drugs impact gut microbiome and may slow gallbladder motility leading to delayed gallbladder emptying. A recent prospective cohort of 0.47 million participants found that regular use of proton-pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) resulted in increased cholelithiasis risk.15 Physicians should be aware of this association when prescribing these medications, especially for patients requiring long-term use or those already at high risk for gallstones. Pharmacists should keep these risks in mind when filling prescriptions for their patients on long-term or high-dose H2RAs and PPIs.

      Ketamine abuse has been associated with chronic biliary colic. Ketamine was developed in 1962 as an anesthetic.16 “Street ketamine”, a close analogue of ketamine, is commonly used for its euphoric effects. Ketamine’s onset of action after oral ingestion is about ten minutes and its hallucinogenic effects are short acting, lasting up to two hours. The most common signs of ketamine abuse are hypertension, tachycardia, and abdominal tenderness. Ketamine abuse is also associated with impaired consciousness, dizziness, abdominal pain, and lower urinary tract symptoms.16 Case reports have shown ketamine abusers presenting with severe bladder dysfunction and recurrent episodes of epigastric pain due to a dilated common bile duct not associated with gallstones.16 Clinicians should collect detailed drug histories for patients presenting with recurrent abdominal pain, namely biliary colic.

      Diets characterized by increased caloric intake with highly refined sugars, high fructose, low fiber, high fat, and consumption of fast food increase the risk of gallstone formation.9 Nutrition and lifestyle changes may be beneficial in the prevention of gallstones. Increased physical activity, consuming smaller more frequent meals, and “heart healthy” diets low in cholesterol and fat and high in fiber can reduce risk of cholelithiasis.7 Fat should not be completely cut out of the diet as too little fat can also precipitate gallstone formation.

      Weight loss can reduce gallstone risk, but rapid weight loss achieved by low-calorie diets (less than 800 kcal/day) or bariatric surgery can cause gallstones.2,9 Patients should seek professional advice before starting diets promoting very low caloric or high fat intake to achieve rapid weight loss (i.e., Atkins, ketogenic). Pharmacists should be aware of patients who have recently undergone bariatric surgery or are taking drugs or supplements for weight loss. These patients may be at a higher risk for gallstones, especially those with past medical histories of GBD or abdominal colic symptoms.

      Some foods and medications seem to be associated with a reduced risk of gallstones:

      • Statins alter bile cholesterol and thus affect gallstone formation, suggesting a role in prevention. While the relationship between statins and gallstone formation is conflicting, studies report reduction in symptomatic gallstone disease with statin use.17
      • Ezetimibe, a selective NPC1L1 inhibitor, has been associated with a reduced incidence of cholesterol gallstones in animal studies. The mechanism involves reduced amounts of absorbed cholesterol, decreasing biliary cholesterol saturation, and in turn, reduced rate of cholesterol gallstone formation.12
      • Vitamin C supplementation has been shown to reduce gallstone prevalence. Researchers have studied vitamin C supplementation’s effects in gallstone formation in guinea pigs; those deficient in vitamin C more often develop gallstones. An observational study of a randomly selected population in Germany (n = 2129) showed a positive correlation between regular vitamin C intake and a reduced gallstone incidence.18
      • Coffee consumption may also offer a protective effect against gallstone formation. Studies suggest coffee stimulates cholecystokinin release, enhancing gallbladder contractility, thereby reducing bile cholesterol crystallization. A 2019 observational analysis published in the Journal of Internal Medicine found a 23% decrease in gallstone formation in subjects consuming six or more cups of coffee daily.19
      • A small study conducted in Spain shows that regular consumption of olive oil containing monounsaturated and polyunsaturated omega-6 fatty acids may prevent gallstones. Similarly, fish (omega-3 fatty acids) and fish oil may reduce triglycerides and prevent gallstones. A group of participants with hypertriglyceridemia taking fish oil supplements for a seven-week study in the Netherlands experienced improved gallbladder motility and a decrease in triglycerides.10

      TREATING GALLBLADDER DISEASE

      Endoscopic retrograde cholangiopancreatography (ERCP) is the most common way to identify and remove common duct stones. ERCP is minimally invasive and carries the risk of acute pancreatitis.8 This diagnostic tool may also identify duct strictures at which time stents are placed to reduce obstruction and improve biliary flow.8,10 Timely stent removal (within three to six months) is crucial to prevent occlusion, stent migration, or cholangitis.22 Cholecystectomy is the definitive treatment for symptomatic gallstones and should commence within 48 hours of symptom onset during the acute inflammatory process, before tissue thickening or scarring develops.8,10

      Surgical Intervention: Cholecystectomy

      The first gallstone removal surgery was a coincidence. In the mid-19th century, a physician was performing investigative surgery on a female patient, and when he cut into her gallbladder, several bullet-like objects spilled out.5 The first planned gallbladder removal was performed 15 years later.5 Before the early 1900s, the surgery was performed through an incision in the RUQ (Kocher’s incision, named after Emil Theodor Kocher, a Swiss physician and medical researcher who performed the first successful cholecystectomy in 1878).6,8 This invasive procedure was outmoded a few years after Erich Muhe, a German surgeon, performed the first laparoscopic cholecystectomy in 1985.8 Today, surgeons perform more than 98% of cholecystectomies laparoscopically, over 70% of which are outpatient day surgeries.8

      Cholecystectomy is associated with fewer gallbladder-specific complications and shorter length of hospital stay when surgery is elective or performed as a single emergency visit without previous surgical admissions.3 A population-based cohort study of outcomes following surgery for benign GBD showed poorer outcomes and risk of readmissions with delayed cholecystectomy. Many studies define emergency or early surgical intervention as operations performed within 48 to 72 hours of symptom onset. A study of 14,200 patients in Canada discovered patients experienced fewer complications when surgery was performed within seven days of hospital admission.3 These studies show value in offering emergency surgery over delaying cholecystectomy for patients presenting with benign GBD.3

      Antibiotic prophylaxis is not routinely recommended for low-risk patients undergoing elective laparoscopic cholecystectomy.13 High-risk patients (age older than 60, type 2 diabetes, acute colic within 30 days of surgery, jaundice, acute cholecystitis, or cholangitis) may benefit. Providers should limit prophylaxis to IV cefazolin 1 g as a single dose one hour prior to surgery.13

      Several studies suggest that pain management before or during, and after laparoscopic cholecystectomy can reduce post-operative pain. A 2018 review of 258 randomized control trials recommended a basic analgesia technique: acetaminophen plus an NSAID or cyclooxygenase-2 inhibitor with local anesthetic infiltration.21 Opioids are reserved for breakthrough pain.21

      Patients are generally discharged a few hours after surgery. Surgeons should be on alert for early signs of complications if there is divergence from the usual course of rapid recovery post-op. Extreme pain shortly after surgery may indicate intra-peritoneal leakage of bile or bowel contents.8 Persistent hypotension (low blood pressure) and pain can suggest bleeding. Re-laparoscopy may be necessary to identify and repair these problems and is preferred to diagnostic imaging.8

      Removal of the gallbladder will not cause weight loss/gain or vitamin deficiencies. Patients should be able to tolerate foods they couldn’t before surgery, but providers should advise them to add those foods back into their diet very slowly. Following gallbladder removal, the liver will continue to make bile, but instead of storing it in the gallbladder, it will drain into the stomach and small intestines. Patients might experience three to five days of soreness post-op and are expected to fully heal within four to six weeks.7

      Diarrhea and bloating due to alternation of biliary flow are common short-term occurrences after surgery.22 A small percentage (1% to 2%) of patients will have loose stools each time they eat greasy or high-fat meals.7 A cystic duct remnant is also possible, potentially leading to stone formation, causing Mirizzi syndrome. Mirizzi syndrome is characterized by fever, jaundice, and RUQ pain due to common hepatic duct obstruction caused by compression from the impacted stone in the remnant cystic duct.22 Endoscopic removal of the stone may be adequate. In rarer cases, surgical excision of the remnant duct may be necessary to prevent further complications.22

      Pharmacologic and Other Non-Surgical Interventions

      Nonoperative methods exist for patients unwilling or unable to undergo surgical intervention. Contraindications for laparoscopic cholecystectomy include10,13

      • Absolute: gallbladder cancer (see Sidebar: Gallbladder Cancer), general anesthesia intolerance, giant gallstones, morbid obesity, uncontrolled bleeding disorder
      • Relative: advanced cirrhosis/liver failure, bleeding disorder, peritonitis, previous upper abdominal surgeries, septic shock

      Gallbladder Cancer20

      Gallbladder cancer is a rare malignancy but accounts for almost 50% of biliary cancers. Biliary cancers have a poor five-year survival rate and a high recurrence rate. Factors affecting prognosis are stage at discovery, tumor location, operability, response to chemotherapy, and presence and location of metastases. Early-stage gallbladder cancer may be curable with surgical resection.

       

      Oral bile acid dissolution drugs include ursodeoxycholic acid (ursodiol) and chenodeoxycholic acid (chenodiol).23 Table 2 lists dosing and adverse effects of these medications. Smaller gallstones (0.5 to 1 cm) may be better suited for pharmaceutical intervention but may take up to 24 months to dissolve.2 Ursodiol is preferred over chenodiol due to its safer adverse effect profile. Use-limiting adverse effects of chenodiol include dose-dependent diarrhea, hypercholesterolemia, hepatotoxicity, and leukopenia.2 Recurrence rate is more than 50% and fewer than 10% of patients with symptomatic gallstones are candidates for this treatment.13

       

      Table 2. Oral Bile Acids2,23,24

      Drug Dosage Duration Adverse Effects
      Ursodiol

      (Actigall)

      8-10 mg/kg/day given in 2-3 divided doses Symptom relief after 3-6 weeks, results may take 6-24 months, continue for 3 months after documented dissolution Dyspepsia (>10%), nausea, vomiting, pruritis, headache, diarrhea, dizziness, constipation
      Chenodiol (Chenodal) 250 mg twice daily for 2 weeks, increase dose by 250 mg/day weekly until maximum tolerable dose reached (13-16 mg/kg/day in 2 divided doses) Discontinue if no response by 18 months, safety not established beyond 24 months Dose-dependent diarrhea* (>10%), hypercholesterolemia, leukopenia, increased serum aminotransferase

      * If diarrhea occurs, reduce dose and restart at previous dose when symptoms resolve.

       

      Extracorporeal shock wave lithotripsy is a noninvasive option for symptomatic patients.13 Complications such as biliary pancreatitis and liver hematoma are rare, however stone recurrence is common. Recent studies show this procedure is beneficial for large pancreatic and common bile duct stones with similar pain relief and duct clearance outcomes compared to surgery.13

      The initial approach for pregnant women with symptomatic gallstones is supportive care.13 Meperidine is the choice agent for pain control as NSAIDs are not recommended in pregnancy.13 Chenodiol is contraindicated in pregnancy.24 Ursodiol has been used in pregnant patients for intrahepatic cholestasis; safety and efficacy of use for gallstones has not been studied.13,23 Laparoscopic cholecystectomy, when indicated, is safe in all trimesters.13

      POST-OPERATIVE CONSIDERATIONS AND THE PHARMACY TEAM

      Post-Cholecystectomy Syndrome

      Persistent or delayed onset abdominal pain after laparoscopic cholecystectomy may indicate post-cholecystectomy syndrome (PCS).22 Additional PCS symptoms include fatty food intolerance, nausea, vomiting, diarrhea, heartburn, indigestion, flatulence, and jaundice. PCS often occurs in the post-operative period but can present months or years after surgery.22 Cholecystectomy carries a low mortality risk, but approximately 10% of patients undergoing cholecystectomy each year develop PCS.22 The risk increases with urgent surgeries and 20% of patients will develop PCS regardless of choledochotomy (surgical incision of common bile duct).22

      PCS etiologies can be extra-biliary (pancreatitis, pancreatic tumors, hepatitis, esophageal diseases, mesenteric ischemia, diverticulitis, peptic ulcer disease) or biliary (bile salt induced diarrhea, retained calculi, bile leak, biliary strictures, stenosis, sphincter dyskinesia) in nature.22 Pathophysiology is related to alterations in bile flow and bile is the main trigger for patients with gastroduodenal symptoms or diarrhea.

      The likelihood of diarrhea post-cholecystectomy ranges from 2% to 50% according to various studies.25 Diarrhea usually improves or resolves over the course of weeks to months. As discussed, in the gallbladder’s absence, bile flows straight from the liver into the small intestine continuously. This redirection of bile flow can overwhelm the ileum’s capacity for reabsorption, leading to increased bile acids in the colon and subsequently cholerheic diarrhea (also known as bile acid diarrhea).25 Patients may respond to treatment with bile acid sequestrants, including cholestyramine and colestipol.25

      Bile acid sequestrants release chloride and bind bile acid in the intestines, preventing bile acid reabsorption. The drugs do not leave the gastrointestinal tract and are eliminated in the feces. They are indicated for hypercholesterolemia but patients use them off-label for chronic diarrhea due to malabsorption (Table 3). The most common adverse effect of bile acid sequestrants is constipation, which occurs in more than 10% of patients.26,27 Clinicians should instruct patients to drink plenty of fluid and increase dietary fiber. Most adverse effects are gastrointestinal-related (e.g., abdominal pain, flatulence, bloating, anorexia, nausea, vomiting, dysphagia), and others include26,27

      • Cholestasis and cholecystitis (with colestipol only)
      • Dental bleeding and caries
      • Diuresis, dysuria, and burnt odor to urine
      • Edema
      • Worsened hemorrhoids

      Bile acid sequestrants bind vitamin K and folate so prescribers should monitor for deficiencies of both. Patients should supplement with folate. Patients may supplement with vitamin K; however preexisting coagulopathy is a contraindication. These drugs should be used with caution in patients with renal insufficiency.26,27

       

      Table 3. Bile Acid Sequestrants26,27

      Drug Dosage Administration
      Cholestyramine

      (Prevalite, Questran)

      2-4 g daily as a single dose or divided, increase by 4 g weekly based on response and tolerability, maximum 24 g/day Mix dose in 60-180 mL of any beverage, soup, or pulpy fruit, should not be sipped or held in mouth for long periods*

       

      Take with meals, administer oral medications ≥1 hour before or 4-6 hours after dose

      Colestipol (Colestid) Granules: 5 g once or twice daily, increase by 5 g in 1-2 month intervals, maintenance dose 5-30 g once daily or in divided doses

       

      Tablets: 2 g once or twice daily, increase by 2 g in 1-2 month intervals, maintenance dose 2-16 g once daily or in divided doses

      Administer other medications ≥1 hour before or 4 hours after dose

       

      Granules: do not administer in dry form to avoid GI distress or accidental inhalation, should be added to at least 90 mL of any beverage, soup, or pulpy fruit

       

      Tablets: administer one at a time; swallow whole; do not cut, crush, or chew

      *May cause tooth discoloration or enamel decay. GI, gastrointestinal.

       

      PCS is a temporary diagnosis until further investigation establishes organic or functional diagnosis.22 Misdiagnosis of preexisting conditions is possible. The healthcare team should order a complete blood count and consider patients re-presenting with ongoing or new-onset abdominal pain post-cholecystectomy for CT scan.8 Presence of gas and fluid in the gallbladder bed may be normal but fluid or gas build-up elsewhere may indicate a bile leak. Elevated liver function tests may also suggest a bile leak or retained common bile duct stone. The most common cause of PCS is the presence of stones in the biliary tree.10 ERCP, both diagnostic and therapeutic, is the most common procedural approach to PCS.22

      Medication: Treatment Goals

      Pharmacologic treatment goals in GBD are to prevent complications and reduce morbidity.22 Administration of bulking agents like psyllium fiber can help patients with symptoms of irritable bowel syndrome (IBS) and/or diarrhea. Psyllium husk (Metamucil, Benefiber) is an over-the-counter (OTC) option for patients looking to increase fiber intake. It is usually used to treat constipation and works by stimulating intestinal contractility, speeding up the movement of stool through the colon.28 Psyllium can also treat diarrhea by soaking up excess water from the intestines, bulking stool, and promoting regularity.28 Psyllium may reduce absorption and effectiveness of many medications; it is important that patients seek pharmacist counseling before initiating a psyllium fiber regimen.

      Antispasmodics (e.g., loperamide) may help patients with IBS symptoms like cramping. Cholestyramine may help symptoms of diarrhea alone. Antacids (Maalox, Mylanta, Tums), H2RAs (e.g., famotidine), and PPIs (e.g., esomeprazole, lansoprazole, omeprazole) can improve gastritis or gastric reflux symptoms by reducing acid production.22 One study showed a correlation between dyspeptic symptoms and gastric bile salt; these patients may benefit from bile acid sequestrants.22 Patients should consult their gastroenterologist for recommended dosing of these drugs, as they may vary depending on clinical presentation and severity of symptoms.

      The Pharmacy Team’s Role

      Pharmacists and pharmacy technicians are integral members of the healthcare team. Pharmacists can educate patients about GBDs, the risk factors for their development, and how to mitigate them with a proper diet and exercise.

      Pharmacy technicians can help by directing patients in the right direction when looking for OTC antacids, fiber supplements, or anti-diarrheal agents. Many patients may not ask questions about OTC products before purchase. Pharmacy technicians are often the patients’ first point of contact in the pharmacy and should ask open-ended questions at the register before or during the transaction.

      Patients should use the products as directed by their gastroenterologists. Pharmacy technicians should refer patient questions relating to administration, dosing, adverse effects, and drug interactions to the pharmacist on duty. Consider possible scenarios that may arise in the pharmacy and how pharmacy technicians and pharmacists should approach them:

      • Mark is a pharmacy technician at XYZ Pharmacy. Jaclyn enters the pharmacy, approaches the pick-up window, and places several OTC items on the counter. She states she would like to pick up a prescription her doctor called in today. Mark retrieves Jaclyn’s prescription and notices it is for omeprazole 40mg. The items on the counter include Tums, famotidine 20mg, docusate sodium 100mg, and lansoprazole 30mg. Mark knows that omeprazole and lansoprazole are in the same drug class. What questions can Mark ask Jaclyn? Should Mark involve the pharmacist?
      • Jaclyn comes back to the pharmacy a week later to pick up a prescription for cholestyramine. She wants to know if she can take this with omeprazole and famotidine. Mark refers Jaclyn’s question to the pharmacist. How should the pharmacist respond to Jaclyn’s question and what counseling points are important to include?

      CONCLUSION

      Gallbladder diseases typically occur secondary to cholelithiasis. Most gallstone cases are asymptomatic, but some develop into symptomatic disease. Factors that may increase GBD risk include gender, age, family history, ethnicity, diet, and medical conditions. Surgical gallbladder removal is the most common treatment, but many nonsurgical alternatives exist when surgery is nonpreferred or contraindicated. Additionally, PCS can occur months to years after surgery and treatment should be directed based on specific diagnosis post-examination. Healthcare providers should collaborate to develop the best procedural and/or pharmaceutical treatment plan as each patient’s clinical presentation and symptoms will vary.

      The pharmacy team should take an active role in GBD management, especially following cholecystectomy. Pharmacy technicians should be weary when patients complain of abdominal pain or attempt to purchase multiple OTC products to treat their symptoms; they should relay specific disease- and drug-related questions to the pharmacist on duty. GBD is a common and highly manageable condition, and patients can live normal and healthy lives once symptoms are properly controlled and treated.

       

       

      Pharmacist Post Test (for viewing only)

      After completing this continuing education activity, pharmacists will be able to
      • DESCRIBE the functions of the gallbladder and how it aids digestion
      • RECOGNIZE gallbladder disease based on various presentations
      • EXPLAIN gallstone prevalence, risk factors, and pathogenesis
      • DISCUSS treatment approaches for gallbladder disease and post-cholecystectomy management

      1. How do gallstones form?
      A. Fat soluble vitamin deficiency
      B. Gallbladder hypermotility
      C. Imbalances in bile components

      2. Which of the following are risk factors for GBD?
      A. Female gender; high fat, high calorie, low fiber diet; and type 2 diabetes
      B. Female gender; low fat, high calorie, high fiber diet; and rapid weight loss
      C. Male gender; high fat, high calorie, low fiber diet; and type 2 diabetes

      3. MB is a 44-year-old female who presents to the emergency department with severe RUQ pain and nausea. She states this is the third time this year that she has presented to the ED with these symptoms. MB is admitted and the hospitalist starts her on IV fluids, acetaminophen, and ketorolac. Which of the following interventions is most appropriate?
      A. MB should also receive meperidine to manage her pain
      B. MB should undergo cholecystectomy within 72 hours of admission
      C. MB is at high risk for infection and should be given IV cefazolin for prophylaxis

      4. Gallstone recurrence is common with which of the following?
      A. Oral bile acid dissolution drugs
      B. Endoscopic retrograde cholangiopancreatography
      C. Asymptomatic cholelithiasis

      5. Which of the following is FALSE about gallbladder removal surgery?
      A. Patients should have higher tolerability for foods they could not tolerate before surgery
      B. Patients should supplement with fat soluble vitamins post-cholecystectomy
      C. Up to 50% of patients may experience diarrhea following cholecystectomy

      6. Why is diarrhea a common complication post-cholecystectomy?
      A. Overproduction of bile
      B. Vitamin deficiencies
      C. Altered biliary flow

      7. Which of the following statements is TRUE regarding the use of oral bile acid dissolution agents?
      A. They can cause vitamin K and folate deficiencies
      B. Chenodiol is preferred in pregnant women due to its safer adverse effect profile
      C. Fewer than 10% of symptomatic patients are candidates for treatment

      8. AP is a 37-year-old female, weighing 80 kg with symptomatic gallstones. She is not a candidate for laparoscopic cholecystectomy due to previous anesthesia intolerance. AP brings a prescription to the pharmacy for ursodiol 250 mg TID. How long will AP most likely need to take this medication?
      A. 3 to 6 weeks
      B. 6 months to 2 years
      C. 1 to 3 years

      9. KM is a 42-year-old female whose gastroenterologist recommends she try psyllium husk twice daily for her chronic diarrhea post-cholecystectomy. She seems confused when you hand her Metamucil because she thought it was used for constipation. What should you tell KM?
      A. Psyllium husk treats diarrhea by binding bile acids in the gut and excreting them in the stool
      B. Psyllium husk treats diarrhea by soaking up excess water in the intestines to bulk the stool
      C. Psyllium husk treats diarrhea by increasing intestinal contractility

      10. Which of the following is an appropriate counseling point for bile acid sequestrants?
      A. Their most common adverse effects are diarrhea and edema
      B. They are contraindicated in patients with uncontrolled bleeding disorders
      C. Take other oral medications at least 1 hour before or 4 hours after dose

      Pharmacy Technician Post Test (for viewing only)

      After completing this continuing education activity, pharmacy technicians will be able to
      • DESCRIBE the functions of the gallbladder and how it aids digestion.
      • EXPLAIN gallstone prevalence, risk factors, and pathogenesis.
      • LIST over the counter medications used often by patients with gallbladder disease and post-cholecystectomy.
      • IDENTIFY patient questions that need to be referred to a pharmacist.

      1. How do gallstones form?
      A. Fat soluble vitamin deficiency
      B. Gallbladder hypermotility
      C. Imbalances in bile components

      2. Which of the following are risk factors for GBD?
      A. Female gender; high fat, high calorie, low fiber diet; and type 2 diabetes
      B. Female gender; low fat, high calorie, high fiber diet; and rapid weight loss
      C. Male gender; high fat, high calorie, low fiber diet; and type 2 diabetes

      3. Gallstone recurrence is common with which of the following?
      A. Oral bile acid dissolution agents
      B. Endoscopic retrograde cholangiopancreatography
      C. Asymptomatic cholelithiasis

      4. Which of the following may reduce the risk of developing gallstones?
      A. Statins
      B. Oral contraceptives
      C. Ketogenic diet

      5. Why was the gallbladder more essential centuries ago?
      A. Humans consumed smaller meals containing less fat
      B. Humans consumed larger meals containing more fat
      C. Humans consumed meals containing more protein

      6. What is cholelithiasis?
      A. Gallstones caused by bilirubin
      B. The presence of stones in the gallbladder
      C. The presence of gallstones in the cystic duct

      7. Which of the following statements is TRUE regarding the use of oral bile acid dissolution agents?
      A. They can cause vitamin K and folate deficiencies
      B. Chenodiol is preferred in pregnant women due to its safer adverse effect profile
      C. Fewer than 10% of symptomatic patients are candidates for treatment

      8. How does psyllium husk help patients with diarrhea?
      A. Psyllium husk treats diarrhea by binding bile acids in the gut and excreting them in the stool
      B. Psyllium husk treats diarrhea by soaking up excess water in the intestines to bulk the stool
      C. Psyllium husk treats diarrhea by increasing intestinal contractility

      9. Which of the following patients should pharmacy technicians refer to a pharmacist?
      A. A patient holding a container of Metamucil and Fibercon fiber capsules and wants to know which contains psyllium
      B. A patient asking for help locating famotidine, which their gastroenterologist recommended for acid indigestion
      C. A patient who has failed several OTC therapies wants to know what to try for persistent diarrhea post-cholecystectomy

      10. Which of the following statements is TRUE regarding OTC products for patients with GBD and/or PCS?
      A. Antispasmodics like loperamide may help patients’ gastritis symptoms
      B. Famotidine can relieve gastritis symptoms by reducing acid production
      C. Patients can take an antacid like omeprazole to calm IBS symptoms

      References

      Full List of References

      1. Division of General Surgery. History of Medicine: The Galling Gallbladder. Columbia University Irving Medical Center, New York, NY; 1999-2022. Accessed April 26, 2022. https://columbiasurgery.org/news/2015/06/11/history-medicine-galling-gallbladder
      2. Afamefuna S, Allen SN. Gallbladder disease: Pathophysiology, diagnosis, and treatment. US Pharm.2013;38(3):33-41. https://www.uspharmacist.com/article/gallbladder-disease-pathophysiology-diagnosis-and-treatment
      3. CholeS Study Group, West Midlands Research Collaborative, et al. Population‐based cohort study of outcomes following cholecystectomy for benign gallbladder diseases. [published correction appears in Br J Surg. 2018 Aug;105(9):1222]. Br J Surg. 2016;103(12):1704-1715. doi:10.1002/bjs.10287
      4. Jones MW, Small K, Kashyap S, Deppen JG. Physiology, Gallbladder. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 8, 2022.
      5. 5 surprising truths about the gallbladder. Surgical Consultants of Northern Virginia; Reston, VA. 2023. PatientPopInc. Accessed September 21, 2022. https://www.scnv.com/blog/5-surprising-truths-about-the-gallbladder
      6. De U. Evolution of cholecystectomy: A tribute to Carl August Langenbuch. Indian J Surg. 2004;66(2):97-100.
      7. Haelle T. 10 essential facts about your gallbladder. Everyday Health. August 15, 2015. Accessed September 21, 2022. https://www.everydayhealth.com/news/essential-facts-about-your-gallbladder/
      8. Beckingham IJ. Gallstones. Surgery (Oxford). 2020;38(8):453-462. doi:10.1016/j.mpsur.2020.06.002
      9. Di Ciaula A, Garruti G, Frühbeck G, et al. The role of diet in the pathogenesis of cholesterol gallstones. Curr Med Chem. 2019;26(19):3620-3638. doi:10.2174/0929867324666170530080636
      10. Ahmed A, Cheung RC, Keeffe EB. Management of gallstones and their complications. Am Fam Physician. 2000;61(6):1673-1688.
      11. Jones MW, Gnanapandithan K, Panneerselvam D, Ferguson T. Chronic Cholecystitis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; October 24, 2022. Accessed March 29, 2023. https://www.ncbi.nlm.nih.gov/books/NBK470236/
      12. Di Ciaula A, Portincasa P. Recent advances in understanding and managing cholesterol gallstones. F1000Res. 2018;7:F1000 Faculty Rev-1529. doi:10.12688/f1000research.15505.1
      13. Abraham S, Rivero HG, Erlikh IV, Griffith LF, Kondamudi VK. Surgical and nonsurgical management of gallstones. Am Fam Physician. 2014;89(10):795-802.
      14. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseasesA systematic review and meta-analysis of randomized clinical trialsJAMA Intern Med.2022;182(5):513–519. doi:10.1001/jamainternmed.2022.0338
      15. Yang M, Xia B, Lu Y, et al. Association between regular use of gastric acid suppressants and subsequent risk of cholelithiasis: A prospective cohort study of 0.47 million participants. Front Pharmacol. 2022;12:813587. Published 2022 Jan 28. doi:10.3389/fphar.2021.813587
      16. Al-Nowfal A, Al-Abed YA. Chronic biliary colic associated with ketamine abuse. Int Med Case Rep J. 2016;9:135-137. Published 2016 Jun 2. doi:10.2147/IMCRJ.S100648
      17. Pulkkinen J, Eskelinen M, Kiviniemi V, et al. Effect of statin use on outcome of symptomatic cholelithiasis: a case-control study. BMC Gastroenterol. 2014;14:119. Published 2014 Jul 3. doi:10.1186/1471-230X-14-119
      18. Walcher T, Haenle MM, Kron, M, et al. Vitamin C supplement use may protect against gallstones: An observational study on a randomly selected population. BMC Gastroenterol. 2009;9:74. doi:10.1186/1471-230X-9-74
      19. Nordestgaard AT, Stender S, Nordestgaard BG, et al. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study. J Intern Med. 2020;287(1):42-53. doi:10.1111/joim.12970
      20. Mukkamalla SKR, Kashyap S, Recio-Boiles A, et al. Gallbladder Cancer. In: StatPearls. Treasure Island, FL: StatPearls Publishing; July 10, 2022. Accessed December 20, 2022. https://www.ncbi.nlm.nih.gov/books/NBK442002/
      21. Barazanchi AWH, MacFater WS, Rahiri JL, et al. Evidence-based management of pain after laparoscopic cholecystectomy: a PROSPECT review update. Br J Anaesth. 2018;121(4):787-803. doi:10.1016/j.bja.2018.06.023
      22. Zackria R, Lopez RA. Postcholecystectomy Syndrome. In: StatPearls. Treasure Island, FL: StatPearls Publishing; August 29, 2022. Accessed November 21, 2022. https://www.ncbi.nlm.nih.gov/books/NBK539902/
      23. Ursodeoxycholic Acid, Ursodiol. Clinical Pharmacology. New York, NY: Elsevier Inc.; 1960. Updated August 6, 2018. Accessed October 25, 2022. Available from: http://www.clinicalkey.com
      24. Chenodiol. Clinical Pharmacology. New York, NY: Elsevier Inc; 1960. Updated September, 29 2015. Accessed October 25, 2022. Available from: http://www.clinicalkey.com
      25. Bonis PA, Lamont JT. Approach to the adult with chronic diarrhea in resource-abundant settings. UpToDate. UpToDate Inc.; 1978-2022. Last Updated May 2, 2022. Accessed November 28, 2022. https://www.uptodate.com/contents/approach-to-the-adult-with-chronic-diarrhea-in-resource-abundant-settings
      26. Cholestyramine Resin. Lexicomp. UpToDate Inc.; 1978-2022. Updated November 25, 2022. Accessed November 29, 2022. Available from: https://online.lexi.com
      27. Colestipol. Lexicomp. UpToDate Inc., 1978-2022. Updated October 22, 2022. Accessed November 29, 2022. Available from: https://online.lexi.com
      28. Sruthi M. What does psyllium husk do? MedicineNet. Updated October 7, 2021. Accessed November 29, 2022. https://www.medicinenet.com/what_does_psyllium_husk_do/article.htm

       

       

      An Over-The-Counter Lifesaver: Increased Intranasal Naloxone Accessibility

      Learning Objectives

       

      After completing this application-based continuing education activity, pharmacists and pharmacy technicians will be able to

      ·       DISCUSS naloxone nasal spray’s shift to over-the-counter (OTC) availability
      ·       DESCRIBE how to use naloxone nasal spray safely and effectively
      ·       IDENTIFY the pharmacist’s role in OTC naloxone access

       

      Watercolor image of person reaching out to help another individual on the ground

       

      Release Date: May 20, 2023

      Expiration Date: May 20, 2026

      Course Fee

      Pharmacists $4

      Pharmacy Technicians $2

       

      There is no grant funding for this CE activity

      ACPE UANs

      Pharmacist: 0009-0000-23-018-H08-P

      Pharmacy Technician: 0009-0000-23-018-H08-T

      Session Codes

      Pharmacist:   23YC18-FXK23

      Pharmacist Technician:  23YC18-KFX48

      Accreditation Hours

      1.0 hours of CE

      Accreditation Statements

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-018-H08-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

       

      Disclosure of Discussions of Off-label and Investigational Drug Use

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Faculty

      Kelsey Giara, PharmD
      Adjunct Assistant Professor
      University of Connecticut
      Storrs, CT

       

       

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Dr. Giara has no financial relationships with ineligible companies and therefore has nothing to disclose.

       

      ABSTRACT

      Recently, the US Food and Drug Administration approved an over-the-counter naloxone product. This is a welcome change that will hopefully reduce the number of opioid-related deaths in the United States, which have escalated over the last two decades. Used appropriately, naloxone can be lifesaving. In addition, its wide margin of safety contributed to the FDA's decision to move this medication from prescription status to over-the-counter (OTC) status. This continuing education (CE) activity covers important information about naloxone, signs of overdose, and naloxone use by bystanders who observe potential opioid overdoses. It also discusses the legal repercussions of using OTC naloxone. Finally, this CE covers counseling tips that are critical for laypeople who purchase OTC naloxone.

      CONTENT

      Content

      INTRODUCTION

      The opioid epidemic has gripped the United States (U.S.) for more than two decades.1 Opioid overdose is the number one cause of death for adults aged 25 to 64 years old, which significantly contributes to the decline in the average lifespan.1 The rise of synthetic opioids (primarily fentanyl) augments the uptick in overdoses, referred to as the “3rd wave” of the opioid epidemic.1,2 In fact, 8 in 10 fatal opioid overdoses in the U.S. now involve synthetics.1 Non-fatal overdose is also significant; for every opioid-induced fatality, up to 8.4 non-fatal overdoses occur.1

       

      Prescription opioids are also a noteworthy contributor to the rise in opioid overdose deaths.2 Healthcare providers started prescribing opioids for chronic, non-cancer pain (e.g., arthritis, back pain) in the 1990s.3 In the decades since, patients started receiving increasingly higher doses of prescription opioids for long-term chronic pain management.2,3 In 2015, the amount of opioids prescribed per person was three times higher than it was in 1999.3 Even when patients take opioids as prescribed, they are still at risk of accidental overdose and drug-drug (e.g., benzodiazepines) or drug-alcohol interactions.2 Their household contacts are also at risk.

       

      Naloxone—an opioid antagonist—is the only approved treatment to reverse opioid overdose.4 The drug competes for the same receptor sites opioids use, effectively and rapidly reversing their effects (i.e., respiratory depression, sedation, and hypotension).4 Naloxone is available in intranasal, subcutaneous, and intramuscular formulations for outpatient use and intravenous formulations for inpatient use.5,6 Naloxone is a safe antidote for suspected overdose, and its use has caused the number of opioid overdose deaths to decrease in communities where it is readily available.2

       

      The U.S. Food and Drug Administration (FDA) has undertaken a series of measures to increase accessibility to this lifesaving medication.7 Until recently, naloxone was only available via prescription. In March 2023, the FDA approved the first naloxone product for over-the-counter (OTC), nonprescription use.6,7 This aims to improve access to naloxone, increase the number of locations where it is available (e.g., drug stores, convenience stores, grocery stores, the Internet), and help reduce opioid overdose deaths across the country.

       

      INCREASED ACCESSIBILITY

      The FDA first approved naloxone in 1971 as a prescription drug.6 It wasn’t until 2014 that the agency approved the first naloxone auto-injector for use outside of a healthcare setting, followed by a nasal spray formulation in 2015.8 Its status as a prescription-only medication made initial access difficult and inconsistent across the country and various high-risk groups.

       

      In the mid-1990s, community-based programs implemented efforts to increase distribution to high-risk individuals.6 Consequently, naloxone dispensing from retail pharmacies increased substantially from 2010 to 2015, with a 1170% increase between 2013 and 2015.6 Naloxone dispensing remains inadequate, however, with only one naloxone prescription dispensed for every 70 high-dose opioid prescriptions.

       

      Pharmacist Naloxone Prescribing

      It’s common knowledge that pharmacists are highly accessible, trusted healthcare professionals, so their role in naloxone distribution is not surprising. Their accessibility, medication expertise, access to patients’ medical records, and regular patient interaction are valuable tools for increasing naloxone availability.6

       

      Many states across the U.S. have enacted naloxone access laws (NALs) to expand pharmacists’ scope of practice through standing orders or collaborative practice agreements, allowing them to distribute naloxone without a patient-specific prescription.6 Studies show that NALs significantly increased naloxone prescribing, but not enough.6 Despite NALs, many pharmacists remain uncomfortable dispensing the drug without a patient-specific order given limited training, lack of understanding state laws, and lack of reimbursement for patient education. Some evidence also exists that pharmacists are afraid of potential legal ramifications.6

       

      Shifting to the Other Side of the Counter

      The FDA has a specific process for shifting from prescription to OTC approval.9 Prescription products can undergo a full switch or partial switch. A full switch converts the drug product covered under a New Drug Application (NDA) to nonprescription marketing status entirely. A partial switch only converts some of the conditions of use (e.g., indications) to nonprescription status and retains others within prescription status. A full switch requires a sponsor to submit an efficacy supplement to an approved NDA or a 505(b)(2) application, but a partial switch requires an entirely new NDA.9 Ultimately, approval of a prescription-to-OTC switch application depends on the FDA deciding that prescription status is “not necessary for the protection of the public health by reason of the drug’s toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, and…the drug is safe and effective for use in self-medication as directed in proposed labeling.”9

       

      The FDA has been working to authorize an OTC version of naloxone since 2019 by prioritizing applications and assisting manufacturers pursuing OTC naloxone approval.8 The agency announced in January 2019 that preliminary assessment showed that consumers understood a model drug facts label well for OTC naloxone nasal spray and manufacturers found the label acceptable, a slow but steady step in the right direction.8 In late 2022, the FDA issued a Federal Register notice indicating that certain naloxone products—up to 4 mg nasal spray and up to 2 mg intramuscular or subcutaneous autoinjector—may be approvable for nonprescription use.10 This did not immediately approve naloxone products for safe and effective OTC use, but it did provide the framework for manufacturers to pursue approval.

       

      The FDA granted priority review status to the application to approve branded naloxone nasal spray (Narcan) for OTC use.11 It was then the subject of an advisory committee meeting in February 2023 where the committee voted unanimously to approve naloxone for nonprescription marketing.11

       

      What’s Next?

      It’s important to note that the prescription to OTC switch does not automatically apply to all forms of naloxone. Only branded Narcan 4 mg nasal spray is now granted OTC status, not its generic counterparts.7 Manufacturers of generic products with Narcan listed as their reference listed drug product will need to submit a supplemental application to switch their products to OTC status. Other brand name naloxone nasal spray products of 4 mg or less must also update labeling and apply individually for a switch to OTC status.7

       

      Pharmacy teams should also be aware that the drug will not be available on drug store shelves immediately.12 The manufacturer will need to implement manufacturing and supply chain changes to support nonprescription packaging requirements. According to the drug’s manufacturer, pharmacies can expect the OTC formulation to be available in late summer 2023. Until then, the prescription product will be readily available through current access channels.12

       

      Cost is also important to consider. The drug’s manufacturer has yet to reveal pricing plans for the OTC version, but it plans to work with public interest groups who are now charging about $47.50 per box.13 Health economists predict that the price of OTC Narcan could land somewhere between $35 and $65, plus a retailer’s markup.13 Unfortunately, this price could be prohibitive for many individuals, especially those who misuse opioids. Some also fear that this could encourage individuals to shoplift the drug, forcing locations to move the product behind the pharmacy counter or behind glass and creating a barrier to those who can afford it but are uncomfortable asking for it.13

       

      As for accessing the drug outside of a pharmacy setting (e.g., convenience stores, gas stations), additional barriers may exist. Some states require a special license for non-pharmacy businesses to sell OTC medications, which can effectively create “naloxone deserts” where the drug is not available for purchase. In the state of Connecticut, for example, 28 towns currently do not have stores with permits to sell OTC medications, causing residents to travel to obtain the lifesaving antidote.14 Pharmacy teams should check their state’s law regarding OTC sales to direct interested individuals on where to obtain the drug.

       

      NEW OPPORTUNITIES FOR THE PHARMACY TEAM

      Naloxone shift to OTC availability may seem to take the load off pharmacy teams when it comes to collaborative practice agreements and NALs, but the pharmacy team should remain heavily involved in naloxone distribution. OTC medications are often not covered by insurance, so pharmacists should stay vigilant about active NALs and collaborative practice agreements to prescribe the drug for people with cost concerns.

       

      Assessing Overdose Risk

      Prescription or not, a crucial role for pharmacy staff is identifying patients for whom naloxone is appropriate. Anyone exposed to opioids, regardless of the source, is at risk of overdose and should be considered for naloxone.15 This applies to people taking opioids for pain with or without other medications and those who misuse opioids. As the drug is bystander-administered, caregivers of individuals at risk of overdose may also request naloxone and should be educated about its use.15

       

      Paying attention to opioid dosing is important when considering patients for naloxone. A dose of 50 morphine milligram equivalents (MME) per day doubles the risk of fatal opioid overdose compared to 20 MME or less.3 Patients taking 90 MME or more daily are 10-times more likely to die from an overdose.3 Other overdose risk factors include15

      • concurrent benzodiazepine and/or alcohol use
      • history of substance use disorder, including opioid addiction
      • comorbid mental illness (e.g., depression, anxiety)
      • filling prescriptions at multiple pharmacies and/or from multiple prescribers
      • receiving a methadone prescription
      • recent emergent medical care for opioid poisoning, intoxication, or overdose
      • recent period of abstinence (e.g., release from incarceration, discharge from an opioid detox or abstinence-based program)
      • renal or hepatic dysfunction
      • comorbid respiratory conditions (e.g., smoking, chronic obstructive pulmonary disease, emphysema, asthma, sleep apnea)

       

      Counseling on Naloxone Nasal Spray Use

      The FDA deemed naloxone nasal spray safe enough for OTC use, but that doesn’t preclude the need to counsel individuals on its safe and appropriate use. Pharmacists should counsel all patients buying OTC naloxone nasal spray about signs of an opioid overdose, how to administer naloxone, and other important clinical pearls. Signs of an opioid overdose include15

      • pale and/or clammy skin
      • limp body
      • pinpoint pupils
      • blue or purple lips, nose, and/or fingernails
      • vomiting or making gurgling noises
      • unconscious or unarousable
      • breathing very slow or not at all

       

      Pharmacists should advise individuals to administer naloxone in the event of suspected overdose even if they are not 100% sure the victim is in fact suffering from an overdose.16 Administering naloxone to someone who is not actually suffering from opioid overdose is better than withholding care from an overdose victim based on uncertainty. See Sidebar: Saving a Life is Scary for additional information to ease concerns regarding naloxone administration.

       

      SIDEBAR: Saving a Life Is Scary15,17

      Often, individuals are trained and ready to perform lifesaving first-aid procedures like CPR or the Heimlich maneuver, but they are afraid of the implications if things take a turn for the worse. Naloxone administration is subject to these same liability concerns. Individuals may also be concerned about legal repercussions when calling for help at the scene of an overdose. Ensure that individuals know about supporting laws and regulations that protect them to increase comfort and confidence with administering the drug:

      • Good Samaritan*: Protects people who call for emergency medical assistance at the scene of an overdose from being arrested for drug possession.
      • Liability protection/third party administration: Protects naloxone prescribers and bystanders who administer the drug and allows bystanders to obtain naloxone for use on opioid overdose victims.

       

      *Some states have Good Samaritan laws that differ from general ones. For example, Ohio places limits on the number of times someone can be granted Good Samaritan immunity and requires that overdose victims seek referral for addiction treatment within 30 days. Pharmacy teams should stay current with state-specific Good Samaritan laws regarding naloxone.

       

      Naloxone nasal spray is available in a two-pack of single-use, prefilled devices that cannot be reused.4,5 The device should not be primed. Pharmacists should advise people buying OTC naloxone nasal spray about the following administration steps4,16:

      • Check for a suspected overdose (i.e., yell “wake up,” shake the person gently)
      • If the individual does not wake up, lay them on their back
      • Hold the nasal spray device with a thumb on the bottom of the plunger
      • Insert the nozzle into one nostril and press firmly to administer the dose
      • Call 911 immediately
      • Stay until medical assistance arrives, even if the person wakes up
      • Give another dose if the person does not wake up after 2 to 3 minutes or they become very sleepy again initial arousal
      • Continue giving doses every 2 to 3 minutes until the person wakes up or medical assistance arrives (it is safe to keep giving doses)

       

      Naloxone is a relatively safe drug, but it still comes with risks and clinical pearls that cannot be ignored. Abrupt opioid reversal in physically dependent individuals can cause acute withdrawal.4,7 Signs and symptoms include body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia.4 Patients may also become aggressive upon sudden reversal of opioids. Naloxone is only effective in reversing opioid overdoses, not in treating other types of overdoses, so it is crucial that individuals seek emergency medical attention following naloxone administration.

       

      CONCLUSION

      Naloxone is a vital tool for preventing fatal opioid overdose. Pharmacists should be prepared to identify people at risk of overdose and assess their need for this lifesaving drug, make all individuals aware of its OTC availability, and counsel on its safe and appropriate use.

      Pharmacist Post Test (for viewing only)

      Learning Objectives
      • DISCUSS naloxone nasal spray’s shift to over-the-counter (OTC) availability
      • DESCRIBE how to use naloxone nasal spray safely and effectively
      • IDENTIFY the pharmacist’s role in OTC naloxone access

      1. Which of the following is required for a prescription-to-OTC switch?
      A. Evidence that the drug is safe for self-medication
      B. Evidence of bioavailability to the prescription product
      C. A lower dose than the prescription formulation

      2. Which of the following is an appropriate course of action following the naloxone prescription-to-OTC switch?
      A. Move all naloxone products to the customer-facing shelves of the pharmacy immediately
      B. Warn patients that naloxone nasal spray will be unavailable until late summer 2023
      C. Review state NALs and collaborative practice agreements to continue dispensing naloxone

      3. Which of the following is TRUE about naloxone nasal spray administration?
      A. Bystanders should administer a maximum of 2 doses before emergency care arrives
      B. It can cause patients to act aggressively or show signs of withdrawal
      C. Bystanders should only use it if they are 100% sure the victim used opioids

      4. It’s 2024 and your customer-facing pharmacy shelf is stocked with naloxone nasal spray. A woman presents to the counter with the product stating she knows her father is on opioids for cancer pain, but she is afraid he will accidentally take too many doses. She asks if there is anything important she should know about naloxone nasal spray and expresses that she is concerned she will not know how to identify when he is experiencing an overdose. Which of the following is the BEST counseling point for this individual?
      A. The Good Samaritan law will protect you from liability if you administer naloxone on your father and it does not work or he was not actually overdosing on opioids.
      B. If your father experiences an overdose, he will show signs of respiratory distress (slowed or stopped breathing) and be unconscious. Even if you are not 100% sure, administer the naloxone anyways.
      C. Your father is not at risk of overdose because he is using prescription opioids for cancer pain, so naloxone nasal spray is unnecessary. Use a pill organizer to ensure he uses the opioids as prescribed.

      5. Which of the following people are most likely at high risk of opioid overdose?
      A. An individual with an expired prescription for methadone who was recently released from incarceration
      B. An individual with no opioid use history who takes lorazepam (a benzodiazepine) as needed for panic attacks
      C. An individual diagnosed with gout who fills prescriptions for naproxen from both his primary care provider and an urgent care facility

      Pharmacy Technician Post Test (for viewing only)

      Learning Objectives
      • DISCUSS naloxone nasal spray’s shift to over-the-counter (OTC) availability
      • DESCRIBE how to use naloxone nasal spray safely and effectively
      • IDENTIFY the pharmacist’s role in OTC naloxone access

      1. Which of the following is required for a prescription-to-OTC switch?
      A. Evidence that the drug is safe for self-medication
      B. Evidence of bioavailability to the prescription product
      C. A lower dose than the prescription formulation

      2. Which of the following is an appropriate course of action following the naloxone prescription-to-OTC switch?
      A. Move all naloxone products to the customer-facing shelves of the pharmacy immediately
      B. Warn patients that naloxone nasal spray will be unavailable until late summer 2023
      C. Review state NALs and collaborative practice agreements to continue dispensing naloxone

      3. Which of the following is TRUE about naloxone nasal spray administration?
      A. Bystanders should administer a maximum of 2 doses before emergency care arrives
      B. It can cause patients to act aggressively or show signs of withdrawal
      C. Bystanders should only use it if they are 100% sure the victim used opioids

      4. It’s 2024 and your customer-facing pharmacy shelf is stocked with naloxone nasal spray. A woman presents to the counter with the product stating she knows her father is on opioids for cancer pain, but she is afraid he will accidentally take too many doses. She asks if there is anything important she should know about naloxone nasal spray and expresses that she is concerned she will not know how to identify when he is experiencing an overdose. Which of the following is the BEST counseling point for this individual?
      A. The Good Samaritan law will protect you from liability if you administer naloxone on your father and it does not work or he was not actually overdosing on opioids.
      B. If your father experiences an overdose, he will show signs of respiratory distress (slowed or stopped breathing) and be unconscious. Even if you are not 100% sure, administer the naloxone anyways.
      C. Your father is not at risk of overdose because he is using prescription opioids for cancer pain, so naloxone nasal spray is unnecessary. Use a pill organizer to ensure he uses the opioids as prescribed.

      5. Which of the following people are most likely at high risk of opioid overdose?
      A. An individual with an expired prescription for methadone who was recently released from incarceration
      B. An individual with no opioid use history who takes lorazepam (a benzodiazepine) as needed for panic attacks
      C. An individual diagnosed with gout who fills prescriptions for naproxen from both his primary care provider and an urgent care facility

      References

      Full List of References

      REFERENCES

      1. Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther. 2022;233:108019. doi:10.1016/j.pharmthera.2021.108019
      2. U.S. Department of Health and Human Services. U.S. Surgeon General’s advisory on naloxone and opioid overdose. Updated April 8, 2022. Accessed April 13, 2023. https://www.hhs.gov/surgeongeneral/reports-and-publications/addiction-and-substance-misuse/advisory-on-naloxone/index.html
      3. Centers for Disease Control and Prevention. Opioid prescribing: Where you live matters. July 2017. Accessed April 13, 2023. https://www.cdc.gov/vitalsigns/pdf/2017-07-vitalsigns.pdf
      4. Narcan [prescribing information]. Emergent BioSolutions; 2023.
      5. College of Psychiatric & Neurologic Pharmacists. Naloxone product comparison. Prescribe to Prevent. January 2023. Accessed April 13, 2023. https://prescribetoprevent.org/wp2015/wp-content/uploads/Naloxone-Product-Comparison-2023.pdf
      6. Xu J, Mukherjee S. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies. Drug Alcohol Depend. 2021;227:109012. doi:10.1016/j.drugalcdep.2021.109012
      7. U.S. Food and Drug Administration. FDA approves first over-the-counter naloxone nasal spray. March 29, 2023. Accessed April 11, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray
      8. U.S. Food and Drug Administration. Timeline of selected FDA activities and significant events addressing substance use and overdose prevention. Accessed April 16, 2023. https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose
      9. U.S. Food and Drug Administration. Prescription-to-Nonprescription (Rx-to-OTC) Switches. Updated June 28, 2022. Accessed April 16, 2023. https://www.fda.gov/drugs/drug-application-process-nonprescription-drugs/prescription-nonprescription-rx-otc-switches
      10. U.S. Food and Drug Administration. FDA announces preliminary assessment that certain naloxone products have the potential to be safe and effective for over-the-counter use. November 15, 2022. Accessed April 13, 2023. https://www.fda.gov/news-events/press-announcements/fda-announces-preliminary-assessment-certain-naloxone-products-have-potential-be-safe-and-effective
      11. U.S. Food and Drug Administration. FDA approves first generic naloxone nasal spray to treat opioid overdose. April 19, 2019. Accessed April 13, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-naloxone-nasal-spray-treat-opioid-overdose
      12. Emergent BioSolutions. U.S. FDA approves over-the-counter designation for Emergent BioSolutions’ NARCAN® nasal spray, a historic milestone for the opioid overdose emergency treatment. March 29, 2023. Accessed April 14, 2023. https://investors.emergentbiosolutions.com/news-releases/news-release-details/us-fda-approves-over-counter-designation-emergent-biosolutions
      13. The New York Times. Over-the-Counter Narcan Could Save More Lives. But Price and Stigma Are Obstacles. March 29, 2023. Accessed April 26, 2023. https://www.nytimes.com/2023/03/28/health/narcan-otc-price.html
      14. News 8 WTNH. 28 Conn. towns won't be able to sell Narcan drug. April 19, 2023. Accessed April 26, 2023. https://www.wtnh.com/video/28-conn-towns-wont-be-able-to-sell-narcan-drug/8572715/
      15. College of Psychiatric & Neurologic Pharmacists. Naloxone access: A practical guideline for pharmacists. Prescribe to Prevent. 2015. Accessed April 16, 2023. https://prescribetoprevent.org/wp2015/wp-content/uploads/naloxone-access.pdf
      16. Narcan [over-the-counter packaging]. March 2023. Accessed April 16, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208411Orig1s006lbl.pdf
      17. The Network for Public Health Law. Naloxone access and overdose Good Samaritan law in Ohio. September 2018. Accessed April 16, 2023. https://www.networkforphl.org/wp-content/uploads/2020/01/Ohio-Naloxone-Good-Sam-Laws-Fact-Sheet.pdf

       

       

      Colon on Fire? Novel Suppression of Ulcerative Colitis InFLAMmation

      Learning Objectives

        After completing this application-based continuing education activity, pharmacists will be able to
      1. Differentiate UC from Crohn’s disease
      2. Describe currently available and novel UC medications under development in the United States
      3. Outline the relationship between the types of treatment for UC, patient characteristics and disease severity
      4. Identify patient education pearls to address inflammation and advance to remission
      After completing this application-based continuing education activity, pharmacy technicians will be able to:
      1. Differentiate UC from Crohn’s disease
       2. Describe currently available and novel UC medications under development in the United States
      3. Outline the relationship between the types of treatment for UC, patient characteristics and disease severity
      4. List symptoms that a patient with UC may share with a pharmacy technician

      Woman holding her abdomen with a cartoon picture of the large intestine superimposed

      Release Date:

      Release Date:  May 15, 2023

      Expiration Date: May 15, 2026

      Course Fee

      FREE

      This CE was funded by an educational grant from Bristol Meyer Squibb

      ACPE UANs

      Pharmacist: 0009-0000-23-014-H01-P

      Pharmacy Technician: 0009-0000-23-014-H01-T

      Session Codes

      Pharmacist:  23YC14-HTX49

      Pharmacy Technician:  23YC14-XHT82

      Accreditation Hours

      2.0 hours of CE

      Accreditation Statements

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-014-H01-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

       

      Disclosure of Discussions of Off-label and Investigational Drug Use

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Faculty

       


      Pamela Sardo, PharmD, BS
      Freelance Medical Writer
      Sardo Solutions
      Josephine, TX

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Dr. Sardo worked for Rhythm Pharma until March 2022.  We identified no potential financial or other conflicts of interest.

      ABSTRACT

      Ulcerative colitis is an idiopathic relapsing/remitting disease that is increasing in incidence and prevalence. It is characterized by inflammation, abdominal cramping, bloody diarrhea, fatigue, and bowel urgency among other symptoms. It often presents in teens and young adults with various degrees of severity and significantly impacts quality of life. Primary treatment objectives include achieving rapid resolution of symptoms, mucosal healing, clinical and endoscopic remission, and improving a patient’s quality of life. In moderate to severe disease, prescribers employ immunosuppressive medications, anti-TNF agents, IL 12/23 antagonists, adhesion molecule inhibitors, JAK inhibitors, and S1P receptor modulators. Two organizations have published joint recommendations regarding these pharmaceuticals’ place in therapy. As more data is published and investigational therapies are approved, the treatment approach will continue to evolve. Ulcerative colitis is incurable, so some patients may require surgery. Optimizing care with a multidisciplinary team, including pharmacy personnel, remains an opportunity in this complex condition.

      CONTENT

      Content

      INTRODUCTION

      Fiery inflammation in the bowel can be due to several conditions. In inflammatory bowel disease (IBD), gastrointestinal (GI) tract inflammation episodes are common. Crohn’s disease (CD) and ulcerative colitis (UC) are two IBDs differentiated by location and bowel involvement.1 That’s a point to remember: that IBD is an umbrella term that includes CD and UC. In 10% to 15% of patients, the features of CD and UC are so similar that it is impossible to differentiate between them and misdiagnosis may result.1,2 Besides the GI tract, both CD and UC also may be accompanied by symptoms outside the intestine, called extraintestinal symptoms.

       

      DIFFERENTIATING CD AND UC

      CD results in patchy ulceration of any portion of the GI tract (see Figure 1) from the mouth to the anus. It frequently affects the terminal ileum and colon, and bleeding is uncommon. Typically, patients experience pain in the lower right abdomen.3 UC, this continuing education’s primary focus, involves inflammation of the colon mucosa. UC often affects the rectum, referred to as proctitis, and bleeding during bowel movements is common. Typically, patients experience pain in the lower left abdomen. It may extend into the left (sigmoid) part of the pelvis or beyond the sigmoid, or include the entire colon, referred to as pancolitis.4 In UC, inflammation leads to edema, ulcers, bleeding, and electrolyte losses.

      Figure 1. The Gastrointestinal Tract

      Cartoon image showing the entire gastrointestinal tract, from mouth to anus

      UC is a chronic idiopathic relapsing/remitting condition (meaning it waxes and wanes) with interactions between the environment, immune system, gut microbiome, and a genetic predisposition to the disease suspected as causes.UC’s incidence and prevalence is increasing worldwide.6 From 1990 to 2017, its incidence increased from 3.7 million individuals to 6.8 million affected individuals worldwide.7 UC is incurable, so treatment goals aim to achieve rapid resolution of symptoms, mucosal healing, and clinical and endoscopic remission. An additional goal is to improve a patient’s quality of life (QoL).6.

       

      Individuals with this complex condition have a high level of disability and high healthcare resource utilization. Beyond medical management, 15% to 20% of patients with UC will require surgery. Compared to adults without IBD, adults with IBD experienced $11,029 higher direct costs per patient per year according to one report.8 Documenting this diagnosis in the pharmacy’s profile can help pharmacists and technicians screen for potential problems more efficiently.

       

      Differentiating the two forms of IBD drives treatment. Both CD and UC present as similar repetitive episodes of GI inflammation and create significant patient burden. In CD, inflammation or ulceration commonly occurs in the ileum and colon.4 Outside of the intestine, CD may affect the esophagus, duodenum, or stomach, and gallstones may occur. In UC, extraintestinal manifestations may appear most commonly as inflammatory arthropathies (joint disease) and bile duct inflammation and scarring, but may include bone, eye, and skin involvement.9,10 Although IBD’s incidence peaks at age 15 to 29 years, 10% to 15% of new diagnoses occur among adults aged 60 years or older.11 Both forms of IBD are more prevalent among non-Hispanic White people than among people in other racial/ethnic groups.12

       

      PAUSE AND PONDER: What support can you provide to a patient who tells you that wherever they go, their first action is to scan for the closest bathroom?

       

      UC’S PATHOPHYSIOLOGY AND ASSESSMENT

       

      The normal colon is five or six feet long and three inches wide. Its layers of circular and longitudinal muscles and tissues contract to move food and liquid forward. It wraps around the outside of the small intestine, has segments, and looks somewhat flat. A seam runs vertically down the middle so the segments bulge on either side of the seam. As UC becomes chronic, the colon becomes more rigid and short, leading to a pipe-like appearance.9

       

      The most important risk factor for UC is a family history of IBD in a first-degree relative.14 Patients with disease extension to the left side of the colon, or extensive colitis, are more likely to need medication, undergo colectomy (removal of a portion of the colon), and develop colorectal cancer.15  Risk factors for colorectal dysplasia (abnormal that are not cancerous but can sometimes lead to cancer) or cancer include disease duration and extent, active inflammation, presence of a stricture (inelastic narrowing of a section of the GI tract), polyps, and family history of colorectal cancer. The bile duct may also become diseased in 3% to 7% of patients with UC.15,16

       

      UC’s pathophysiology involves defects in the epithelial barrier, defective immune response, the presence of leukocytes, and microflora imbalance in the colon.17,18 UC’s inflammation deteriorates the epithelium, and exposure to certain intestinal microbes worsens the inflammation.9 Other immune-related factors that affect UC’s pathophysiology and the body’s response include tumor necrosis factor-alpha (TNF-alpha), numerous interleukins, and elevated immune globulin levels.17

       

      Two measures are recognized in UC. Gastroenterologists and researchers tend to use the erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) components of the Truelove and Witts criteria. Researchers frequently measure ESR and CRP before and during treatments as outcome measures. The prescribing information for anti-TNFs, JAK inhibitors, and IL-12/23 antagonists also include ESR and CRP measures. Table 1 illustrates UC disease severity measured by assessment in the modified Truelove and Witts criteria.15

       

       Table 1. Modified Truelove and Witts Criteria15

      Parameter Mild Moderate Severe
      Bloody stools/day (n) <4 4-6 >6
      Pulse (beats/minute) <90 ≤90 >90
      Temperature (T) °C

      (T°F )

      <37.5

      (<99.5)

      37.5 – 37.8

      (99.5 – 100.4)

      >37.8

      (>100.4)

      Hemoglobin (g/dL) >11.5 11.5 – 10.5 <10.5
      ESR (mm/hr)

      [or CRP mg/l]

      <20 (normal) 20 – 30 (<30) >30 (>30)

      °C=degree Celsius; CRP = c-reactive protein; ESR = erythrocyte sedimentation rate; °F = degree Fahrenheit

       

      In the clinical setting, the simpler Mayo score (see Table 2) is used more widely than Truelove and Witts criteria.19 It reflects stool frequency, rectal bleeding, a physician’s global assessment, and a measure of mucosal inflammation at endoscopy, with a maximum score of 12. Clinical response in UC is defined as19

      • a reduction of Mayo score by at least 3 points and a decrease of 30% from the baseline score, or
      • a decrease of at least 1 point on the rectal bleeding subscale or
      • a total rectal bleeding score of 0 or 1

       

      Table 2. Mayo Score for Ulcerative Colitis15,20,19

        Points
      Mayo Variables 0 1 2 3
      Stool frequency Normal 1-2/day more than normal 3-4/day more than normal 5/day more than normal
      Rectal bleeding None Streaks of blood with stool <50% of the time Obvious blood with stool most of the time Blood passed without stool
      Mucosa (endoscopic subscore) Normal or inactive disease Mild disease (erythema, decreased vascular pattern, mild friability) Moderate disease (marked erythema, lack of vascular pattern, friability, erosions) Severe disease (spontaneous bleeding, ulcerations)
      Physician’s global assessment Normal Mild disease Moderate disease Severe disease

      Mayo score = sum of scores for each of the four variables (maximum score 12)

       

       

      Beyond clinical response, clinical remission is a desired objective and is defined as a Mayo score of 2 or less and no individual subscore exceeding 1.19 Mucosal healing is defined as a mucosa subscore of 1 or less. Disease activity is a measure used to decide what treatments to prescribe. Mild disease activity is defined as scores of 3 to 5. Moderate and severe disease activity are defined as scores between 6 and 10 and 11 and 12, respectively.19

       

      The clinician’s patient assessment must be global (all encompassing).21 During patient interviews, clinicians should inquire about extraintestinal symptoms, which may include joint, mood, ocular, oral, or skin changes. They should order laboratory evaluation for anemia and liver function abnormalities. Clinicians should explore QoL issues, such as impact on school, work, or personal relationships. Treatment plans should incorporate patients’ unmet needs and preferences. Exploring the need for social and emotional support, financial resources, and adequacy of patient education regarding their disease are important.21

       

      Throughout treatment, it’s important to assess the patient’s clinical response and remission periodically. Clinicians should monitor cross-sectional imaging, specifically MRI, CT and ultrasound, and surrogate markers, such as fecal calprotectin (FCP; type of white blood cell that migrates to inflamed tissue) and CRP.15,22 A sigmoidoscopy or colonoscopy is recommended within three to six months of initiating treatment to determine the level of suppression of the inflammation, treatment response, or the need to modify the treatment.22

       

      THE PATIENT’S JOURNEY

      The journey through symptoms, diagnosis, and treatment to quell the fiery inflammation associated with UC can be long and difficult. In one study, one in four individuals with IBD reported GI symptoms to their primary care physician more than six months before receiving a diagnosis.23 Of these individuals, 10.4% reported symptoms five years before receiving a UC diagnosis. Delayed diagnosis often results in disease progression, worsening tissue, and mucosal damage, surgery, colectomy, or colitis-associated cancer.  Patients with a previous diagnosis of irritable bowel syndrome or depression were less likely to receive a timely specialist appointment.23

       

      UC is vastly heterogeneous. Table 3 presents two cases with distinct disease journeys.

       

       

      Table 3. Two Distinct Patient Journeys24,25

      UC Patient Case 1   UC Patient Case 2
      9-year-old girl diagnosed after ileocolonoscopy reveals diffuse moderate inflammation UC since age 18
      Moderate clinical disease activity, Mayo score = 8 Symptoms included bleeding, severe pain and swelling in lower abdomen, gas, and nausea
      Low hemoglobin, low vitamin D Lifestyle: Undergraduate, lifeguard, swim coach
      Oral corticosteroids started followed by dose tapering dose and mesalamine started Daily regimen of oral medication, rectal suppositories, nightly enemas
      At week 4, active disease remained Symptoms worsened so → ED
      IFX started at 10 mg/kg at 0, 2, and 6 weeks Barely able to eat or drink, covered with rash and inflamed eyes
      At 26 weeks with IFX, she remained in clinical remission Incontinence in street, bus, and post office
      At 1 year, she remained in remission Acute diarrhea with each BM → became homebound
      Follow-up flexible sigmoidoscopy demonstrated mucosal healing At age 29, married → then 10 weeks of hospitalization without remission
        Agreed to surgical colectomy → difficult recovery, diarrhea, and intestinal blockages
        Finally exercising, back to work, and monitoring the quantity, texture, and timing of food. Remained on pre-surgical medications.

      BM = bowel movement; ED = emergency department; IFX = inFLIXimab

       

      UC affects many distinct populations. In the pediatric population with UC, unlike in adults, the clinical condition can present atypically with a more severe, early onset and continuous inflammation of the rectum and colon.26,27,28 In these patients, clinicians should assess disease location and severity. One study indicated 62% of pediatric patients with UC from birth to age 5 years had extensive pancolitis, and 38% and 31% from ages 6 to 11 and from ages 12 to 18, respectively, had pancolitis.27   Children can also experience rectal sparing (a normal/unaffected rectum) and limited distal disease.26,28

       

      To optimize management, enhance QoL, and minimize complications in all patients, continued patient engagement is important.29

       

      GOALS OF UC MANAGEMENT

       

      The UC treatment guidelines recommend goals of therapy to include29

      • induction and maintenance of clinical and endoscopic remission
      • maintaining steroid-free remission
      • improving QoL, and
      • preventing complications, hospitalizations and surgery.

      Pursuing these goals can also contribute to minimizing cancer risk.21,30,31 Long-term mucosal healing may reduce the risk of dysplasia.31

       

      The Treat-To-Target Approach                                                         

      UC is considered relapsing/remitting because it presents as relapses of symptoms and then periods of symptomless response and remission. Beyond symptom remission, a treat-to-target (T2T) approach focuses on32,33

      • minimizing disease activity
      • reducing futures risks and
      • reducing future relapses or complications such as ileal strictures (narrowing), fistulas, functional impairment, or colon cancer.

       

      In 2015, the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative recommended that UC treatment goals should address two targets: clinical and endoscopic outcomes.32 IBD experts recommend using measures of inflammation such as FCP.32  FCP detects GI inflammation sensitively and is used to monitor disease activity and predict relapse.

       

      PAUSE AND PONDER: Which UC treatments do you see in your practice location most often?

       

      UC’s treatment options are plentiful and evolving. Pharmacy team members can collaborate with multidisciplinary professionals regarding patient care for UC. (See SIDEBAR). Pharmacists’ drug therapy and disease management expertise can promote individualized treatment decisions for these complex patients.

       

       

      SIDEBAR: Working with the Multidisciplinary Team

      Team collaboration can increase patient and provider education, enhance quality of care, and reduce disease burden, and morbidity. Many pharmacists don’t know how to introduce themselves to or work with multidisciplinary teams. Sometimes, team members from other disciplines will call with questions or concerns, and the call opens the door for regular communication. Often, however, pharmacy staff will need to take the initiative and introduce themselves. Here are four tips to working better with the UC care team.

      • Ask patients if they are seeing a nutritionist, primary care provider, gastroenterologist, or behavioral health provider (for stress support). If UC is severe, inquire if they have a surgeon or know their radiologist. Record these providers’ names in the patient record and contact them when questions or concerns arise.
      • Make the patient your ally and be your patient’s ally. When you educate patients well and show them your capabilities, they will report back to their clinicians.
      • When you work with a patient who has UC, let the professional team members know. Sending a quick note to say that, for example, the patient’s adherence was poor and you discussed ways to improve it with the patient sheds light on possible non-response. It also makes clinicians aware that you have skills and you’re not afraid to use them!
      • Don’t be afraid to make team members aware of issues like cost or availability of less expensive options. Often, prescribers have no idea that patients experience sticker shock when they fill their prescriptions.

       

      TREATMENT

      Medication is a mainstay of treatment for patients with UC. Prescribers may combine, dose-escalate, reduce, or discontinue medications, depending on the patient’s disease severity.

       

      Traditional Treatments

      When a patient presents with mild to moderate UC, the expert consensus is to start treatment with an oral 5-aminosalicylate (5-ASA; sulfasalazine, mesalamine, and diazo-bonded 5-ASA [the prodrugs, balsalazide and olsalazine, which convert to mesalamine]34) with or without a rectal 5-ASA.34,35 In many cases, rectal dosing improves symptoms; using a suppository, enema, or rectal foam applies the medication exactly where needed. Sulfasalazine, balsalazide, and mesalamine are similarly effective and safe.34 Some patients will respond inadequately and may need to escalate therapy to systemic corticosteroids, immunomodulators (IMM), biologics, or other agents. If symptoms persist, it is important to rule out infection, optimize adherence, increase the oral dose, and add rectal 5-ASA if not yet prescribed.34,35

       

      Comparative efficacy studies are helpful to clinicians. One technical review of multiple drugs in mild to moderate UC compared rectal 5-ASAs (5-ASA enemas 1 to 4 g/day or 5-ASA suppositories 1g/day) to rectal corticosteroids (hydrocortisone enema 100mg/day, prednisolone enema 25–30 mg/day, budesonide enema 2 mg/day, beclomethasone 3 mg/day or comparable foam) in 13 trials.36 In mild to moderate ulcerative proctosigmoiditis cases treated for two to eight weeks, rectal 5-ASAs were superior to rectal corticosteroids for induction of clinical remission.36

       

      Table 4 lists the broad categories of medications for mild, moderate, or severe UC and dosing information.

       

      Table 4. Medications for UC22,37-42

      Category Substance Dosage
      5 – ASA Mesalamine

       

       

      Balsalazide

       

      Olsalazine

       

      Sulfasalazine

      2 – 4.8 g/day (oral)

      1 – 2 g/day (rectal)

       

      6.75 g/day (rectal)

       

      1 g/day (oral)

       

      2 – 4 g/day

      Corticosteroids Budesonide

       

      Budesonide MMX

       

      Prednisone

       

      Hydrocortisone

       

      Methylprednisolone

      2 mg/day (rectal)

       

      9 mg/day (oral)

       

      0.75 – 1 mg/kg/day

       

      100 mg IV 4 times/day

       

      125 mg IV/day

      Thiopurines

      Immunosuppressives

      Azathioprine

       

      6-mercaptopurine

      2 – 2.5 (max 3) mg/kg/day

       

      1 – 1.5 mg/kg/day

      Calcineurin inhibitors Cyclosporine

       

      Tacrolimus

      2 mg/kg/day IV

       

      0.2 mg/kg/day

      Anti-TNF agents Adalimumab

       

       

       

      Golimumab

       

       

       

      Infliximab

      160 mg wk 0, 80 mg wk 2, 40 mg wk 4, then 40 mg every 2 wks; may ↑ to 40 mg/wk SUBQ

       

      200 mg wk 0, 100 mg wk 2, 50 mg wk 4, then 50 mg every 4 wks; may ↑ to 100 mg if pt>80 kg SUBQ

       

      5 mg/kg wk 0, 2, 6, then every 8 wks IV

      Adhesion molecule inhibitors

      (anti-integrin)

      Vedolizumab 300 mg wk 0, 2, 6, then every 8 wks IV
      Janus kinase inhibitor Tofacitinib

       

       

       

       

       

       

       

      Upadacitinib

      5 – 10 mg/day (oral)

      First 8 wks: 10 mg twice/day

      10 mg twice/day for 8 more wks if partial response

      Then 5 mg twice/day

      or 22 mg XR/day for 8 weeks; then evaluate

       

      45 mg/day for 8 wks then 15 mg/day (oral)

      Interleukin 12/23 antagonist Ustekinumab 250 mg to 55 kg IV

      390 mg if >55 kg – 85 kg IV

      520 mg if >85 kg IV

      Then 90 mg SUBQ every 8 wks

      Sphingosine 1-phosphate receptor modulator Ozanimod 0.23 mg days 1-4, 0.46 mg days 5-7, then

      0.92 mg/day (oral)

      G = grams; IV= intravenous; kg=kilogram; mg= milligrams; MMX = Multi-Matrix System technology drug release; SUBQ=subcutaneous; wk= week

       

      Sulfasalazine

      If sulfasalazine is prescribed, 4 g provides approximately 1.6 g of 5-ASA equivalence.34 Typical doses are 2 tablets 4 times a day.37,43 In some cases, prescribers may initiate therapy with a smaller dose, (e.g., 1 to 2 g daily) to reduce possible GI intolerance and slowly increase as tolerated. They may also try enteric-coated sulfsalazine.37,43 Sulfasalazine is commonly prescribed for individuals with UC and rheumatologic comorbidities.43 Periodic monitoring of complete blood counts (CBC) and liver function tests (LFT) is recommended.

       

      Sulfasalazine may be poorly tolerated due to adverse effects such as headache, nausea, diarrhea, and rash.43 Additional adverse events with sulfasalazine include folate metabolism interference, male infertility, and rare cutaneous side effects such as Stevens-Johnson syndrome. Anemia, leukopenia, or thrombocytopenia are also possible. Pneumonitis and hepatitis have been reported.43  Sulfasalazine is contraindicated if a patient has a sulfa allergy. Sulfasalazine tablets are a yellow/orange color; individuals who take it may notice an orange tinge in urine, tears, and sweat that can stain clothing and contact lenses. Auxiliary labels and counseling should emphasize drinking plenty of fluids, taking the drug on an empty stomach, and avoiding antacids.

       

      Mesalamine and Balsalazide

      Low dose mesalamine may be prescribed initially at less than 2 grams per day(g/d). Some patients need 2 to 3 g/d. Higher doses of 3 g/d or more may be required to induce remission.36 Combining oral and rectal therapy may deliver a higher effective dose of 5-ASA to the involved area and lead to higher rates of induction and maintenance of remission. This approach may avoid escalation to corticosteroids or other agents.36

       

      Mesalamine and balsalazide are associated with rare idiosyncratic worsening of colitis.22 Rare interstitial nephritis may also occur. The prescribing information recommends periodic renal function monitoring. Olsalazine is generally less well tolerated than either mesalamine or balsalazide. Headache, nausea, diarrhea, leukopenia and hepatitis are possible. 5-ASA treatments should be avoided in pregnancy.22

       

      Steroids and Other Traditional Treatments

      Corticosteroids, such as budesonide, are generally prescribed for a short duration or for induction of remission.34 Some experts suggest prescribing oral mesalamine, balsalazide or olsalazine over budesonide because hepatic first-pass metabolism lowers budesonide’s systemic activity.34,44 As the patient’s condition improves, withdrawing the steroids and reaching steroid-free remission (SFR) is important. Long-term corticosteroid use may lead to infection, diabetes mellitus, weight gain, insomnia, osteoporosis, or glaucoma.45 Mood changes, cataracts and delayed wound healing are possible.45

       

      Thiopurines and Cyclosporine

      Thiopurines, including azathioprine and 6-mercaptopurine, may improve inflammation in patients with UC. They inhibit the proliferation of lymphocytes and are used to maintain remission. Their dosing is weight-based and their onset of action can be slow, taking up to three months.22 They are often used in combination with biologics. Monitoring for drug interactions is necessary. Allopurinol interactions with thiopurines are especially important because allopurinol inhibits thiopurine metabolism.46 The dose of mercaptopurine or azathioprine may need to be reduced to one-third or one-quarter of the normal dose if allopurinol is also prescribed. Prescribers determine dose reductions based on therapeutic response and toxicity.47

       

      Even though thiopurines and cyclosporine have been prescribed for many years, remaining aware of their side effects is important. Possible adverse events of thiopurines include nausea, vomiting, fever, leukopenia, thrombocytopenia, pancreatitis, and hepatotoxicity. Rare adverse events may include non-Hodgkin lymphoma. Individuals prescribed calcineurin inhibitors, such as cyclosporine, may experience hypertension, nephrotoxicity, hyperkalemia, infection, lymphoma, or diabetes mellitus.37

       

      Additional therapies include biologics and newer small molecules (tofacitinib, ozanimod). Before discussing newer therapies, a short review of step-up and step-down approaches is reasonable. If a patient presents with moderate to severe ulcerative colitis, philosophies differ among gastroenterologists regarding beginning with a step-up versus a step-down approach.36,48

      • The step-up approach begins with the traditional therapies mentioned above and followed by biologics and IMM if symptoms persist, if remission is not achieved, and the patient is considered high-risk. Extensive inflammation and the need for repetitive use of corticosteroids are examples of high-risk status.
      • The step-down approach occurs when prescribers begin with a more intensive treatment with biologics and IMM and then step down to the medications mentioned above if patients improve.

       

      Step Up or Step Down?

      A 2021 study (N = 1891) examined UC’s clinical presentation in the five years before starting biologic therapy. The researchers analyzed patients’ experiences, comorbidities, morbidity, and treatment burden over time. Figure 2 summarizes participants’ health burden, disease progression, medication burden, and increased comorbidities. Across the study period, the need for treatment with oral corticosteroids, 5-ASA, and other non-biologic immunomodulators (IMM) increased progressively. Due to the increasing burden, the researchers supported early use of biologics (a step-down approach) rather than gradual step-up after failing conventional therapies for adult patients with moderate to severe UC.30 

      Figure showing results from the trials mentioned

       

      Figure 2. Treatment and Health Experience Beginning Five Years Before First Biologic30

      5-ASA = 5-aminosalicylates; ED = emergency department; OC = oral corticosteroids; Pts = patients

       

       

      Anti-TNF agents

       

      Anti-TNF agents are commonly prescribed for moderate to severe UC due to their effectiveness, length of time on the market, and healthcare professional comfort prescribing them.44 The U.S. Food and Drug Administration (FDA) has approved many anti-TNFs, but has approved only adalimumab, golimumab, or inFLIXimab for treating UC. Usually, prescribers use anti-TNFs after 5-ASA and corticosteroids in patients with mild to moderate severity and the step-up approach to treatment. Prescribers may prescribe the step-down approach, using biologics earlier, in some cases.38 They often employ concomitant IMM to decrease immunogenicity seen with anti-TNFs.38,47

       

      Because biologics like anti-TNFs are made with living cells, patients may develop an unintended immune response (immunogenicity) in the form of anti-drug antibodies; if they develop, these antibodies may render the anti-TNF medication less effective. The antibodies may bind to the anti-TNF, interfere with its mechanism of action, reduce the anti-TNF’s serum concentration, increase its clearance, and lead to loss of effectiveness. Antibodies may also occur upon restarting an anti-TNF if a patient starts and stops an anti-TNF over time. It is unknown why some people develop anti-drug antibodies and others do not. The presence of antibodies and reduced response often prompt prescribers to switch the anti-TNF to regain effectiveness, and doing so often works. The addition of an IMM can suppress the antibodies which may reduce the risk of switching therapies or avoiding an anti-TNF dose increase.47

       

      Pharmacy team members should remain diligent about look-alike, and sound-alike names of the anti-TNF agents and should remember that doses of anti-TNF agents vary by indication.

       

      SIDEBAR: TECH TALK about Look-alike, Sound-alike medications

      Medications with names that look-alike and/or sound alike are classified as high-alert medications.

      • Know that inFLIXimab had been confused with riTUXximab, so the Institute for Safe Medication Practices recommends using TALL Man lettering.
      • Prevent medication errors between therapies for UC, such as adalimumab and golimumab, ustekinumab and upadacitinib, or vedolizumab and ustekinumab or adalimumab. Segregate the medications in different locations or consider stickers or other alert methods prior to medication dispensing.

       

       

      An Anti-integrin

      Integrins are adhesion receptors that mediate cell-to-cell and cell-to-extracellular adhesion. Vedolizumab is a humanized monoclonal antibody that binds to the α4β7 integrin, blocks the interaction of α4β7 integrin, and inhibits lymphocyte migration into inflamed GI tissue.49 With fewer lymphocytes in the GI tract, vedolizumab helps reduce inflammation and UC symptoms. Vedolizumab can be referred to as a B-anti-integrin and an adhesion molecule inhibitor. Patients with steroid-dependent disease have treatment options, including treatment with thiopurines, anti-TNF agents (may be combined with azathioprine or 6-mercaptopurine), or vedolizumab.38

       

      Prescribers and patients may ask about outcomes in clinical trials. A vedolizumab study enrolled patients with an inadequate response or intolerance to IMM therapy (i.e., azathioprine or 6-mercaptopurine) and/or an inadequate response, loss of response, or intolerance to an anti-TNF.49 Participants received IV vedolizumab 300 mg or placebo at week 0 and week 2. Concomitant stable dosages of 5-ASA, corticosteroids (prednisone dose of 30 mg/day or less or equivalent), and IMM (azathioprine or 6-mercaptopurine) were permitted through week 6. The percentage of patients achieving a clinical response at week 6 was 47%. The researchers also measured remission and found 17% of participants achieved remission at week 6. Those with a clinical response at week 6, or receiving open-label vedolizumab, were invited to enter a 52-week study with every 8-week dosing. At week 52, 42% of participants achieved clinical remission.49

       

      JAK inhibitors

       

      Tofacitinib and upadacitinib are referred to as small molecules because their molecular structure is smaller and simpler than the biologics’, which are large three-dimensional structures. The JAK inhibitors are dosed orally and require a loading dose. JAK inhibitors are indicated for adults with moderately to severely active UC who responded inadequately or couldn’t tolerate one or more anti-TNF agents.39 Many individuals are willing to visit an infusion suite for treatment; however, younger patients and those with very busy lifestyles or heavy travel schedules may prefer the small molecule oral drugs for their convenience.

       

      When prescribing JAK inhibitors, pretreatment screening should include assessment for hepatitis B and tuberculosis. When patients start biologics or JAK inhibitors, their immune response may decrease, increasing risk of certain infections, such as hepatitis B or tuberculosis. If patients have active hepatitis B or tuberculosis, they need treatment to eradicate those infections before beginning biologics or JAK inhibitors. A risk of bacterial, viral, and herpes zoster infections exists, so prescribers must assess vaccination status before treatment. CBC and lipid panel monitoring is recommended. Prescribing tofacitinib in combination with biologics for UC or with potent IMM, such as azathioprine and cyclosporine, is not recommended.40

       

       

      IL-12/23 antagonist

      Interleukin 12 (IL-12) and IL-23 are proteins that can cause inflammation. Ustekinumab is a human monoclonal antibody against the shared p40 subunit of IL-12 and IL-23 cytokines. Ustekinumab disrupts inflammation by blocking IL-12/23.41 The FDA has approved this biologic for adults with various forms of psoriasis, CD, and UC. (It is also approved for children 6 and older for various forms of psoriasis.) In UC in adults, it is typically administered as an IV induction dose, followed by subcutaneous maintenance dosing every eight or 12 weeks. Clinicians should screen for hepatitis B and tuberculosis and monitor CBC every six months.41 To minimize the risk of medication errors, pharmacy staff should double-check the prescribed route (IV or subcutaneous). They should also be alert for look-alike, sound-alike issues, to prevent prescription transcribing errors or other confusion between ustekinumab and the JAK inhibitor upadacitinib.

       

      Research has documented outcomes for this monoclonal antibody, too. A ustekinumab clinical trial assessed efficacy and safety in adults with UC; the primary endpoint was clinical remission at week 8.41 The researchers randomized participants to a single IV dose of ustekinumab of approximately 6 mg/kg, 130 mg (a lower dose than recommended), or placebo at week 0. Enrollment required previous inadequate response to corticosteroids, IMM, or at least one biologic. At week 8, 19% of participants successfully reached clinical remission.41

       

      S1P Modulator

      Ozanimod is an oral sphingosine 1-phosphate receptor (S1P) modulator indicated for the treatment of moderately to severely active UC in adults.42 It is also approved for relapsing forms of multiple sclerosis, and the pharmacy team may field questions about this medication’s various indications. Ozanimod binds with high affinity to S1P receptors 1 and 5. It blocks lymphocyte trafficking from lymph nodes, reducing the number of lymphocytes in peripheral blood. Ozanimod may transiently decrease heart rate and cause atrioventricular conduction delays, so a low-dose starter titration pack is available. Prescribers should escalate the dosing slowly to avoid rare but significant bradycardia. Progressive multifocal leukoencephalopathy, a disabling, sometimes deadly adverse event, is rare but possible. Pharmacy teams should counsel patients regarding the need for effective contraception to prevent pregnancy; patients should use contraceptives for three months after discontinuing ozanimod.42

       

      An ozanimod clinical trial assessed efficacy and safety using a primary study endpoint of clinical remission at week 10.42 It enrolled adults with moderately to severely active UC if they had an inadequate response, or were intolerant, to specific other treatments. The treatments included oral 5-ASA, corticosteroids, IMM (e.g., 6-mercaptopurine and azathioprine), or a biologic (e.g., anti-TNF and/or vedolizumab). The proportion of patients reaching clinical remission at week 10 was 18% with an ozanimod dose of  0.92 mg once daily. Those achieving a clinical response were invited to be re-randomized to a 52-week study extension. The primary endpoint was the proportion of patients in clinical remission at week 52. The proportion of patients with an ozanimod dose of 0.92 mg once daily with clinical remission at week 52 was 37%.42

       

      MEDICATIONS IN DEVELOPMENT

      Etrasimod is a once-daily, oral S1P receptor modulator in development for the treatment of UC. Results from the phase 2 OASIS trial and open-label extension study revealed patients with moderately to severely active UC who received etrasimod showed improvements in clinical remission and symptom relief beginning as early as week 2. In the phase 3 ELEVATE UC 52 study, 27% of patients in the etrasimod group achieved clinical remission compared with 7% of patients in the placebo group at 12 weeks.50 Use of etrasimod in UC is not FDA-approved and regulatory authorities have not yet evaluated its safety and efficacy.

       

      Risankizumab-rzaa is an IL-23 inhibitor that is FDA-approved for psoriasis and Crohn’s disease. It is in development for treatment of individuals with UC. In the INSPIRE trial, 20.3% of participants with intolerance or inadequate response to conventional or advanced therapies (biologics, JAK inhibitors, and S1P receptor modulators) achieved clinical remission at week 12.51 The FDA has not approved risankizumab in UC or evaluated its safety and efficacy.

       

      Considerations for Medications in Therapy

      Decision-making regarding UC treatment requires consideration of many factors, including

      • disease and inflammation location, severity, and extent
      • comparative effectiveness and long-term safety of available treatments
      • treatment availability
      • product labeling
      • guideline recommendation
      • prior treatment successes or failures
      • cost, and
      • patient preferences

      Since some prescribers may dose escalate to an off-label (higher) dose or off-label shorter dosing interval, pharmacy teams need to remain alert regarding insurance policies that may impact treatment decisions.

       

      Safety Information

      Each medication’s full prescribing information includes comprehensive safety and efficacy details. The information in this section is not all-inclusive. It’s critical to keep in mind that all UC treatments have limitations. Because most infusions have similar adverse events, Table 5 summarizes select safety information and limitations regarding newer agents used in UC.

       

       

      Table 5. Newer Agents: Select Safety Information and Limitations 37,41,42,49,52

      Limitations and Safety Considerations Anti-TNF agents Anti-IL-12/23

      Agents

      JAK Inhibitors Anti-integrin S1PR

      modulator

      Immuno-suppression
      Infection

      (herpes zoster)

      (upper respiratory)

      Venous thrombo-embolism        
      Psoriasis      
      Major CV adverse event      
      Infusion/ injection site reaction  
      Malignancy
      Tuberculosis  
      Worsen CHF        
      Lymphoma

      (if combine with thiopurines)

         
      Lymphocyte abnormalities        
      Anemia      
      Elevated lipids        
      Headache
      Nausea  
      Fatigue
      Liver function test elevations    
      Contra-indication if post-MI within 6 months, or unstable angina, stroke or TIA        
      Contraindicated if severe untreated sleep apnea        
      PML      

      MI = myocardial infarction; PML = progressive multifocal leukoencephalopathy; TIA = transient ischemic attack

       

      Identifying drug interactions is a key skill for pharmacists. Of note, JAK inhibitors can interact with CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and CYP2C19 inhibitors (e.g., fluconazole, omeprazole).40 Drug interactions may be a concern with the use of ozanimod and concurrent IMM, tyramine, antiarrhythmics, beta blockers, or calcium channel blockers.42

       

      ACG and AGA Guidelines for the Management of Moderate-to-Severe UC

      The American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) published comprehensive treatment guidelines and interventions for UC.31,44 Both guidelines cover achieving a response, induction of remission, and maintenance of remission. Select highlights presented below are not all-inclusive.

       

      For remission induction, ACG recommends the following options31:

      • In moderately active UC, oral budesonide MMX
      • In moderately to severely active UC, oral corticosteroids
      • In moderately to severely active UC, anti-TNF therapy
      • When inFLIXimab is used as induction therapy for patients with moderately to severely active UC, it should include a thiopurine
      • In moderately to severely active UC, or if failed anti-TNF, vedolizumab
      • In moderately to severely active UC, tofacitinib 10 mg orally twice a day for 8 weeks
      • For induction of remission in moderately to severely active UC with previous failure of anti-TNF therapy, tofacitinib

       

      For maintenance of remission, ACG recommends the following options31:

      • For previously moderately to severely active UC in remission due to corticosteroid induction, thiopurines
      • Continue anti-TNF therapy after anti-TNF induction in patients with previously moderately to severely active UC
      • Continue vedolizumab in previously moderately to severely active UC now in remission after vedolizumab induction
      • Continue tofacitinib in previously moderately to severely active UC now in remission after induction with tofacitinib

       

      The AGA provides the following recommendations for response and remission44:

      • Current evidence supports use of inFLIXimab, adalimumab, golimumab, vedolizumab, and tofacitinib for remission induction and maintenance in moderate-severe UC
      • Thiopurine monotherapy should not be used for induction of remission but may be considered for remission maintenance
      • Meta-analysis suggests that inFLIXimab and vedolizumab may be preferred first-line therapy in biologic-naïve patients, rather than standard-dose adalimumab or golimumab
      • In patients with prior inFLIXimab exposure, particularly those with primary non-response to induction therapy, vedolizumab or tofacitinib may be preferred over adalimumab or golimumab
      • Combination of a biologic agent with an immunomodulator is more effective than monotherapy with either agent
      • In patients with moderate-severe disease activity, at high risk of colectomy, biologic agents with or without an IMM, or tofacitinib, should be used early rather than gradual step-up therapy after failure of 5-ASA
      • Patients in remission with biologic agents and/or IMM, or tofacitinib, after prior failure of 5-ASA, may discontinue 5-ASA

       

      PAUSE AND PONDER: What patient support questions may uncover a patient’s adherence challenges?

       

      Patient Education Pearls for Patient Counseling

       

      Pharmacy teams have numerous opportunities to provide UC patient education. Because the condition appears differently in affected individuals, conversations should align with the individual patient’s situation. Supportive patient education pearls addressing inflammation and advancing opportunities to remission should be individualized from these topics53:

      • UC’s exact cause is unknown
      • UC affects people differs widely
      • UC is a chronic condition and symptoms wax and wane
      • Medications are available to control UC
      • The number of people with UC has been increasing
      • It can occur at any age and in any racial or ethnic group
      • Symptoms will occur in the intestine and may occur outside of the intestine
      • Ulcers in the intestine lining that bleed may lead to low red blood cell count (anemia)
      • Ask the doctor what tests are needed
      • Diet and nutrition plans differ for each patient
      • Managing stress is important
      • Have supportive friends and family
      • Locate restrooms when outside the home
      • Carry extra underclothes, toilet paper or moist wipes
      • Ask for school or work accommodations

       

      SIDEBAR: OTC and Alternative Therapies for Patient Discussion34,35,44,54

       

      Patients with UC may use these OTC products:

      • Patients with UC may eat less, thinking it will decrease diarrhea. However, they need proteins, water, vitamins, and minerals to promote healing. Patients need vitamin D and calcium for bones if reduce their dairy intake.
      • Bismuth subsalicylate (Pepto Bismol) is an antidiarrheal liquid, chewable tablet, and also swallowable tablet. It helps reduce inflammation in the intestinal lining. Remind patients that it darkens stool and the tongue. That darkening is not a medical concern.
      • Simethicone (Gas-X) is an anti-flatulent that helps form gas bubbles in the digestive tract, making them easier to pass and relieving gas pain.
      • Loperamide (Imodium) should be taken with caution. It slows digestion. Occasional use may be effective, but patients should consult healthcare providers if they contemplate ongoing use.
      • If mild disease persists, such as seen with a Mayo score of 1, the AGA guidelines and some advocacy web sites mention curcumin (a phytochemical from turmeric) or suggest adding curcumin and probiotics for some individuals suffering with UC.
      • Patients with severe disease, frequent bleeding, anemia, or abnormal laboratory results may need folic acid. The usual folic acid dose is 1 mg/day. Asparagus, broccoli, and spinach are also foods that contain folate or folic acid.

      Patients who have UC should avoid these OTC products:

      • Patients should consult their healthcare providers whether to avoid aspirin, nonsteroidal anti-flammatories (ibuprofen, naproxen), lactose, sugar substitutes, or preservatives.
      • Patients who take sulfasalazine or mesalamine should not take them with antacids.

       

      Many institutions, hospitals and healthcare providers have created UC resources. Table 6 lists  examples of supportive options that can be shared with individuals with UC.

       

      Table 6. Patient and Clinician Resources to Support Individuals with UC

      Resource Contact
      American College of Gastroenterology https://gi.org/topics/ulcerative-colitis/

      ·       Describes symptoms, tests, diagnosis, risks, surgery and treatments

      Cleveland Clinic: Butts and Guts podcast https://my.clevelandclinic.org/podcasts/butts-and-guts

      ·       Covers a wide range of gastrointestinal issues including management and surgery

      ·       Use the search term “ulcerative colitis”

      Crohn’s and Colitis Foundation (CCF)

       

      Help Center (referrals, insurance info)

      https://www.crohnscolitisfoundation.org/

      info@crohnscolitisfoundation.org

      1-888-MY-GUT-PAIN

      (888-694-8872- extension 8)

      Signs and Symptoms https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/living-with-ulcerative.pdf

      Spanish Help Center
      https://www.crohnscolitisfoundation.org/es/home

      School Accommodation Suggestions

      https://www.crohnscolitisfoundation.org/justlikeme/living-with-crohns-and-colitis/school/school-accommodations

      Mayo Clinic https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/symptoms-causes/syc-20353326

      ·       Includes a video and written materials on diagnosis, symptom management, and treatment

      Downloadable Mobile Apps

      ·       Download from the App Store or Google Play

      My IBD Care: tracks symptoms, flares, medical appointments, BMs, medications

      Bathroom Scout: Identifies 1.3 million public toilets

      MyPlate: Monitors calories, the nutrition content of food

      MyColitis: Health tracking of bowel movements, medications, moods, symptoms, tests

       

      CONCLUSION

      UC is a debilitating chronic IBD that usually requires long-term treatment to control symptoms and prevent disease-related complications. Many treatments are available; however, the effectiveness, safety, and durability of response and remission vary, and careful assessment of these factors must drive a personalized approach to care. Pharmacy teams must recognize that every patient’s disease is different, and results in diverse manifestations. Pharmacists and pharmacy technicians are ideally positioned to collaborate with multidisciplinary teams to support strategies tailored to each patient to optimize care and to help patients maintain a positive outlook.

       

      Many unanswered questions remain about UC. Researchers will continue to evaluate treatment advances and explore disease management opportunities while pharmacy teams encourage patients suffering from UC to have routine doctor visits, adhere to their medication regimen, and maintain a healthy lifestyle.

       

       

       

       

      Pharmacist Post Test (for viewing only)

      Learning Objectives
      After completing this continuing education activity, pharmacists will be able to
      1. Differentiate UC from Crohn’s disease
      2. Describe currently available and novel UC medications under development in the United States
      3. Outline the relationship between the types of treatment for UC, patient characteristics and disease severity
      4. Identify patient education pearls to address inflammation and advance to remission

      1. Which is true regarding the difference between Crohn’s and ulcerative colitis (UC)?
      a. Crohn’s disease is limited to inflammation of the colon mucosa
      b. Ulcerative colitis can appear anywhere between the mouth and anus
      c. Ulcerative colitis involves inflammation of the colon mucosa

      2. Which is the usual adalimumab starting dose for a newly diagnosed UC patient?
      a. Adalimumab 160 mg at week 0, 80 mg at week 2, 40 mg at week 4
      b. Adalimumab 20 mg at week 0, 40 mg at week 2, 50 mg at week 3
      c. Adalimumab 200mg at week 0, 90 mg at week 2, 60 mg at week 4

      3. Which statement reflects a novel characteristic of ozanimod?
      a. Ozanimod is an IL 12/23 monoclonal antibody
      b. Ozanimod is an oral S1P modulator
      c. Ozanimod is a oral JAK inhibitor

      4. When inducing remission, which statement(s) describe(s) ACG recommended UC treatment, patient characteristics, and disease severity?
      a. In moderately to severely active UC or if failed anti-TNF, a 5-ASA is recommended
      b. In moderately to severely active UC oral corticosteroids may be prescribed
      c. In mild-to-moderate UC, lifestyle changes are usually sufficient to induce remission

      5. Which are patient education pearls to discuss with a patient suffering with UC?
      a. The number of people with UC has been decreasing
      b. Intestinal ulcers that bleed will not lead to anemia
      c. Many medication options are available to control UC

      6. You receive a prescription or order for tofacitinib. Which of the following would be an appropriate dose for a patient who has UC?
      a. 5 mg orally once a week
      b. 5-10 mg orally daily
      c. 10 mg IV every 8 weeks

      7. Which statement contains safety information to be aware of with UC treatments?
      a. Sulfasalazine carries a risk for venous thromboembolism, herpes zoster, and major cardiovascular adverse events
      b. JAK inhibitors may interfere with folate metabolism, affect male fertility, cause rare cutaneous adverse effects
      c. Ustekinumab may cause infections, infusion or injection site reactions and may increase the risk of malignancy

      8. A 22-year-old college student with newly diagnosed UC is experiencing daily blood in the stool, cramping, and had bowel incontinence on the way to the parking lot after class. Multiple options are available to treat this patient. What are the goals of treatment?
      a. To prescribe medication to obtain response in 1 week and remission in 8 days
      b. To induce and maintain clinical and endoscopic remission and quality of life
      c. To use oral medications only (and avoid infusions) because of her youth and lifestyle

      9. A 17-year-old restaurant worker presents with pancolitis. She has no other significant past medical history. She was treated with adalimumab, but the condition is worse with daily blood in the stool, 5 BMs/day, and weight loss of 10 pounds in the past 2 months. She has been reading about UC and is interested in switching to an infusion. Which is a possible IV treatment option?
      a. Prednisone
      b. Vedolizumab
      c. Balsalazide

      10. A 30-year-old newly married patient with UC works as a flight attendant. She has pancolitis and was told she is anemic and today has a fever. She comes to the pharmacy before her doctor’s appointment asking which UC medications are oral. Which product names are options to provide this patient?
      a. Methylprednisolone
      b. Ustekinumab
      c. Ozanimod

      Pharmacy Technician Post Test (for viewing only)

      Pharmacy Technician Learning Objectives
      After completing this continuing education activity, the pharmacy technician will be able to
      1. Differentiate UC from Crohn’s disease
      2. Describe currently available and novel UC medications under development in the United States
      3. Outline the relationship between the types of treatment for UC, patient characteristics and disease severity
      4. List symptoms that a patient with UC may share with a pharmacy technician

      1. Which is true regarding the difference between Crohn’s and ulcerative colitis (UC)?
      a. Crohn’s disease is limited to inflammation of the colon mucosa
      b. Ulcerative colitis can appear anywhere between the mouth and anus
      c. Ulcerative colitis involves inflammation of the colon mucosa

      2. Which is the usual adalimumab starting dose for a newly diagnosed UC patient?
      a. Adalimumab 160 mg at week 0, 80 mg at week 2, 40 mg at week 4
      b. Adalimumab 20 mg at week 0, 40 mg at week 2, 50 mg at week 3
      c. Adalimumab 200mg at week 0, 90 mg at week 2, 60 mg at week 4

      3. Which statement reflects a novel characteristic of ozanimod?
      a. Ozanimod is an IL 12/23 therapeutic
      b. Ozanimod is an oral S1P modulator
      c. Ozanimod is an oral JAK inhibitor

      4. A patient who visits the pharmacy often for medication related to his UC brings a few OTC products to the register. Which of the following might be a problem?
      a. Simethicone
      b. Naproxen
      c. Curcumin

      5. Which symptoms might a new patient suffering with UC reveal to a pharmacy technician?
      a. cold sores, stomach ulcers, 1 BM/day, miss 1 day of work/year
      b. bloody stools, 6 BMs/day, mood changes, had to quit work
      c. 1 BM/day, cold sore, dental pain, perfect work attendance

      6. You receive a prescription or order for tofacitinib. Which of the following would be an appropriate dose for a patient who has UC?
      a. 5 mg orally once a week
      b. 5-10 mg orally daily
      c. 10 mg IV every 8 weeks

      7. Which statement contains safety information to be aware of with UC treatments?
      a. Sulfasalazine carries a risk for venous thromboembolism, herpes zoster, and major cardiovascular adverse events
      b. JAK inhibitors may interfere with folate metabolism, affect male fertility, cause rare cutaneous adverse effects
      c. Ustekinumab may cause infections, infusion or injection site reactions and may increase the risk of malignancy

      8. A 22-year-old college student with newly diagnosed UC is experiencing daily blood in the stool, cramping, and had bowel incontinence on the way to the parking lot after class. Multiple options are available to treat this patient. What are the goals of treatment?
      a. To prescribe medication to obtain response in 1 week and remission in 8 days
      b. To induce and maintain clinical and endoscopic remission and quality of life
      c. To use oral medications only (and avoid infusions) because of her youth and lifestyle

      9. A 17-year-old restaurant worker presents with pancolitis. She has no other significant past medical history. She was treated with adalimumab, but the condition is worse with daily blood in the stool, 5 BMs/day, and weight loss of 10 pounds in the past 2 months. She has been reading about UC and is interested in switching to an infusion. Which is a possible IV treatment option?
      a. Prednisone
      b. Vedolizumab
      c. Balsalazide

      10. A 30-year-old newly married patient with UC works as a flight attendant. She has pancolitis and was told she is anemic and today has a fever. She comes to the pharmacy before her doctor’s appointment asking which UC medications are oral. Which product names are options to provide this patient?
      a. Methylprednisolone
      b. Ustekinumab
      c. Ozanimod

      References

      Full List of References

      REFERENCES

      1. Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26(6):349-355. doi: 10.1053/j.sempedsurg.2017.10.003
      2. Guindi M, Riddell RH. Indeterminate colitis. J Clin Pathol. 2004;57(12):1233-1244. doi: 10.1136/jcp.2003.015214
      3. Joo M, Odze RD. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. Am J Surg Pathol. 2010;34(5):689-696. doi: 10.1097/PAS.0b013e3181db84cd
      4. Maaser C, Sturm A, Vavricka SR, et al. European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR] ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi:10.1093/ecco-jcc/jjy113
      5. Kobayashi T, Siegmund B, Le Berre C et al. Ulcerative colitis. Nat Rev Dis Prim. 2020;6:74. doi: 10.1038/s41572-020-0205-x
      6. Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond). 2021;21(2):135-139. doi: 10.7861/clinmed.2021-0080
      7. Alatab S, Sepanlou SG, Ikuta K, et al.; GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. doi: https://doi.org/10.1016/S2468-1253(19)30333-4
      8. Pilon D, Zhijie D, Muser E, et al. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. CurrMed Res Opin. 2020;36(8):1285-129. doi: 10.1080/03007995.2020.1771293
      9. Sturm A, Maaser C, Calabrese E, et al. European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR] ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13(3):273-284. doi: 10.1093/ecco-jcc/jjy114
      10. Trivedi PJ, Adams DH. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. J Crohns Colitis. 2018;12(suppl_2):S641-S652. doi: 10.1093/ecco-jcc/jjx145
      11. Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohn’s Colitis. 2015;9:507–15. doi: https://doi.org/10.1093/ecco-jcc/jjv059
      12. Xu F, Dahlhamer JM, Zammitti EP, Wheaton AG, Croft JB. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease—United States, 2015 and 2016. MMWR Morb Mortal Wkly Rep. 2018;67:190-5. doi: https://doi.org/10.15585/mmwr.mm6706a4
      13. Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004)
      14. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2
      15. Lamb CA, Kennedy NA, Raine T et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106. doi: 10.1136/gutjnl-2019-318484
      16. Shah SC, Itzkowitz SH. Reappraising risk factors for inflammatory bowel disease-associated neoplasia: implications for colonoscopic surveillance in IBD. J Crohn’s Colitis. 2020;14:1172-1177. doi: 10.1093/ecco-jcc/jjaa040
      17. Terry R, Chintanaboina J, Patel D, et al. Expression of WIF-1 in inflammatory bowel disease. Histol Histopathol. 2019;34(2):149-157
      18. Yamamoto-Furusho JK, Fonseca-Camarillo G, Furuzawa-Carballeda J, et al. Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. J Inflamm (Lond).2018;15:13. doi: 10.1186/s12950-018-0189-4.
      19. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis2008;14:1660–1666. doi:10.1002/ibd.20520
      20. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629. doi: 10.1056/NEJM198712243172603
      21. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501-523; doi: 10.1038/ajg.2009.727
      22. Dipentum. Prescribing information. Viatris Inc.; June 2021. Accessed April 12, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019715s029lbl.pdf
      23. Blackwell J, Saxena S, Jayasooriya N, et al. Prevalence and Duration of Gastrointestinal Symptoms Before Diagnosis of Inflammatory Bowel Disease and Predictors of Timely Specialist Review: A Population-Based Study. J Crohns Colitis. 2021;15(2): 203-211. doi:https://doi.org/10.1093/ecco-jcc/jjaa146
      24. Colman RJ, Dhaliwal J, Rosen MJ. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Front Pediatr. 2021;9:634739. doi: 10.3389/fped.2021
      25. Finkelstein A. You Will Have a New Life. Ann Fam Med. 2018;16(2):166-167. doi: 10.1370/afm.2181
      26. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis.2011;17:1314–1321. doi:10.1002/ibd.21493
      27. Aloi M, Lionetti P, Barabino A, et al. Phenotype and Disease Course of Early-onset Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2014;20(4):597-605.
      28. Levine A, de Bie CI, Turner D, et al. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis.2013;19:370-377. doi:10.1002/ibd.23013
      29. Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis. 2021;53(7):803-808. doi: 10.1016/j.dld.2021.03.002
      30. Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol. 2021;21(1):121. doi: 10.1186/s12876-021-01708-6.
      31. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. J Am Coll Gastroenterol.2019;114:384–413. doi: 10.14309/ajg.0000000000000152
      32. Peyrin-Biroulet L, Sandborn W, Sands B, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol2015;110:1324-1338. doi: 10.1038/ajg.2015.233
      33. Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14(2):254-266. doi:10.1093/ecco-jcc/jjz131
      34. Ko C, Singh S, Feuerstein J, et al. American Gastroenterological Institute Guideline on the management of mild-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748-764. doi: 10.1053/j.gastro.2018.12.009
      35. Diaz G. Mild-to-moderate ulcerative colitis. GrepMed. Updated July 31,2020. Accessed April 9, 2023. https://www.grepmed.com/images/9608/moderate-algorithm-management-colitis-treatment-
      36. Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2019;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008
      37. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553-63. doi: 10.1016/j.mayocp.2014.07.002
      38. Burri E, Maillard M, H, Schoepfer A, M, et al. Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update. Digestion. 2020;101(suppl 1):2-15. doi: 10.1159/000504092
      39. Rinvoq. Prescribing information. Abbvie Inc; April 2023. Accessed April 11, 2023. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf
      40. Xeljanz. Prescribing information. Pfizer Labs; January 2022. Accessed April 11, 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=959
      41. Stelara. Prescribing information. Janssen; July 2022. Accessed April 10, 2023. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf
      42. Zeposia. Prescribing information. Bristol-Myers Squibb; November 2022. Accessed April 10, 2023. https://packageinserts.bms.com/pi/pi_zeposia.pdf
      43. Azulfidine. Prescribing information. Pfizer Labs: October 2022. Accessed April 11, 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=524
      44. Feuerstein JD, Isaacs K, Schneider Y, et al. American Gastroenterological Association Institute clinical guideline on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450-1461. doi: 10.1053/j.gastro.2020.01.006
      45. Rubin WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255-260. doi: 10.1053/gast.2001.26279
      46. Zyloprim. Prescribing information. Casper Pharma. December 2018. Accessed April 9, 2023 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016084s044lbl.pdf
      47. Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D'Haens GR. Suppression of anti-drug antibodies to inFLIXimab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1128-1134. doi:10.1111/apt.13994
      48. Kim M, Kim E, Kang B, Choe Y. Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy. Yonsei Med J. 2021;62(7):608-614. doi: 10.3349/ymj.2021.62.7.608
      49. Entyvio. Prescribing information. Takeda Pharmaceuticals USA, Inc.; June 2022. Accessed April 10, 2023. https://content.takeda.com/?contenttype=PI&product=ENTY&languag e=ENG&country=USA&documentnumber=1

      50. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2
      51. Rizankizumab (SKYRIZI®) achieves primary and all secondary endpoints in phase 3 induction study in patients with ulcerative colitis. Abbvie. News Center. March 23, 2023. Accessed April 10, 2023. https://news.abbvie.com/news/press-releases/risankizumab-skyrizi-achieves-primary-and-all-secondary-endpoints-in-phase-3-induction-study-in-patients-with-ulcerative-colitis.htm
      52. Remicade. Prescribing information. Janssen Biotech, Inc. October 2021. Accessed April 8, 2023
      53. Living with Ulcerative Colitis. Crohn’s and Colitis Foundation. December 2018. Accessed April 11, 2023. https://issuu.com/ccfa1/docs/living-with-ulcerative-colitis-brochure-final?fr=sN2ZhYjM3MDAxNzI
      54. Patrick E. Over the counter medication for ulcerative colitis. Ulcer Talk. April 10, 2023. Accessed April 15, 2023https://www.ulcertalk.com/over-the-counter-medication-for-ulcerative-colitis/

       

       

       

      Patient Safety: Medication Refusal: Understanding the Why “They Just Say No”

      Learning Objectives

       

      After completing this application-based continuing education activity, pharmacists will be able to

      Recognize and define types and leading causes of treatment/medication refusal
      Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
      Determine treatment alternatives for patients with dietary, religious, or other restrictions
      Identify and implement key components of a medication refusal protocol

        After completing this application-based continuing education activity, pharmacy technicians will be able to

        Recognize and define types and leading causes of treatment/medication refusal
        Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
        Determine treatment alternatives for patients with dietary, religious, or other restrictions
        Identify and implement key components of a medication refusal protocol

         

        Release Date: October 17, 2023

        Expiration Date: October 15, 2026

        Course Fee

        Pharmacists: $7

        Pharmacy Technicians: $4

        There is no grant funding for this CE activity

        ACPE UANs

        Pharmacist: 0009-0000-23-047-H05-P

        Pharmacy Technician: 0009-0000-23-047-H05-T

        Session Codes

        Pharmacist:  20YC80-TRX39

        Pharmacy Technician:  20YC80-XRT42

        Accreditation Hours

        2.0 hours of CE

        Accreditation Statements

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-047-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

         

        Disclosure of Discussions of Off-label and Investigational Drug Use

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Faculty

        Danielle Haskins, PharmD
        CVS Pharmacy Manager
        Santee, CA

         

        Ming May Zhang, PharmD Candidate 2022
        University of Connecticut School of Pharmacy
        Storrs, CT

        Faculty Disclosure

        In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

        Danielle Haskins and Ming May Zhang  do not have any financial relationships with ineligibile companies.

         

        ABSTRACT

        Based on the principle of informed consent, competent patients always
        have the right to refuse medical treatment. Patients may refuse treatment
        for a variety of reasons, including dietary restrictions, religious reasons, medical
        misconceptions, a desire to avoid adverse effects, and mistrust of the medical
        team. Patient refusals can create serious dilemmas in the healthcare setting. On
        the one hand, clinicians have an ethical and legal obligation to honor patient autonomy.
        On the other hand, a patient’s refusal of treatment often leads to adverse
        medical outcomes, resulting in harm to the patient. Healthcare
        professionals should search for acceptable treatment alternatives that honor patients’
        wishes while meeting their medical needs. Every institution—whether in
        the community, long-term care, or inpatient setting—should have a protocol to
        guide and standardize the approach to managing treatment refusals. In complex
        cases, it may be beneficial to use expert ethics consultations.

        CONTENT

        Content

        ONLY PDF version is Available for this CE

         

         

        Pharmacist Post Test (for viewing only)

        Medication Refusal: Understanding the Why "They Just Say No"
        After participating in this activity, pharmacists and pharmacy technicians will be able to
        1. Recognize and define types and leading causes of treatment/medication refusal
        2. Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
        3. Determine treatment alternatives for patients with dietary, religious, or other restrictions
        4. Identify and implement key components of a medication refusal protocol

        1. Which of the following is an example of ACTIVE medication refusal?
        a. A patient ingests her medication when the caregiver administers it, but secretly spits it out half an hour later.
        b. A patient states that she does not wish to take her oral medication, then refuses to open her mouth to ingest the medication.
        c. A patient initially refuses to take her medication, but concedes when the caregiver repeatedly asks her to.

        2. A patient states that he is vegetarian and wishes to avoid animal products. Which of the following excipients is INAPPROPRIATE for this patient?
        a. Gelatin
        b. Peanut oil
        c. Mannitol

        3. Which of the following best describes motivational interviewing?
        a. An interviewing style that involves the use of ethics counselors, who help healthcare professionals navigate complicated cases
        b. The process by which patients are educated about a treatment’s risks, benefits, and alternatives
        c. A behavioral technique that motivates patients to change by empowering them and motivating them with their own values

        4. Which of the following statements is FALSE about the practice of covert medication?
        a. It refers to administering medications without a patient’s knowledge, such as by concealing medications in food or drink.
        b. It is justifiable in mentally competent patients who refuse treatment against medical advice.
        c. It may be better received than more aggressive methods, such as forced injections.

        5. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which of the following best describes her reasons for refusing Medication X?
        a. Dietary restriction
        b. Medical misconception
        c. Mistrust of the medical team

        6. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which is the best resource to refer her to?
        a. Pillbox, so she can research medications’ ingredients and avoid those containing animal products
        b. The primary literature and PubMed or GoogleScholar, so she can find the most recent data
        c. The patient should not be referred; Medication X is the most effective option for her illness, and she should take it regardless of her beliefs

        7. Why might an ethics consultation be useful in certain instances of treatment refusal?
        a. Ethics counselors are authorized to make healthcare decisions on behalf of incompetent patients.
        b. Ethics counselors are compensated based on patient outcomes, so they persuade patients to choose the most medically effective option.
        c. Ethics counselors are trained in core ethics and healthcare competencies and can help navigate difficult situations.

        8. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. This is an example of:
        a. Beneficence
        b. Primum non nocere
        c. Autonomy

        9. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. Which of the following is the LEAST appropriate response to BT?
        a. Inform BT of the risks and benefits of OTC products, and show him how to interpret the Drug Facts labels.
        b. Identify BT’s reason for refusal—ask about his beliefs, perceptions, and concerns. Counsel him accordingly.
        c. Inform BT that you will request an ethics consultation to advise in this situation, which in your opinion is untenable.

        10. Patient WG is prescribed a new medication and told to take one capsule twice a day. WG misunderstands—he takes two capsules once a day, instead. Which of the following best describes WG’s behavior?
        a. Intentional non-adherence
        b. Unintentional non-adherence
        c. Passive refusal

        11. Patient AU tells you, “Dr. S prescribed five different pills for me, but I’m not taking any of them. I’m a regular churchgoer and I know I should love and respect all people, but I don’t have a good feeling about Dr. S. I think she has it out for me. I’m going to get the meds from Dr. G instead.” Based on this statement, AU’s primary reason for refusal is:
        a. Religious refusal
        b. Lack of belief in the medications’ effect
        c. Mistrust of the medical provider

        12. Patient LG is a 5-year-old female who requires a life-saving blood transfusion. Her caretaker refuses to consent to the procedure since it goes against her religious beliefs. Which of the following statements is TRUE of this situation?
        a. The attending physician must request an ethics consultation, since this is legally required for all cases involving a minor.
        b. LG’s caretaker has the ultimate say in her medical decisions but LG’s doctors are ethically obligated do what is beneficial for the patient.
        c. Since LG does not suffer from any brain disorders, she can make her own medical decisions. The medical team only needs LG’s consent, not the caretaker’s.

        Pharmacy Technician Post Test (for viewing only)

        Medication Refusal: Understanding the Why "They Just Say No"
        After participating in this activity, pharmacists and pharmacy technicians will be able to
        1. Recognize and define types and leading causes of treatment/medication refusal
        2. Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
        3. Determine treatment alternatives for patients with dietary, religious, or other restrictions
        4. Identify and implement key components of a medication refusal protocol

        1. Which of the following is an example of ACTIVE medication refusal?
        a. A patient ingests her medication when the caregiver administers it, but secretly spits it out half an hour later.
        b. A patient states that she does not wish to take her oral medication, then refuses to open her mouth to ingest the medication.
        c. A patient initially refuses to take her medication, but concedes when the caregiver repeatedly asks her to.

        2. A patient states that he is vegetarian and wishes to avoid animal products. Which of the following excipients is INAPPROPRIATE for this patient?
        a. Gelatin
        b. Peanut oil
        c. Mannitol

        3. Which of the following best describes motivational interviewing?
        a. An interviewing style that involves the use of ethics counselors, who help healthcare professionals navigate complicated cases
        b. The process by which patients are educated about a treatment’s risks, benefits, and alternatives
        c. A behavioral technique that motivates patients to change by empowering them and motivating them with their own values

        4. Which of the following statements is FALSE about the practice of covert medication?
        a. It refers to administering medications without a patient’s knowledge, such as by concealing medications in food or drink.
        b. It is justifiable in mentally competent patients who refuse treatment against medical advice.
        c. It may be better received than more aggressive methods, such as forced injections.

        5. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which of the following best describes her reasons for refusing Medication X?
        a. Dietary restriction
        b. Medical misconception
        c. Mistrust of the medical team

        6. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which is the best resource to refer her to?
        a. Pillbox, so she can research medications’ ingredients and avoid those containing animal products
        b. The primary literature and PubMed or GoogleScholar, so she can find the most recent data
        c. The patient should not be referred; Medication X is the most effective option for her illness, and she should take it regardless of her beliefs

        7. Why might an ethics consultation be useful in certain instances of treatment refusal?
        a. Ethics counselors are authorized to make healthcare decisions on behalf of incompetent patients.
        b. Ethics counselors are compensated based on patient outcomes, so they persuade patients to choose the most medically effective option.
        c. Ethics counselors are trained in core ethics and healthcare competencies and can help navigate difficult situations.

        8. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. This is an example of:
        a. Beneficence
        b. Primum non nocere
        c. Autonomy

        9. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. Which of the following is the LEAST appropriate response to BT?
        a. Inform BT of the risks and benefits of OTC products, and show him how to interpret the Drug Facts labels.
        b. Identify BT’s reason for refusal—ask about his beliefs, perceptions, and concerns. Counsel him accordingly.
        c. Inform BT that you will request an ethics consultation to advise in this situation, which in your opinion is untenable.

        10. Patient WG is prescribed a new medication and told to take one capsule twice a day. WG misunderstands—he takes two capsules once a day, instead. Which of the following best describes WG’s behavior?
        a. Intentional non-adherence
        b. Unintentional non-adherence
        c. Passive refusal

        11. Patient AU tells you, “Dr. S prescribed five different pills for me, but I’m not taking any of them. I’m a regular churchgoer and I know I should love and respect all people, but I don’t have a good feeling about Dr. S. I think she has it out for me. I’m going to get the meds from Dr. G instead.” Based on this statement, AU’s primary reason for refusal is:
        a. Religious refusal
        b. Lack of belief in the medications’ effect
        c. Mistrust of the medical provider

        12. Patient LG is a 5-year-old female who requires a life-saving blood transfusion. Her caretaker refuses to consent to the procedure since it goes against her religious beliefs. Which of the following statements is TRUE of this situation?
        a. The attending physician must request an ethics consultation, since this is legally required for all cases involving a minor.
        b. LG’s caretaker has the ultimate say in her medical decisions but LG’s doctors are ethically obligated do what is beneficial for the patient.
        c. Since LG does not suffer from any brain disorders, she can make her own medical decisions. The medical team only needs LG’s consent, not the caretaker’s.

        References

        Full List of References

        References

           

          These can be found on the pdf version of the CE

          Patient Safety: Seven Secrets for Patient Safety with Dietary Supplements

          Learning Objectives

           

          After completing this application-based continuing education activity, pharmacists will be able to

          ·       Discuss the importance of knowing about a patient’s dietary supplement usage
          ·       Identify commonly used dietary supplements, their regulation, and the value of certification
          ·       Recognize potential medication-dietary supplement interactions
          ·       Demonstrate the ability to locate different sources of information about dietary supplements

          After completing this application-based continuing education activity, pharmacy technicians will be able to

          ·       Discuss the importance of knowing about a patient’s dietary supplement usage
          ·       Identify commonly used dietary supplements, their regulation, and the value of certification
          ·       Recognize potential medication-dietary supplement interactions
          ·       Recognize the need for pharmacist counseling when a patient is taking a dietary supplement

          a dinner plate with a variety of colorful capsules with a fork and spoon on the table

           

          Release Date: January 16, 2026

          Expiration Date: January 16, 2029

          Course Fee

          Pharmacists: $7

          Pharmacy Technicians: $4

          There is no grant funding for this CE activity

          ACPE UANs

          Pharmacist: 0009-0000-26-002-H05-P

          Pharmacy Technician: 0009-0000-26-002-H05-T

          Session Codes

          Pharmacist:  23YC01-FKE24

          Pharmacy Technician:  23YC01-EFK68

          Accreditation Hours

          2.0 hours of CE

          Accreditation Statements

          The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-26-002-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

           

          Disclosure of Discussions of Off-label and Investigational Drug Use

          The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

          Faculty

          Jennifer Salvon, RPh
          Clinical Pharmacist
          Mercy Medical Center

          Springfield, MA

          Adjunct Faculty Member
          University of Connecticut School of Pharmacy
          Storrs, CT

          Faculty Disclosure

          In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

          Jennifer Salvon does not have any relationships with ineligible companies and therefore has nothing to disclose.

           

          ABSTRACT

          Consumer consumption of dietary supplements is at an all-time high. Available products number in the tens of thousands, generating millions in annual spending. Increasing interest in overall health and wellness, preventive medicine, and immune function contribute to the rise in usage. It is a common misconception that dietary supplements are safe because they are “natural.”
          Ingestion of dietary supplements poses serious health risks including adverse reactions, drug interactions, and toxicity. Adulterated, mislabeled, and contaminated products exist in the marketplace, further increasing consumer risk. Existing federal regulation and oversight for supplements differs from prescription and over-the-counter medications, occurring primarily on a post-marketing basis. Self-reporting by consumers, healthcare professionals, and industry personnel identifies these issues. Patients often omit dietary supplements from medication histories, leaving healthcare professionals unaware that patients are using them. While misinformation abounds on the Internet, many online clinically-backed sources exist.

          CONTENT

          Content

          Introduction

           

          Consuming natural substances to produce a desired effect on the body dates back thousands of years to ancient Egypt, Rome, China, and many other cultures. Records from early Mesopotamia include written formulas using many oils still in use today, including cedar, cypress, and licorice. Around 300 B.C., the Greek philosopher Theophrastus described the medicinal benefits of natural substances in his History of Plants. Throughout the centuries, many philosophers, scientists, and physicians continued collecting, combining, and documenting the use of natural products to treat different illnesses.1

           

          As the science of medicine developed, so did the science of pharmacology. Isolation of the active ingredients found in herbal substances lead to the development of synthetic compounds with similar properties. The first synthetic medication, chloral hydrate, derived from chloroform and discovered in the 1800s by German chemist Justus von Lieberg, is still in use today.2

           

          Fast forward to modern day, and the interest and use of prescription medications, over-the-counter (OTC) products, and dietary supplements are at an all-time high. In 2020, consumers filled 6.3 billion prescriptions in the United States3 (U.S.) and purchased more than 6 billion OTC products.4 The dietary supplement market reached an unprecedented level in 2020 with a global spend of $61.2 billion. Experts predict it will reach $128.64 billion by 2028.5

           

          The COVID-19 pandemic, caused by the SARS-CoV-2 acute respiratory coronavirus, significantly impacted our perception and approach to healthcare.6 More and more people use complementary and alternative approaches to healthcare than ever before.7 For example, sales of elderberry supplements more than doubled and zinc products quadrupled shortly after the pandemic's start.8

           

          Pharmacists, widely recognized as drug information experts, and pharmacy technicians routinely field consumers' questions about dietary supplements. Many pharmacists lack the necessary knowledge or don't know where to look to answer these questions. Pharmacy schools educate future pharmacists on prescription and OTC medications with courses about nutrition and dietary supplementation, if offered, available as electives. This continuing education activity presents information about dietary supplements through a series of seven common pharmacy situations and lets learners in on seven secrets they can apply to their practices.

           

           

           

          Situation: Continuing education is a professional requirement many pharmacists find tedious. Looking through the UCONN online CE library and seeing a new continuing education activity entitled ‘Seven Secrets of Patient Safety with Dietary Supplements,’ a pharmacist remarks to the pharmacy team, "What a waste, no one even takes dietary supplements."

           

          Secret #1: Almost 60% of people in the United States used a dietary supplement in the last 30 days.11,12

           

          Dietary supplements crowd the aisles in drug stores, supermarkets, warehouse clubs, and even corner convenience stores. The sheer number of products is staggering. The Dietary Supplement Database (DSLD) is an online, searchable database developed by the Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH). The database contains product labeling information on dietary supplements sold in the United States, including both on and off-market products. DSLD currently lists more than 140,000 labels.9

           

          In the early 1960s, the National Center for Health Statistics began a program named the National Health and Nutrition Examination Survey (NHANES). NHANES is a continuous program focusing on various health and nutritional measurements and assesses adults' and children's health and nutritional status in the U.S.10 Scientific and technical journals publish the study results.

           

          One section of the program assesses dietary supplement use among adults. Results from the 2017-2018 NHANES show that11,12

          • 57.6% of adults 20 years or older used a dietary supplement in the past 30 days
          • Women (63.8%) had a higher utilization than men (50.8%)
          • Use of dietary supplements increased with age, with women 60 years or older reporting the highest usage at 80.2%
          • Use of multiple dietary supplements increased with age
          • Most common dietary supplements used by all age groups include multivitamin-mineral supplements, vitamin D, and omega-3 fatty acids

           

          The Council for Responsible Nutrition (CRN) is a trade association for the dietary supplement and functional food industry. Annually, the CRN performs a survey gathering data on consumer use of dietary supplements. The 2019 survey conducted by the CRN underscored dietary supplement usage with the following results13:

          • 77% of US adults take dietary supplements, including 79% of American women and 74% of males
          • Top reasons for taking supplements included:
            • Energy
            • Immune health
            • Filling nutrient gaps
            • Healthy aging
            • Heart health

           

          The COVID-19 pandemic significantly impacted our perception and approach to healthcare.6 As of August 5, 2022, SARS-CoV-2 has infected more than 580 million people worldwide.14 Interest in boosting our overall immunity and protecting ourselves from viral infections has dramatically increased as a result.7 Many vitamins and minerals play essential roles in proper immune function.7,15 Sales of supplements associated with boosting immunity increased over the last two years, including vitamins C and D, zinc, omega-3, garlic, ginger, and turmeric.16

           

          Table 1. Common Dietary Supplements and Potential Uses7,17,18

           

          Dietary Supplement Potential Use
          Black Cohosh Menopausal symptoms
          Calcium Dyspepsia

          Osteoporosis

          Premenstrual syndrome

          Echinacea Prevention and treatment of the common cold

          Promotion of wound healing

          Elderberry Prevention of upper respiratory tract infections

          Reduction in duration and severity of symptoms of the common cold

          Folic acid Folate deficiency

          Kidney failure

          Neural tube defects

          Ginkgo Anxiety

          Dementia

          Memory improvement

          Premenstrual syndrome

          Ginger Dysmenorrhea

          Nausea and vomiting

          Osteoarthritis

          Ginseng Cognitive function

          Erectile dysfunction

          Iron Anemia

          Restless leg syndrome

          Magnesium Constipation

          Dyspepsia

          Melatonin Sleep disorders
          Multivitamin with minerals General supplementation
          Omega-3 fatty acids

           

           

          Alzheimer’s disease

          Cardiovascular disease

          Dementia

          Depression

          Reduction of triglycerides

          Potassium Hypokalemia

          Hypertension

          Kidney stones

          Probiotics

           

           

          Atopic dermatitis

          Antibiotic-associated diarrhea

          Irritable bowel syndrome

          St. John’s Wort Anti-depressant

          Menopausal symptoms

          Turmeric Allergic rhinitis

          Osteoarthritis

          Pruritis

          Valerian Insomnia
          Vitamin A Aging skin

          Healthy vision

          Vitamin B-12 Vitamin B-12 deficiency
          Vitamin C Anemia

          Antioxidant effects

          Prevention of the common cold

          Vitamin C deficiency

          Vitamin D Osteomalacia

          Osteoporosis

          Vitamin D deficiency

          Vitamin E Alzheimer's disease

          Dysmenorrhea

          Premenstrual syndrome

          Zinc Acne

          Depression

          Diabetes

          Diarrhea

          Treatment of common cold

           

           

          Eating a healthy diet is essential for good health and nutrition. The Dietary Guidelines for Americans advise professionals, including policymakers, health care providers, and nutrition educators, about what to eat to meet the body’s nutritional needs. It emphasizes eating a diet rich in nutrient-dense foods, such as fruits and vegetables, as the best way to meet the body’s nutritional needs. The guideline identifies specific populations in which dietary supplementation may be necessary, such as women who are pregnant or lactating and adults older than 50.19

           

          In addition to these defined special populations, many pharmacy patients may find it necessary to take specific vitamins or minerals due to medication-induced nutrient deficiencies.

           

          Table 2. Examples of Nutrient Depletion Induced by Medications7,17

           

          Nutrient Medication(s) Mechanism
          Vitamin D Anticonvulsants

           

          Increase hepatic metabolism
          Bile acid sequestrants

           

          Decrease absorption
          Orlistat

           

          Decrease absorption
          Magnesium

           

          Estrogens

           

          Decrease serum levels by increasing uptake into tissues
          Loop diuretics

           

          Increase excretion
          Proton pump inhibitors

           

          Decrease absorption
          Vitamin B12

           

           

          Biguanides

           

          Decrease absorption
          Proton pump inhibitors

           

          Decrease absorption
          H-2 blockers

           

          Decrease absorption
          Potassium Loop diuretics

           

          Increase excretion
          Thiazide diuretics

           

          Increase excretion
          Corticosteroids

           

          Increase excretion

           

          The pharmacist's dismissal of dietary supplement education is understandable. No one wants to waste precious time on irrelevant continuing education. However, the facts presented here illustrate the need for pharmacist education on dietary supplements.

          Pause and ponder: A patient presents information about taking lemon and baking soda tea to prevent COVID-19 infection and asks you if it really works. How would you approach this conversation?

           

          Situation: Sunday afternoons sometimes (but not often!) present the opportunity to catch up on administrative activities. While completing an inventory reconciliation of the vitamin section, a technician inquires, "Why does the FDA approve so many different products?" Looking up distractedly from the CII safe count, the pharmacist pauses, then replies in a weary voice, "You know, I’m not sure, probably just to make it more confusing for us."

           

          Secret #2: Regulatory oversight of dietary supplements differs from prescription and OTC medications.

           

          What is a Dietary Supplement?

           

          On the most basic level, a dietary supplement is a substance consumed to add nutrients to a diet or to lower the risk of certain health problems. The use of natural substances has been around for millennia, but it is only within the last five decades that countries worldwide have formalized language and regulations around dietary supplements. Terminology, quality control, and safety assessment differ depending on the country and governing legislative body.20

           

          In 1994, the United States Congress passed the Dietary Supplement Health and Education Act (DSHEA), an amendment to the Food, Drug, and Cosmetic Act. DSHEA defines the term dietary supplement as a product intended for ingestion and containing an ingredient that supplements the diet. Dietary supplement labeling must include the term ‘dietary supplement’ or an equivalent term such as ‘herbal supplement’ or ‘magnesium supplement.’ DSHEA also stipulates that a dietary supplement must be free of contamination, adulteration, and properly labeled.21 We will discuss dietary supplement product integrity and labeling later in this activity.

           

          According to DSHEA, dietary supplements include vitamins, minerals, herbs, other botanicals, amino acids, and live microbials (probiotics). Dietary supplements are available in many different formulations including tablets, capsules, soft gels, gel caps, powders, and liquids.21

           

          DSHEA defined the term ‘new dietary ingredient’ as an ingredient that meets the above criteria and was unavailable in the U.S. before October 15, 1994. If manufacturers want to market a product containing a new dietary ingredient, they must notify the U.S. Food and Drug Administration (FDA) before marketing. The FDA then reviews the product for safety but not effectiveness.21

           

          Regulation of Dietary Supplements

           

          The FDA and the Federal Trade Commission (FTC) share regulation and oversight of dietary supplements. The FDA is responsible for the information provided on dietary supplement product labeling, including the package labeling, product inserts, and information available at the point of sale. The FTC monitors dietary supplement advertising, ensuring advertisements are truthful, substantiated, and not misleading. Both agencies have the authority to address violations and work together to ensure their efforts are consistent with one another.22

           

          The FDA does not have the authority to approve dietary supplement products before manufacturers market, distribute, and sell them to consumers. Manufacturers are responsible for ensuring the products they produce and distribute meet all quality standards defined by federal law. Quality standards include22

          • Ensuring the safety of the dietary ingredients used in the product
          • Following current Good Manufacturing Practices (cGMP)
          • Meeting all product labeling requirements
          • Ensuring substantiation of all claims made about the product
          • Ensuring products are free of adulteration or misbranding

           

          cGMP, defined and regularly updated by the FDA, establish the minimum requirements for manufacturing, packaging, and labeling products to ensure product quality. cGMP includes guidance on obtaining quality ingredients, operating procedures, and quality controls.23 Failure to follow cGMP results in possible product contamination.

           

          While the FDA may not have the authority to approve dietary supplements before the product marketing and distribution, it can monitor products via post-marketing surveillance and auditing. The FDA routinely performs manufacturer inspections, monitors the marketplace, and investigates adverse event reports. Follow-up includes working with the manufacturer to bring the product into compliance, issuing warning letters, and recalling products.21

           

          Reporting Issues with Dietary Supplements

           

          Post-marketing surveillance is essential for documenting and monitoring any issues with dietary supplements. Information about severe reactions and product quality are important issues to report. The FDA Safety Reporting Portal is an online tool used to report safety issues on several categories of products, including pet or livestock foods, tobacco products, animal drugs, and dietary supplements.24

           

          The website address for the portal is https://safetyreporting.hhs.gov. Anyone can use the portal to report issues, including consumers, healthcare professionals, manufacturers, and researchers. Generating a new report starts on the home screen. The reporter chooses to file the report as a guest or by creating an account. Creating an account streamlines data entry and allows the reporting individual to save a draft of the report, follow up on a report, and view previous submissions.24

           

          Generation of an Individual Case Safety Report ID (ICSR) occurs after report submission. The ICSR allows the reporter to identify the report for future reference including submission of a follow-up report with additional information. FDA reviewers assess the seriousness of the reported issue and assign follow-up. Submission of this information allows the FDA to identify potentially dangerous products and potentially remove them from the market.24

           

          Traditionally, insurance companies limit coverage to prescription medications. Recent trends show an expansion of coverage to include some dietary supplements. Insurance coverage of dietary supplements blurs the regulatory differences between prescription medications and dietary supplements. Understanding the differences in oversight is beneficial and allows the pharmacy staff to counsel patients effectively.

          Situation: While running back to the pharmacy after a much-needed bathroom break, a pharmacist stops when approached by a customer asking for advice about an iron supplement. Overhearing the inquiry, another customer comments, "You should buy that online; it’s cheaper, and the quality is just as good." The pharmacist nods assent, turns, and hurries back to the pharmacy amid the erupting sounds of chaos behind the counter.

           

          Secret #3: Product integrity fluctuates between manufacturers and sources of dietary supplements.

           

          Integrity of Dietary Supplements

           

          The lack of government oversight opens the door for substandard products to flood the market. Poor ingredient quality, heavy metal or microbial contamination, adulteration, and mislabeling occur regularly. In the current economy, with rising prices, consumers are turning to less expensive options, and cheaper is not necessarily better, especially with dietary supplements.

           

          In the literature, many studies exist that analyze dietary supplement product integrity. A study published in 2021 tested multiple bottles of 29 herbal supplements for consistency of ingredient activity and the presence of metal and fungal contaminants. The analysis showed inconsistent ingredient activity not only between bottles of the same product manufactured by the same company, but also between bottles manufactured by different companies. Assaying for metal contamination found zinc in 88% of bottles and nickel in 40% of bottles. In 37 of 58 bottles tested, fungal contamination was present, with 21 bottles having multiple strains.25

           

          Another study analyzed 41 dietary supplements for the presence of cadmium, lead, and mercury. Results revealed that 68.3% of samples contained contamination with cadmium and lead, and 29.3% with mercury.26 One research team evaluated 121 dietary supplements along with 49 prescription drugs for levels of toxic element contamination. A small percentage of the dietary supplement products exceeded safety levels for mercury, lead, cadmium, arsenic, or aluminum. None of the prescription products exceeded these safety levels.27

           

          Adulterated products contain substances not listed on the product labeling, substitution of inferior materials for active ingredients, or may contain a lesser amount of ingredients. Weight loss, sports enhancement, and sexual function supplements commonly contain banned substances.28

           

          The FDA created and currently maintains the Health Fraud Product Database to increase awareness. This database contains information about products cited in warning letters, advisory letters, recalls, public notifications, and press announcements for various issues. Issues cited include products claiming to cure, treat, or prevent a disease and products containing undeclared ingredients or a new dietary ingredient.29 The database is available in the consumer section of the FDA website at https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database.

           

          On January 2, 2022, the FDA issued a warning letter to the manufacturers of Nasitrol, a nasal spray based on the ingredient iota carrageenan. A review of the product’s website found claims that the product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Federal regulations define products making these claims as drugs and subject to review by the FDA before approval and subsequent marketing. As discussed earlier, this is in direct violation of federal regulations.30

           

          In another example, on July 15, 2022, the FDA issued a public notice advising consumers to refrain from purchasing Adam’s Secret Extra Strength Amazing Black, a product promoted for sexual enhancement. Laboratory analysis found that the product contained tadalafil, a prescription medication used for erectile dysfunction.31 Due to the potential for severe side effects such as hypotension, tadalafil administration requires medical supervision by a physician.32

           

          A study published in 2018 analyzed FDA warning letters issued from 2007 through 2016, using data from the Health Fraud Product Database. During this time frame, the FDA found 776 adulterated dietary supplements from 146 different companies. A total of 157 products contained more than one unapproved ingredient. Products marketed for sexual enhancement accounted for 45.5% of letters, weight loss 40.9%, and muscle building 11.9%. Unapproved ingredients included sildenafil in sexual enhancement, sibutramine in weight loss, and synthetic steroids or steroid-like ingredients in muscle building supplements.33

           

          One way for consumers to know they are purchasing a valid product is by looking for a certified product. The certification process involves an independent, third-party company testing a company’s products, offering quality assurance for dietary supplements. Parameters tested include34

          • Product contains the ingredients stated on the label
          • Presence of harmful ingredients
          • Presence of contamination
          • Proper dissolution
          • cGMP followed during manufacture

           

          Three independent, private, third-party certifying organizations operate in the United States: the US Pharmacopeial Convention (USP), NSF International, and Consumerlabs.com. All three companies offer product certification programs for a fee. Each company allows products passing certification to display a seal on product labeling. Table 3 summarizes information about each organization.

           

          Table 3. Dietary Supplement Certification Organizations

           

          Certifying Organization US Pharmacopeial Convention NSF International Consumerlab.com
          Website www.usp.org

          www.qualitysupplements.org

           

          www.nsf.org www.consumerlab.com
          Services offered Dietary supplement verification program including GMP facility audits, product QCM process evaluation, and product testing Product and ingredient certification

          GMP Certification

          Certified for Sport

          Product reviews

          Quality Certification Program

          Information available on the website Program information, list of verified products, and educational resources Program information, product search engine, and educational resources Product reviews, health condition information
          GMP = Good Manufacturing Practice

          Source: adapted from reference 33

           

          Online product ordering is a convenient shopping option rapidly gaining popularity in recent years, especially during the pandemic. While tempting to order the least expensive product, investigating the source and quality of dietary supplements available online is essential. Proactive training of the entire pharmacy team aids in providing patients with accurate information.

          Situation: A weary technician finally finishes ringing out the last customer after two hours straight at the register. A sigh of relief quickly turns into a disgruntled groan as another customer approaches. With a bottle labeled ‘Menopausal Support’ in hand, the customer points to the bottle label and asks, "What does ‘proprietary blend’ mean?" The technician glances over her shoulder, sees the pharmacist engaged in an intense phone conversation, and replies to the customer, "The bottle label clearly lists the ingredients."

           

          Secret #4: Federal regulations define required dietary supplement label information. Unfortunately, ambiguity still exists, making it challenging to identify exactly what the product contains.

           

          Federal regulations define the information required on dietary supplement product labeling in detailed, specific terms. Product labeling must include35

          • Product name
          • The term ‘dietary supplement’ or similar term (i.e., herbal supplement)
          • Name and location of the manufacturer, along with a domestic address and phone number for reporting serious adverse events
          • Nutrition labeling in the form of a “Supplement Facts” panel with the following information (see Figure 1):
            • Serving size
            • Number of servings per container
            • Listing of each dietary ingredient in the product
            • Amount of dietary ingredient per serving (Exception: ingredients in a proprietary blend)
            • Amount per serving listed as a quantitative amount by weight, as a percentage of the Daily Value, or as both
          • A list of other ingredients not declared on the Supplement Facts label (usually excipients such as preservatives or dyes)
          • Net quantity of contentsImage of a Supplemental Facts label found on dietary products.

          Figure 1. Supplemental Facts Label (sourced from reference 36)

          One area of ambiguity in dietary supplement product labeling is the listing of a proprietary blend. The term proprietary blend refers to a blend of dietary ingredients unique to a manufacturer and product. Federal labeling regulations allow the listing of proprietary blends on dietary supplement products, however, only the total weight of the blend is required, not the weight of individual ingredients.35 There is no way for the healthcare professional or consumer to know exactly how much of a particular ingredient the proprietary blend contains.

           

          Consumerlabs.com cautions consumers about products containing proprietary blends or formulas. In many instances, the blend's name sounds like a desired, expensive ingredient that is only a small part of the formula. Marketing of products containing proprietary blends may mislead the consumer with claims meant to impress the consumer and drive sales of the product.37

           

          FDA regulations do allow structure/function claims on dietary supplement labeling. Structure/function claims describe how a nutrient or dietary ingredient may affect or act to maintain the structure or function of the body.35 Examples of structure/function claims include35

          • Calcium builds strong bones
          • Antioxidants maintain cell integrity
          • Fiber maintains bowel integrity

           

          If a dietary supplement label contains a structure/function claim it must also contain the following statement: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."35

           

          The example in this situation involved a product marketed for menopausal support. Menopausal symptoms affect more than 1 million women in the US annually and include symptoms such as hot flashes and sleep disturbances.38 A search of the DSLD using the term ‘menopausal support’ and filtering for on-market products containing the ingredient ‘proprietary blend’ returned almost 3,000 products.9 This abundance of products illustrates the ambiguity that exists on dietary supplement labeling.

           

          Pharmacy technicians are often the first line of contact at the pharmacy. Training and development of pharmacy technicians on the facts surrounding dietary supplements empower technicians, allowing them to answer factual questions and provide effective patient education.

           

          Situation: The pharmacy phone constantly rings throughout the day, and today is no exception. The new COVID vaccine is out, and everyone wants to know if the pharmacy has it in stock. Answering yet another call, the technician is surprised when a patient asks to talk to the pharmacist, complaining about dizziness. The pharmacist checks the patient’s profile, finding no underlying causative medication. Further questioning the patient, the pharmacist uncovers the recent addition of melatonin at night for sleep.

           

          Secret #5: Like prescription medications, dietary supplements have pharmacologic and physiologic effects on the body, potentially resulting in health risks and side effects.

           

          Consumers perceive dietary supplements as safe due to their source from natural substances. While generally well tolerated, dietary supplements affect the body like prescription medications, capable of producing an undesired effect. Lack of regulatory oversight allows products to reach consumers without adequate safety evaluation.

           

          Information describing adverse effects of dietary supplements is anecdotal, derived from case reports and reports submitted through the FDA Safety Reporting Portal. Most dietary supplements have not been studied in pregnant or lactating women or children.

           

          A study published in 2015 evaluated ten years of emergency room data to assess the number of annual visits resulting from dietary supplement adverse events. The authors calculated an average of more than 23,000 emergency room visits stemmed from the consumption of dietary supplements, resulting in more than 2,000 hospitalizations annually.39

           

          Events in older adults accounted for the highest percentage of visits, with 40% of visits due to difficulty swallowing. Incidence in young adults aged 20 to 34 was significant at 28% and primarily involved weight loss and energy products. Side effects reported include heart palpitations, chest pain, and tachycardia.39

           

          Unsupervised child ingestions accounted for 21% of visits. Unlike prescription medications, regulations do not require child-resistant packaging for dietary supplements, except for iron-containing products.39 The authors note the numbers evaluated in the study are likely underreported as patients do not always include dietary supplements with the current medication list.39

           

          Table 4. Adverse Effects of Common Dietary Supplements7,17

           

          Supplement Adverse Effects
          Black Cohosh

           

          Breast tenderness, diarrhea, gastrointestinal upset, nausea/vomiting
          Calcium

           

          Burping, constipation, gastrointestinal upset
          Echinacea

           

          Diarrhea, constipation, gastrointestinal upset/pain, heartburn, nausea/vomiting, skin rashes
          Ginseng Gastrointestinal side effects, headache, sleep difficulty
          Ginger

           

          Burping, diarrhea, heartburn
          Iron

           

          Abdominal pain, constipation, diarrhea, nausea/vomiting
          Magnesium

           

          Diarrhea, gastrointestinal irritation, nausea/vomiting
          Melatonin

           

          Dizziness, drowsiness, headache
          Omega-3 fatty acids Bad breath, headache, heartburn, nausea, diarrhea, unpleasant taste
          Potassium

           

          Abdominal pain, burping, diarrhea, nausea/vomiting
          St. John’s Wort

           

          Diarrhea, dizziness, dry mouth, fatigue, headache, insomnia
          Turmeric

           

          Constipation, dyspepsia, gastrointestinal reflux, nausea/vomiting
          Vitamin C

           

          Abdominal cramping, heartburn, kidney stones (if history of kidney stones)
          Zinc

           

          Abdominal cramping, diarrhea, metallic taste, nausea/vomiting

           

           

          Patients often fail to report usage of dietary supplements and most pharmacy software lacks the ability to note dietary supplement usage in the patient profile. In this situation, the pharmacist took the extra time to further question the patient about dietary supplement usage and successfully identified the causative agent.

           

          Pause and Ponder: In what ways could you incorporate activities into the daily workflow to increase awareness of patients’ use of dietary supplements?

           

          Situation: Today, the workload in the pharmacy is lighter than usual. With a grateful sigh, the pharmacist sinks onto a stool reaching for a quick snack. Then the phone rings… The caller is a triage nurse from the local hospital to verify a patient’s medication profile. Pulling up the profile, the pharmacist verifies the list of medications, including digoxin. The triage nurse confirms atrial fibrillation as the cause for admission, adding that the patient recently started taking St. John’s Wort for depression.

           

          Secret #6: Some dietary supplements affect the CYP450 liver enzymes, potentially altering the pharmacokinetics of medications, leading to treatment failure and/or toxicity.

           

          Dietary supplement-drug interactions

           

          Drug-drug interactions result in altered absorption, metabolism, or excretion. Drug-dietary supplement interactions occur through the same pathways as those used by FDA-approved drugs. The cytochrome P450 (CYP P450) enzymes in the liver are responsible for the metabolism of most medications.41,42 The ability of a drug to either induce or inhibit these enzymes is a significant factor in drug-drug interactions. The natural ingredients found in dietary supplements are capable of inhibition or induction, also having the potential to interact with medications.

           

          St. John’s Wort, an herbal commonly taken for the relief of mild to moderate depression, induces the activity of CYP3A4.43,44 This induction increases the clearance of medications metabolized by CYP3A4. Examples of medications cleared by CYP3A4 include alprazolam, atorvastatin, cyclosporine, oral contraceptives, oxycodone, and warfarin.43,44 Patients need counseling about potential drug interactions with St. John’s Wort.

           

          Limited clinical studies evaluating the impact of drug-dietary supplement interactions exist. Many interactions are theoretical, based on limited clinical evidence, animal research, and case reports.

           

          Table 5. Examples of Potential Drug-Dietary Supplement Interactions7,17

           

          Dietary Supplement Medication Interaction
          Calcium

           

           

          Quinolone and tetracycline antibiotics Decreased antibiotic efficacy

          Take antibiotic 2 hours before or 4-6 hours after calcium

          Dolutegravir

          Elvitegravir

          Reduced serum levels

          Take medication 2 hours before or 2 hours after calcium

          Ginseng Diabetes medications Increase risk of hypoglycemia
          Immunosuppressants Decreased effectiveness of immunosuppressant
          Ginkgo

           

          Anticoagulants Increased risk of bleeding
          Iron

           

          Quinolone and tetracycline antibiotics Decreased levels of antibiotics due to decreased absorption

          Take antibiotics 2 hours before or 4-6 hours after iron

          Magnesium

           

          Bisphosphonates Decreased absorption

           

          Levodopa/carbidopa Decreased bioavailability of levodopa/carbidopa
          Niacin

           

           

           

          Statins Increased risk of myopathy or rhabdomyolysis
          Thyroid hormones Antagonize the effects of thyroid hormone replacement
          Antihypertensive medications Increased risk of hypotension due to niacin’s vasodilating effects
          St. John’s Wort Alprazolam Decreased effects of alprazolam
          Oral Contraceptives Decreased efficacy

          Counsel patients to use other forms of contraception

          Digoxin Decreased levels of digoxin
          Omeprazole Decreased effects of omeprazole
          Valerian CNS depressant drugs Additive sedative effects
          Vitamin B6

           

          Phenytoin Decrease levels and clinical effects of phenytoin
          Vitamin D

           

          Atorvastatin Decreased absorption of atorvastatin
          Vitamin E

           

          Anticoagulants Increased risk of bleeding
          Zinc

           

          Quinolone antibiotics Decreased levels and effects of antibiotics

          Take antibiotic 2 hours prior or 4-6 hours after zinc

           

          Pharmacy training emphasizes the importance of drug-drug interactions. It is important to remember that any substance introduced to the body, including food, beverages, and dietary supplements, has the potential to interact with medications.

          Situation: It is another busy day in the pharmacy; prescriptions cover the bench, the phone rings constantly, and a pickup queue extends around the corner. A technician nervously approaches the pharmacist about a patient at the counter with a question regarding a supplement. The pharmacist throws down the spatula, muttering angrily about lacking the knowledge and training to answer the question properly. Sighing, he says, "I’ll just Google it."

           

          Secret #7: Many websites provide clinically backed information on dietary supplements (and Google is not one of them!).

           

          The vast amount of health information available via the Internet with just a few clicks of the keyboard is both a blessing and a curse. Google is now a verb, and a simple search returns millions of results in seconds. While this may seem like a blessing, the curse lies in the searcher's inability to recognize valid, accurate sources of information. In many searches, ads appear as search results adding to the confusion.

           

          In addition to the Internet, consumers turn to social media for health information. Social media use increased from 27% in 2009 to 86% in 2019.45 Information posted on social media provides communication about healthcare issues, potentially resulting in improved health care.45 Unfortunately, inaccurate information abounds on the Internet and social media platforms, leading to consumer misinformation.47-49

           

          The FDA recently launched a new dietary supplement education initiative geared towards consumers, healthcare professionals, and teachers. The program, Supplement Your Knowledge, presents information about dietary supplements through a series of three videos. Educational materials, including fact sheets and infographics, are available in English and Spanish.50

           

          Many government agencies provide free access to information about dietary supplements and their side effects, toxicity, and drug interactions. There are also several paid subscription resources available. Table 6 lists many of the available information options.

           

          Table 6. Sources of Information about Dietary Supplements

           

          Resource Website Information
          Dietary Supplement Education Program https://www.fda.gov/food/healthcare-professionals/dietary-supplement-continuing-medical-education-program

           

          • Continuing medical education program
          • Collaboration between FDA and AMA
          • Series of 3 videos about dietary supplements
          • Also contains links to educational materials and other websites with information about dietary supplements
          Dietary Supplement Label Database https://dsld.od.nih.gov

           

          • Current and historical label information on dietary supplement products marketed in the United States
          • Useful to determine the contents of dietary supplement products
          Food and Drug Administration https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements

           

          • Information for consumers on using dietary supplements
          • Links to educational resources and materials, consumer updates, alerts, recalls and other information
          Google Scholar

           

          https://scholar.google.com/

           

          • Source of information from many avenues including journals, books, and conference proceedings
          Lexi-Comp

          Natural Products Database

          Available via mobile app
          • Requires a paid subscription
          • Alphabetical, searchable natural product database
          Memorial Sloane Kettering Cancer Center https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs

           

          • Information on herbs, botanicals, and other products for both consumers and healthcare professionals
          • Dietary supplement monographs
          • IOS app: About Herbs
          • Part of an online integrative medicine resource center
          National Cancer Institute Office of Cancer Complementary and Alternative Medicine https://cam.cancer.gov

           

          • Information for consumers and healthcare professionals about CAM as it relates to cancer therapy
          • Information on current NCI CAM research
          National Center for Complementary and Integrative Health https://www.nccih.nih.gov

           

          • Information for both consumers and healthcare professionals about complementary health products and practices
          National Library of Medicine - Medline Plus https://medlineplus.gov/druginfo/herb_All.html

           

          • Online health information about drugs, herbs, and supplements for consumers
          • Information sourced from the National Center for Complementary and Integrative Health and Natural Medicines Comprehensive Database
          Natural Medicines Comprehensive Database https://naturalmedicines.therapeuticresearch.com

           

          • Requires a paid subscription
          • Professional monographs including information about effectiveness, safety, adverse effects, and interactions
          • Information on specific commercial products
          • Interaction checker
          • Patient handouts in English, Spanish and French
          Office of Dietary Supplements https://ods.od.nih.gov
          • Information for both consumers and healthcare professionals
          • General supplement information
          • Information on supplements for specific purposes
          • Fact sheets on dietary supplements and their ingredients
          PubMed https://pubmed.ncbi.nlm.nih.gov

           

          • Search engine for the National Library of Medicine
          • Source of information from journals
          United States Department of Agriculture https://www.nutrition.gov/topics/dietary-supplements

           

          • Links to general information and resources on dietary supplements

           

           

          Performing an Internet search via Google may seem like the quickest and easiest way to find the answer to an inquiry. Engaging with the patient, gaining additional information, and knowing where to look ultimately saves time. It is not necessary for one to be an expert in all dietary supplements, just to self-educate one supplement at a time.

           

          Pause and Ponder: A patient shares the unfortunate news about a recent cancer diagnosis. He asks you about the use of herbs in the treatment of cancer. What advice would you give? 

          Conclusion

          You may have noticed a recurring theme throughout this activity. Education. Dietary supplement education is essential to patient safety given the current usage patterns and accessibility of the retail pharmacy team. Education needs to include the entire pharmacy team. Technicians are often the first point of contact at the pharmacy, commonly fielding patient questions. Knowing when to answer questions and when to involve the pharmacist is a necessary skill. Understanding the differences in oversight, the physiological effects of dietary supplement consumption, and the potential for drug interactions allows effective management and counseling of patients. It is important for healthcare providers to solicit information regarding patient consumption of dietary supplements.

           

           

          Sidebar: Tips for Counseling Patients about Dietary Supplements

           

          Carefully inspect the product to ensure intact product labeling

          Ensure the safety seal is intact

          Check for an expiration date or best used by date

          Check for customer service or return information before ordering

          Buy direct from a reputable company; many reputable companies sell through Amazon, avoid 3rd party resellers

          Check for the presence of a third-party certification seal

          Before purchase, check the company’s website for information on quality standards

          Pay attention to the appearance and smell of the product upon opening

          Child-resistant packaging is not a requirement for dietary supplements; advise on proper storage of product

          Reinforce the importance of including dietary supplements on a current medication list

           

           

           

           

          Pharmacist Post Test (for viewing only)

          Seven Secrets for Patient Safety with Dietary Supplements

          Pharmacist post-test

          After completing this continuing education activity, pharmacists will be able to:

          1. Discuss the importance of knowing about a patient’s dietary supplement usage (K)
          2. Identify commonly used dietary supplements, their regulation, and the value of certification (K, or A?)
          3. Recognize potential medication-dietary supplement interactions (K)
          4. Demonstrate the ability to locate different sources of information about dietary supplements (A)

          1. According to The National Health and Nutrition Examination Survey more than what percentage of adults have used a dietary supplement in the last 30 days?

          A. 45%
          B. 50%
          C. 55%

          2. Which of the following is a commonly used dietary supplement?

          A. Boswellia
          B. Turmeric
          C. Quercetin

          3. Which government agencies regulate dietary supplements?

          A. USDA, FDA
          B. FTC, DEA
          C. FTC, FDA

          4. Patient MW fills a new prescription for bumetanide. Which potential nutrient depletion may occur?

          A. Magnesium
          B. Vitamin D
          C. Vitamin B12

          5. While completing an inventory reconciliation of the vitamin section, a technician inquires, ‘Why does the FDA approve so many different products?’ Which of the following is the most appropriate answer?

          A. ‘The FDA does not have the authority to approve dietary supplements, the FTC approves dietary supplements, including vitamins.’
          B. ‘The FDA does not have the authority to approve dietary supplements before they are marketed, allowing manufacturers to flood the market with products.’
          C. ‘You know, I’m not sure, probably just to make it more confusing for us.’

          6. Which of the following companies offer independent third-party dietary supplement certification services?

          A. Consumer Reports
          B. NSF International
          C. Certified Naturally Grown

          7. Patient ED is a 58-year-old male new to your pharmacy. He provides the pharmacy team with a list of his current medications including:
          • Warfarin 3 mg PO QD
          • Atorvastatin 10 mg PO QD
          • Donepezil 10 mg PO QHS
          • Metformin 1,000 mg PO BID
          Use of which of the following supplements would be cause for concern in this patient?

          A. Ginkgo
          B. Omega-3 fatty acids
          C. Niacin

          8. A patient calls with questions about a supplement recommended by a friend. The name of the supplement is Mind and Memory Essentials, and the patient does not know the product ingredients. Where would you go to find this information?

          A. Dietary Supplement Label Database
          B. Office of Dietary Supplements
          C. United States Department of Agriculture

          9. A patient asks you about the potential side effects of taking turmeric. Where would you go to find this information?

          A. Google
          B. PubMed
          C. Office of Dietary Supplements

          10. You are verifying a new birth control prescription for a patient, recalling that the patient strongly believes in alternative medicine and dietary supplementation. Thankfully her profile contains a list of dietary supplements. You see St. John’s Wort listed and suspect a drug-supplement interaction. Where would you go to find more information?

          A. Natural Medicines Database
          B. Google Scholar
          C. National Library of Medicine

          11. One of your regular patients stops by the counter to ask your opinion on a dietary supplement product purchased on the Internet. What should you assess when looking over the product?

          A. Product labeling, color of bottle, structure/function disclaimer, certification
          B. Certification, expiration date, product labeling, intact seal
          C. Expiration date, product price, certification, product labeling

          12. Pharmacy patient ML approaches the pharmacy counter to purchase several bottles of oral glucose tablets. When questioned, the patient reveals the recent occurrence of several hypoglycemic episodes. The patient confirms compliance with taking their prescription for metformin 1 gm PO BID. ML reports no changes in other prescriptions or dietary habits but does state they started taking a dietary supplement a few days ago but cannot recall the name. Which product would you suspect based on the information provided?

          A. Vitamin E
          B. Valerian
          C. Ginseng

          Pharmacy Technician Post Test (for viewing only)

          Pharmacy Technician

          After completing this continuing education activity, pharmacy technicians will be able to:

          1. Discuss the importance of knowing about a patient’s dietary supplement usage (K)
          2. Identify commonly used dietary supplements (A)
          3. Define dietary supplement oversight and different levels of quality (K)
          4. Recognize the need for pharmacist counseling when a patient is taking a dietary supplement (K)

          1. Why is it important to ask about a patient’s usage of dietary supplements?

          A. It is not important to ask about dietary supplement usage.
          B. To identify which dietary supplements the pharmacy should feature on the front counter.
          C. Dietary supplements potentially interact with prescription medications.

          2. Which of the following is a commonly used dietary supplement?

          A. Boswellia
          B. Turmeric
          C. Quercetin

          3. Which government agencies regulate dietary supplements?

          A. USDA, FDA
          B. FTC, DEA
          C. FTC, FDA

          4. A patient approaches the counter with 2 different magnesium products and asks your opinion on which to purchase. Which of the following is an appropriate answer?

          A. Let’s look at these a little closer.
          B. Neither, it’s better to buy supplements online.
          C. The one that’s on sale.

          5. Reasons for dietary supplementation include which of the following?

          A. To supplement a poor diet.
          B. Promotion of optimal immune health
          C. No one needs to take dietary supplements.

          6. Which of the following companies offer independent third-party dietary supplement certification services?

          A. Consumer Reports
          B. NSF International
          C. Certified Naturally Grown

          7. You are entering a new patient into the pharmacy system. In addition to asking about allergies, demographics, and current medications, what else should you ask?

          A. How many hours of sleep do you average a night?
          B. Do you take any over-the-counter medications or dietary supplements?
          C. How many children do you have and how old are they?

          8. You are finally heading out for a lunch break and walk past a pharmacy patient in the aisle looking at 2 different brands of St. John’s Wort. What should you do?

          A. Keep going, you already punched out and only have 30 min to eat your lunch.
          B. Stop and offer to accompany them to the pharmacy to talk to the pharmacist.
          C. Stop and help them make a choice between the products.

          9. A patient picks up a medication and purchases a bottle of magnesium at the same time. What should you do?

          A. Advise the patient that there may be an interaction between the prescription and the magnesium.
          B. Ring out the patient as usual.
          C. Touch base with the pharmacist to make sure there are no potential interactions between the products.

          10. Where should adverse reactions or issues with dietary supplements be reported?

          A. FDA Safety Reporting Portal
          B. Federal Trade Commission
          C. Office of Dietary Supplements

          References

          Full List of References

          References

            1. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670-3695. doi:10.1016/j.bbagen.2013.02.008

            2. Jones AW. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test Anal. 2011;3(6):337-344. doi:10.1002/dta.301

            3. Aitken M, Kleinrock M. The Use of Medicines in the U.S. Spending and Usage Trends and Outlook to 2025. IQVIA Institute for Human Data Science. May 2021. Accessed August 5, 2022. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-use-of-medicines-in-the-us/iqi-the-use-of-medicines-in-the-us-05-21-forweb.pdf

            4. OTC Sales Statistics. Consumer Healthcare Products Association. Accessed June 22, 2022. https://www.chpa.org/about-consumer-healthcare/research-data/otc-sales-statistics

            5. Dietary Supplements Market Size, Share & COVID-19 Impact Analysis, By Type (Vitamins, Minerals, Enzymes, Fatty Acids, Proteins, and Others), Form (Tablets, Capsules, Liquids, and Powders), and Regional Forecasts, 2021-2028. Fortune Business Insights. Accessed June 22, 2022. https://www.fortunebusinessinsights.com/dietary-supplements-market-102082

            6. Moynihan R, Sanders S, Michaleff ZA, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021;11(3):e045343. Published 2021 Mar 16. doi:10.1136/bmjopen-2020-045343

            7. Dietary Supplements in the Time of COVID-19. Fact Sheet for Health Professionals. National Institutes of Health, Office of Dietary Supplements. Accessed July 20, 2022. https://ods.od.nih.gov/factsheets/COVID19-HealthProfessional/.

            8. Adams KK, Baker WL, Sobieraj DM. Myth Busters: Dietary Supplements and COVID-19. Ann Pharmacother. 2020;54(8):820-826. doi:10.1177/1060028020928052

            9. US Department of Health and Human Services, National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Label Database (DSLD). Accessed August 5, 2022. https://ods.od.nih.gov/Research/Dietary_Supplement_Label_Database.aspx

            10. About the National Health and Nutrition Examination Survey. National Center for Health Statistics. Accessed July 20, 2022. https://www.cdc.gov/nchs/nhanes/about_nhanes.htm

            11. Mishra S, Stierman B, Gahche JJ, Potischman N. Dietary supplement use among adults: United States, 2017–2018. NCHS Data Brief, no 399. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https://doi.org/10.15620/cdc:101131external icon

            12. Gahche JJ, Bailey RL, Potischman N, et al. Federal Monitoring of Dietary Supplement Use in the Resident, Civilian, Noninstitutionalized US Population, National Health and Nutrition Examination Survey. J Nutr. 2018;148(Suppl 2):1436S-1444S. doi:10.1093/jn/nxy093

            13. 2019 CRN Consumer Survey on Dietary Supplements. Council for Responsible Nutrition. https://www.crnusa.org/2019survey. Published September 30, 2019. Accessed June 1, 2022.

            14. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/. Accessed August 5, 2022.

            15. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients. 2020;12(4):1181. Published 2020 Apr 23. doi:10.3390/nu12041181

            16. Hamulka J, Jeruszka-Bielak M, Górnicka M, Drywień ME, Zielinska-Pukos MA. Dietary Supplements during COVID-19 Outbreak. Results of Google Trends Analysis Supported by PLifeCOVID-19 Online Studies. Nutrients. 2020;13(1):54. Published 2020 Dec 27. doi:10.3390/nu13010054

            17. Natural Medicines. Therapeutic Research Center. Accessed August 2, 2022. https://naturalmedicines.therapeuticresearch.com.

            18. Office of Dietary Supplements Dietary Supplement Fact Sheets. Accessed August 2, 2022. https://ods.od.nih.gov/factsheets/list-all/

            19. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition. December 2020. Available at DietaryGuidelines.gov. https://www.dietaryguidelines.gov/sites/default/files/2021-03/Dietary_Guidelines_for_Americans-2020-2025.pdf

            20. Thakkar S, Anklam E, Xu A, et al. Regulatory landscape of dietary supplements and herbal medicines from a global perspective. Regul Toxicol Pharmacol. 2020;114:104647. doi:10.1016/j.yrtph.2020.104647
            21. FDA 101: Dietary supplements. United States Food and Drug Administration. Accessed July 31, 2022. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements.
            22. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration. Accessed July 31, 2022. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements.

            23. Facts About the Current Good Manufacturing Practices (cGMPs). U.S. Food and Drug Administration. Accessed July 22, 2022.
            https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps

            24. Safety Reporting Portal. Food and Drug Administration. Accessed August 10, 2022. https://www.safetyreporting.hhs.gov/SRP2/en/Home.aspx?sid=da6dc761-7962-4743-82cd-2e62985492d0

            25. Veatch-Blohm ME, Chicas I, Margolis K, Vanderminden R, Gochie M, Lila K. Screening for consistency and contamination within and between bottles of 29 herbal supplements. PLoS One. 2021;16(11):e0260463. Published 2021 Nov 23. doi:10.1371/journal.pone.0260463

            26. Ćwieląg-Drabek M, Piekut A, Szymala I, et al. Health risks from consumption of medicinal plant dietary supplements. Food Sci Nutr. 2020;8(7):3535-3544. Published 2020 May 19. doi:10.1002/fsn3.1636

            27. Genuis SJ, Schwalfenberg G, Siy AK, Rodushkin I. Toxic element contamination of natural health products and pharmaceutical preparations. PLoS One. 2012;7(11):e49676. doi:10.1371/journal.pone.0049676

            28. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings [published correction appears in JAMA Netw Open. 2018 Nov 2;1(7):e185765]. JAMA Netw Open. 2018;1(6):e183337. Published 2018 Oct 5. doi:10.1001/jamanetworkopen.2018.3337

            29. Health Fraud Product Database. United States Food and Drug Administration. Accessed August 10, 2022. https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database

            30. Warning Letter: Amcyte Pharma, Inc. United States Food and Drug Administration. January 03, 2022. Accessed August 12, 2022. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amcyte-pharma-inc-623474-01032022

            31. Public Notification: Adam’s Secret Extra Strength Amazing Black contains hidden drug ingredient. United States Food and Drug Administration. July 15, 2022. Accessed August 12, 2022. https://www.fda.gov/drugs/medication-health-fraud/public-notification-adams-secret-extra-strength-amazing-black-contains-hidden-drug-ingredient

            32. Coward, RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008;4(6):1315-1329. Accessed October 3, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643112/pdf/TCRM-4-1315.pdf

            33. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings [published correction appears in JAMA Netw Open. 2018 Nov 2;1(7):e185765]. JAMA Netw Open. 2018;1(6):e183337. Published 2018 Oct 5. doi:10.1001/jamanetworkopen.2018.3337

            34. Akabas SR, Vannice G, Atwater JB, Cooperman T, Cotter R, Thomas L. Quality Certification Programs for Dietary Supplements. J Acad Nutr Diet. 2016;116(9):1370-1379. doi:10.1016/j.jand.2015.11.003

            35. Dietary Supplement Labeling Guide, U.S. Food and Drug Administration. https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/dietary-supplement-labeling-guide Accessed July 15, 2022.

            36. Frequently Asked Questions for Industry on Nutrition Facts Labeling Requirements. United States Food and Drug Administration. Accessed August 12, 2022. https://www.fda.gov/media/99158/download

            37. Cooperman, T. 6 Red Flags to Watch Out For When Buying Vitamins & Supplements. October 9, 2021. Accessed August 12, 2022. https://www.consumerlab.com/answers/what-to-watch-out-for-when-buying-vitamins-and-supplements/vitamin-and-supplement-red-flags

            38. Research explores the impact of menopause on women’s health and aging. National Institute of Aging. May 6, 2022. Accessed September 6, 2022. https://www.nia.nih.gov/news/research-explores-impact-menopause-womens-health-and-aging

            39. Geller AI, Shehab N, Weidle NJ, et al. Emergency Department Visits for Adverse Events Related to Dietary Supplements. N Engl J Med. 2015;373(16):1531-1540. doi:10.1056/NEJMsa1504267

            40. Code of Federal Regulations. Title 16, Chapter II, Subchapter E, Part 1700. Amended September 6, 2022. Accessed September 6, 2022. https://www.ecfr.gov/current/title-16/chapter-II/subchapter-E/part-1700/section-1700.14

            41. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093-1108. doi:10.1007/s00216-008-2291-6

            42. Matura JM, Shea LA, Bankes VA. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations [published online ahead of print, 2021 Nov 4]. Ir J Med Sci. 2021;10.1007/s11845-021-02828-4. doi:10.1007/s11845-021-02828-4

            43. Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol. 2019;71(1):129-138. doi:10.1111/jphp.12858

            44. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol. 2004;18(2):262-276. doi:10.1177/0269881104042632

            45. Chen J, Wang Y. Social Media Use for Health Purposes: Systematic Review. J Med Internet Res. 2021;23(5):e17917. Published 2021 May 12. doi:10.2196/17917

            46. Moorhead SA, Hazlett DE, Harrison L, Carroll JK, Irwin A, Hoving C. A new dimension of health care: systematic review of the uses, benefits, and limitations of social media for health communication. J Med Internet Res. 2013;15(4):e85. Published 2013 Apr 23. doi:10.2196/jmir.1933

            47. Swire-Thompson B, Lazer D. Public Health and Online Misinformation: Challenges and Recommendations. Annu Rev Public Health. 2020;41:433-451. doi:10.1146/annurev-publhealth-040119-094127

            48. Chou WS, Oh A, Klein WMP. Addressing Health-Related Misinformation on Social Media. JAMA. 2018;320(23):2417-2418. doi:10.1001/jama.2018.16865

            49. Suarez-Lledo V, Alvarez-Galvez J. Prevalence of Health Misinformation on Social Media: Systematic Review. J Med Internet Res. 2021;23(1):e17187. Published 2021 Jan 20. doi:10.2196/17187

            50. Supplement Your Knowledge. Dietary Supplement Education Initiative. United States Food and Drug Administration. May 25, 2022. Accessed July 20, 2022. Reference the Supplement your knowledge program

            Ketamine and Its Kissing Cousins

            Learning Objectives

             

            After completing this application-based continuing education activity, pharmacists and pharmacy technicians will be able to

            ·       Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
            ·       Compare the different formulations of ketamine and its “kissing cousins”
            ·       Describe potential risks associated with ketamine use

             

            Image depicting chemical structure of ketamine.

            Release Date:

            Release Date: October 27, 2025

            Expiration Date: October 27, 2028

            Course Fee

            Pharmacists: $7

            Pharmacy Technicians: $4

            There is no grant funding for this CE activity

            ACPE UANs

            Pharmacist: 0009-0000-25-071-H08-P

            Pharmacy Technician: 0009-0000-25-071-H08-T

            Session Codes

            Pharmacist:  22YC62-FXK22

            Pharmacy Technician:  22YC62-KXT46

            Accreditation Hours

            2.0 hours of CE

            Accreditation Statements

            The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-25-071-H08-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

             

            Disclosure of Discussions of Off-label and Investigational Drug Use

            The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

            Faculty

            Alexis Hicks, PharmD.
            CVS Health
            West Hartford, CT

            Canyon Hopkins, PharmD.
            Medical Professional Ethos Cannabis
            Pittsburgh, PA

            Alexis Redfield, PharmD.
            CVS
            Vernon, CT

            Ashley Walsh, PharmD.
            Mohegan Pharmacy
            Uncasville, CT


             

            Faculty Disclosure

            In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

            Drs. Hicks, Hopkins, Redfield, and Walsh do not have any relationships with ineligible companies and therefore have nothing to disclose.

             

            ABSTRACT

            Ketamine is Food and Drug Administration-approved as a general anesthetic. Researchers found higher dose ketamine therapy had a more desirable adverse effect profile than the previously used anesthetic phencyclidine (PCP). N-methyl-D-aspartate (NMDA) antagonism from subanesthetic ketamine doses produces dissociative and analgesic effects. As such, prescribers are exploring off-label uses for ketamine in patients with agitation, depression, and pain while considering potential risks to multiple organ systems. Ketamine has the potential to cause complications and providers need to monitor patients closely. Illicit and inappropriate use by abusers and untrained law enforcement officers highlight ketamine’s potentially harmful effects. Educating patients and healthcare providers is vital to allow potential benefits while minimizing harm.

            CONTENT

            Content

            Introduction

             

            Consider this: It’s 10:30 PM on a Friday night, 30 minutes before you leave for the weekend. Suddenly, from across the emergency department you hear, “Get OFF me! No, I have not t-t-taken anything! If you come ANY CLOSER, things are going to get physical!” Not a moment later, an order pops up for ketamine hydrochloride 500 mg intramuscularly (IM) for severe agitation. Concerned, a colleague asks you, “Is this safe? Is this effective? I have never seen a dose this high before. Isn’t this just for horses?”

             

            Ketamine made its debut in human clinical practice in the 1960s when several chemists at Parke Davis Company were searching for an anesthetic with similar effects to phencyclidine (PCP). PCP, ketamine’s notorious kissing cousin, was a promising new anesthetic in the 1950s because of its dissociative effects. However, the chemists quickly became unimpressed with its adverse effect profile (i.e., long-lasting psychoactive effects after anesthesia). Humans experienced intense prolonged emergence delirium following PCP anesthesia, relegating its use to veterinary practice.1 Chemists searched for a better anesthetic and found ketamine, which has similar dissociative effects without PCP’s negative consequences. Ketamine is a more desirable anesthetic because it has a shorter half-life (2.5 hours) compared to PCP (21 hours) and it causes less delirium.1,2

             

            Prescribers have begun using ketamine for several off-label uses and patients have also started using the drug or structural analogs in a variety of formulations illicitly. Pharmacists and technicians can ensure ketamine’s safe use by keeping current with new formulations and indications, both approved and unapproved. This continuing education activity will dive into the clinical and social consequences of ketamine use.

             

            What’s Ketamine?

            Ketamine is a schedule III-controlled substance approved by the U.S. Food and Drug Administration (FDA) for use as a general anesthetic for diagnostic and surgical procedures.2 Ketamine is commercially available in the United States as a solution/injection under its brand (Ketalar) and as generic ketamine.2 Healthcare providers most often use intravenous (IV) ketamine, but it may be used IM or compounded into an oral solution. 

             

            Healthcare providers also use ketamine off-label for analgesia, agitation, and major depressive disorder. These indications emanate from ketamine’s mechanism of action: it acts specifically on the N-methyl-D-Aspartate (NMDA) receptor as a non-competitive antagonist to block glutamate binding.3 Glutamate, a major excitatory neurotransmitter, binds to receptors throughout the nervous system. The NMDA receptor is an ionotropic receptor responsible for the brain’s neuroplasticity, memory, learning, and recovery.4-6 Blocking this receptor with high ketamine doses (ranging from 0.5 to 2 mg/kg) results in dissociation, decreases in spinal reflexes, and produces a cataleptic state (loss of voluntary movements and reduced consciousness) that is applicable to its current clinical use in anesthesia.2 However, at low doses, ketamine can produce analgesia and stimulate new pathways within the brain that reduce depressive symptoms and improve mood.

             

            Although ketamine has useful applications in medicine, prescribers must be aware of the adverse effects and risk factors associated with use and should consider how these effects apply to their patients before initiating the medication. Ketamine adversely impacts multiple organ systems (see Table 1), including but not limited to the cardiovascular system. Increases in blood pressure and heart rate are important cardiovascular effects associated with ketamine therapy.2 These cardiovascular effects make it a drug of choice for anesthesia induction in patients with cardiovascular shock, where it anesthetizes patients while improving blood pressure and improving organ perfusion. However, clinicians must avoid ketamine use in patients with preexisting hypertensive conditions or other patients who have limited baroreceptor buffering capacity (baroreceptor buffering is the body’s ability to sense blood pressure) because of those same effects mentioned above.6

             

            Table 1. General Adverse Effects of Ketamine2,6

            System Adverse effects
            Cardiovascular Cardiac arrhythmias, increased blood pressure,* increased heart rate
            Central nervous system Prolonged emergence from anesthesia,* psychosis,* dissociation,* drug dependence, increased intracranial pressure
            Dermatologic Injection site irritation
            Gastrointestinal Nausea,* vomiting, anorexia
            Genitourinary Lower urinary tract dysfunction, bladder dysfunction
            Respiratory Laryngospasm,* respiratory depression,* apnea
            Immunologic Anaphylaxis
            Other Hypersalivation, diplopia (double vision), nystagmus (uncontrollable rapid eye movement)

            *Common or serious adverse effects of ketamine use

             

            Further contraindications include hypersensitivity to ketamine or its components.7 The American College of Emergency Physicians (ACEP) does not recommend ketamine use in patients with schizophrenia or in children younger than three months of age. The ACEP also advises against solely using ketamine as an anesthetic in procedures involving the pharynx, larynx, and bronchial tree. This recommendation primarily applies to patients with airway instability because ketamine can cause laryngospasms.5 Table 2 lists additional considerations in special populations.

            Table 2. Special Population Considerations with Ketamine2,6-8

            Special population Concerns Recommendation
            Pregnancy Crosses the placenta; may have potential risk to fetus Avoid use; evaluate benefits vs risk
            Breastfeeding Compatibility and safety unknown Avoid breastfeeding to children with respiratory risk factors
            Pediatrics Can be given with anticholinergics to minimize hypersalivation Refer to pediatric dosing. Avoid in infants < 3 months of age
            Elderly May be sensitive to dissociative adverse effects Refer to adult dosing
            Kidney dysfunction No additional concerns Refer to dosing parameters
            Liver dysfunction Hepatobiliary dysfunction with recurrent use Refer to dosing parameters; monitor LFTs with repeated ketamine use
            LFTs = liver function tests

             

            Healthcare providers should monitor patients' vital signs closely during treatment with ketamine. Anesthesiologists and pharmacists must continuously watch patients undergoing surgical or diagnostic procedures for proper induction and maintenance of dissociative effects.2 In patients who must take repeated doses of ketamine (e.g., for chronic pain management or psychiatric disorders), healthcare providers should order liver function tests at baseline and every one to two days during treatment.2,6,9,10

             

            Ketamine’s Kissing Cousins

            As shown in Figure 1, ketamine is structurally related to many compounds. The drugs in Figure 1 antagonize the NMDA receptor and exhibit a dissociative effect.1 PCP is one of the most notoriously abused drugs. Compared with ketamine, PCP is 10 times more potent and has a longer duration of action due to its strong affinity for the NMDA receptor. Both ketamine and PCP can replicate schizophrenia’s positive, negative, and cognitive symptoms and exacerbate underlying schizophrenia. But because ketamine has lower potency and a shorter duration of action, it induces fewer severe psychiatric effects than PCP.1

            Image depicting the molecular structure of ketamine and structurally related drugs.

            Figure 1. Molecular structure of ketamine and structurally related dissociative drugs11

                       

            Although ketamine’s labeling includes many precautions, it is an emerging option because of its therapeutic benefits. Xi Biopharmaceuticals is developing a sublingual wafer to treat acute pain while Janssen Pharmaceuticals has developed a nasal spray formulation for treatment resistant depression.12,13 Table 3 compares the current ketamine formulations that are FDA-approved or under investigation.

             

            Table 3. Ketamine Counterparts12-14

             Cousins Formulation Use & Dose Approval or Trial Phase
            Ketalar (ketamine hydrochloride) Injectable Anesthesia

            0.25 – 0.35 mg/kg followed by CIVI 1 mg/kg/hr

            FDA-approved
            Wafermine (ketamine) Sublingual Wafer Acute Pain

            25 mg, 50 mg & 75 mg PRN for 12 hrs

            End-of-Phase 2 Clinical Trials
            Spravato (esketamine) Nasal Spray Treatment Resistant Depressive Disorder

            28 mg, 56 mg, 84 mg twice a week

            FDA-approved
            ABBREVIATION: CIVI = continuous intravenous infusion

             

            ABUSE, ADDICTION, DEPENDENCE

             

            Why is Ketamine Dangerous?

            Long-term ketamine abuse is associated with memory, attention, and judgment impairment. The actual risk of ketamine abuse in the general population is low compared to other substances of abuse, but patients with polysubstance abuse disorder tend to use it.15 A study examining polysubstance abuse conducted in New York City found that polydrug use occurred because of an unexpected opportunity to use ketamine after already consuming other drugs. Researchers also determined that polysubstance abusers purposefully used ketamine with another substance to achieve an individually desired effect. Oftentimes polydrug-using events occurred within a group and each member contributed something: ketamine, knowledge, other drugs, or space to use drugs.16

             

            Currently, ketamine is only commercially available as an injectable liquid. Dealers illegally sell ketamine as a recreational injectable substance or a white powder that resembles cocaine. The Department of Justice and Drug Enforcement Administration report that illegally distributed ketamine is diverted or stolen from veterinary clinics or smuggled into the United States from Mexico.17 Dealers can then synthesize ketamine into a powder or sell it as an injectable liquid.18 Prices average from $20-$25 per dose (50 mg to 100 mg).19 Drug abusers find ketamine’s dissociative sensations and hallucinations appealing. Users can inject liquid ketamine, or snort or smoke powdered ketamine.17 Ketamine is a popular drug to facilitate physical or sexual assault because it is a colorless, tasteless, and odorless liquid making it difficult for victims to detect. Additionally, ketamine is known to cause impaired coordination, confusion, and memory loss.20

             

            Ketamine’s IV administration started in the early 1990s. Injection events occur most frequently in large cities with high rates of homelessness, like New York City and Los Angeles.18 Researchers conducted a study with 213 people who abused IV ketamine.18 Among these users, 84% admitted to abusing ‘harder’ drugs first, with heroin predominating. Users reported their first ketamine injection happening among a group of people. This group often included people well known to them who provided knowledge and the materials for injecting.18

             

            What attracts people to a dissociative drug with unknown psychoactive effects? Exactly that: the unknown. With most abused drugs, the user understands the effects they will experience. When someone takes ketamine, the reaction to each dose is unknown. Some users seek variety. Ketamine users have described an out of body experience that expands internal and external realms and realities.18 On the other hand, abusers also describe a “K-Hole”—an experience that they describe as near-death that results when they ingest too much ketamine.17

             

            Timothy Wyllie, a spiritualist, describes ketamine doses as a curve over time through realms. He describes the domains abusers experience as they dose ketamine21:

            • The realm “I,” for internal reality, occurs at doses 30 to 75 mg roughly 10 minutes after injection.
            • The extraterrestrial reality realm, “They,” occurs at doses 75 to 150 mg approximately 15 minutes after injection.
            • The realm “We,” for network creation realm, occurs at doses from 150 to 300 mg mg approximately 15 minutes after injection.
            • An unknown realm exists at doses of more than 300 mg.

            The doses studied for depression fall in the realm of internal reality. At these doses, users can see areas needing self-improvement that they were unaware they had the ability to fix. Drug users prefer subanesthetic doses but those that are higher than doses studied for treating depression. As the dose increases, users become so far removed from reality that “extraterrestrial” experiences begin.21

             

             

            KETAMINE USES

             

            Anesthesia

            Patients unable to maintain and protect their airways require endotracheal intubation. Healthcare providers use ketamine as a sedative to facilitate rapid sequence induction and intubation (RSII), by inducing an anesthetized state, prior to paralyzing the patient. The decision to intubate is based on the patient’s Glasgow Coma Score.22,23 A score of 8 or less qualifies a patient to receive endotracheal intubation.23 Healthcare providers follow a RSII strict algorithm, shown in Table 4, detailing the order in which medications should be administered based upon the onset and duration of action.

            Table 4. Algorithm of Rapid Sequence Induction & Intubation22,23

            Step of RSII What and Why Medications Used
            Premedication* Airway manipulation causes a sympathetic activation due to a pressor response. This sympathetic response leads to an increase in intracranial pressure and mean arterial pressure. alfentanil, fentanyl, lidocaine, sufentanil
            Sedation Used to induce an anesthetic state before a paralytic is used and the airway manipulated. Crucial that a patient is properly sedated before paralyzed. Also known as induction agents: etomidate, ketamine, midazolam, propofol
            Paralytics± Neuromuscular blocking agents are given to relax pharyngeal and diaphragmatic muscles allowing for an endotracheal tube to be placed. rocuronium, succinylcholine, vecuronium

            *: Based upon time constraints/needs this step may be omitted

            ±: It is imperative to confirm a patient is properly sedated before beginning paralysis because if the patient is awake, they may feel the tube insertion

             

            The drugs used in RSII possess unique characteristics, including IV use, quick onset, and short duration of action.23 Traditionally, etomidate has been the gold standard for RSII, but ketamine is quickly becoming a commonly used alternative.23 Table 5 highlights the differences between etomidate and ketamine.

             

            Table 5. Comparison of Etomidate and Ketamine22,23

              Etomidate Ketamine
            Dose for Induction 0.3 mg/kg 1.5 mg/kg or 0.1-0.5 mg/kg/min with 10% given as induction bolus
            Onset of Action 10-15 seconds < 30 seconds
            Duration of Action 4-10 minutes 10-15 minutes
            Benefits Stable hemodynamic profile, decreases metabolic rate, decreases cerebral blood flow, increases generalized seizure threshold Sedative and analgesic properties,* cardiovascular and respiratory stimulation, and smooth muscle relaxation (beneficial in reactive airway disease, hypotensive, volume depleted, and septic patients)
            Risks Adrenal suppression, do not use in septic shock, lowers focal seizure threshold, increased incidence of ARDS Potentiates effect of epinephrine, increases cardiac oxygen demand, may increase ICP,** emergent reactions, infusion related respiratory depression, hypersalivation
            ABBREVIATIONS: ARDS = acute respiratory distress syndrome, ICP = intracranial pressure

             

            * Ketamine can be used as a combined premedication and induction step

            ** Data is conflicting, however, may not be suitable for patients with head trauma

             

            The differences between etomidate and ketamine create a significant role in RSII for both drugs, but for different presenting conditions. Ketamine is gaining popularity for its use in septic patients, hypotensive patients, and those with reactive airway diseases. Choosing etomidate is preferable for patients with a hemodynamically stable profile and patients with traumatic brain injury where it could be cerebroprotective.

             

            Analgesia (pain)

             

            Ketamine’s use in pain management is controversial due to limited data, but this dataset is growing.15,24 Before considering subanesthetic ketamine doses, prescribers should collaborate with patients and other clinical team members to try other approved pain regimens.25 Using ketamine for its analgesic properties should be based on patient-specific criteria. The prescriber must assess the patient’s treatment goals, current medical conditions, pain types, and available protocols.

             

            Ketamine is not discussed in available pain guidelines. Some literature recommends its use after unsuccessful trials of at least two opioids. Data supporting ketamine’s use in both acute and chronic pain management is mixed in its findings.26,27 Most trials conclude ketamine can reduce acute pain exacerbations but note that prescribers must be cautious of its adverse effects.15 Data from small trials indicate using ketamine to overcome opioid withdrawal and opioid-induced-hyperalgesia (neuropathic pain) may be possible. Ketamine has a unique ability to counteract the unfavorable responses patients might experience on chronic high-dose opioids by its mechanism of action.24,28 Overstimulated opioid receptors from high dose opioid use causes more hyperalgesia. Several small case reports describe patients on high-dose chronic opioid therapy who reduced their opioid doses after low-dose ketamine administration.29

             

            An open labeled audit determined that IV ‘burst’ ketamine therapy improved analgesia in neuropathic pain and painful bone metastases. Researchers enrolled 39 cancer patients who were refractory to opioid therapy. Patients received bursts of low-dose ketamine (100 to 500 mg/day) over three to five days and reported somatic and neuropathic pain relief for up to eight weeks.15

             

            Limited evidence supports oral ketamine’s effect in chronic pain and most studies that examine its use are case reports or non-comparative trials. Compared to IV administration, lower oral ketamine concentrations are associated with analgesic effects. Oral ketamine has been associated with higher serum levels of its metabolite, norketamine. This metabolite seems to contribute to oral ketamine’s analgesic effects due to its shorter half-life and ability to reach much higher peak plasma concentrations than after IV administration. However, researchers have not extensively explored this in current literature.29

             

            Healthcare providers and patients face many hurdles when using ketamine for pain relief. Prescribers should avoid high ketamine doses that may cause a range of serious adverse effects. Unlike opioids, ketamine has a ceiling effect and maximum dose. Oral ketamine administration has a low bioavailability and is directly linked with a high rate of adverse effects.15,27

             

            Agitation

            Due to ketamine’s dissociative properties, clinicians are increasingly using ketamine for treating pre-hospital and in-hospital agitation. Lacking a uniform definition for agitation, healthcare providers, institutions, and organizations may use different criteria to choose medication intervention in an agitated patient. Although the picture of agitation may change depending on the situation, validated scales like the Altered Mental Status Scale (AMSS) can define agitation’s severity.30 The AMSS translates agitation into a quantifiable, real concept. The line between agitation and delirium is often unclear but has major ramifications for a patient’s treatment and outcome.30 For example, excited delirium, an agitation subtype, classifies a patient’s agitation past the emotional component and includes psychomotor, metabolic, and contributing disease states as possible reasons for agitation.30

             

            As with most psychiatric disorders, identifying and treating agitation has been suboptimal. Since the 1980s, a popular cocktail of medications, known among emergency department physicians as the “B-52” order, has been the mainstay of agitation treatment in psychiatric facilities and emergency departments.31 When examining the B-52 order’s components, it is easy to see the correlation between the regimen and the American jet-powered strategic bomber from which it derives its name: Benadryl 50 mg IM, haloperidol 5 mg IM, lorazepam 2 mg IM.31 The B-52 order serves as a reminder of the suboptimal approach traditionally taken when confronted with an agitated patient.

             

            Ketamine’s different routes of administration have benefits and disadvantages. Although less invasive, oral ketamine takes a longer time to reach the therapeutic range, something that is undesirable in an overly aggressive patient. Intravenous administration has the quickest onset but is the most invasive. Securing IV access may not always be possible. The IM route is the most often used method for agitation control for its quick “on/off” onset and duration of action, and its applicable dosage form.

             

            A review explains ketamine’s uses and benefits in comparison to other, more traditional agitation treatments.30 In terms of agitation efficacy, ketamine provides the same, if not better, response when compared to its more traditional counterparts.30 Ketamine has a significantly faster onset of action when compared to haloperidol (5 minutes versus 17 minutes) and requires less redosing (5% of patients re-dosed versus 20% of patients re-dosed, respectively).30 However, ketamine continues to show a higher incidence of adverse effects when compared to its anti-psychotic counterpart (percent incidence calculated from six studies where adverse events were recorded as a secondary outcome):30

            • emergence reaction 12.3% (8/65 patients)
              • An “emergence reaction” is an often hostile, psychiatric episode brought about by ketamine use
            • hypersalivation 31.8% (22/69 patients)
            • nausea and vomiting 8.5% (7/82 patients)
            • respiratory complications 7.6% (9/118 patients)

             

            Although studies report a higher incidence of adverse reactions when using ketamine for agitation, it is important to consider study limitations: small patient populations, co-administration of drugs, and lack of adverse event reporting (only half of 12 studies included adverse reactions).30 If used properly, ketamine can be a safe, quick-acting drug to stop agitation when compared to traditional treatments.

             

            Some law enforcement agencies use ketamine. However, when they use ketamine improperly, or when adverse effects arise, ketamine can have dangerous consequences. Over a four-day period during late August of 2019 in Colorado, police gave 23-year-old Elijah McClain and 25-year-old Elijah McKnight excessive ketamine doses for agitation.32 McClain died from cardiac arrest and McKnight survived but required life support in the hospital.32 It is inappropriate to allow untrained police officers to inject ketamine as a law enforcement tool. However, police defend using ketamine saying suspects with mental health issues or suspects taking drugs can be belligerent and dangerous. A Minnesota whistleblower lawsuit filed by a former emergency medical services worker claims police pressured them to allow ketamine use uneccessarily.32 In Minneapolis, ketamine used by police rose from four incidents per year in 2015 to 62 in 2017.32 This marked increase in ketamine use is upsetting many healthcare professionals. Dr. Mary Dale Peterson, president of the American Society of Anesthesiologists, says that ketamine can have “dangerous complications,” just like any other anesthetic. Dr. Peterson points out that justifiably using ketamine occurs very rarely.32

             

            Whistleblowers cite complications from unwarranted ketamine use are associated with emergence reactions, and improper dosages.32 McClain died when he was given a ketamine dose for a 200-pound man but only weighed 143 pounds.32 Pharmacists can play a role in educating other healthcare professionals about proper dosing and management of ketamine’s serious adverse effects.

             

            Major Depressive Disorders

            Generally, major depressive disorder’s (MDD) treatment focuses on pathophysiology and regulates serotonin, norepinephrine, and dopamine.32 Medications such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibits (SNRIs), tricyclics, tetracyclics, and serotonin modulators all target an increase in synaptic neurotransmitter levels.32 Unfortunately, these drugs are not consistently effective for all patients, require an 8-week trial period, and have unfavorable adverse effects. For many providers and their patients, MDD treatment can feel like an awful waiting game—one that they sometimes lose.

             

            Ketamine is becoming increasingly popular for its use in treating refractory depression. However, it requires healthcare providers to understand how it works to avoid putting patients into a “K-hole.” It offers a different approach to the current FDA-approved drugs for MDD. Ketamine prevents glutamate reuptake; excess glutamate produces an antidepressant effect. Ketamine, at subanesthetic doses, produces euphoria, and improves symptoms within 24 hours after infusion.4,14,32,33 Depressive symptoms improve rapidly, but the effects last only a few days to weeks. As a result, ketamine is most useful as an adjunctive treatment option. Patients feel better for a brief period, giving their antidepressants a chance to start working.

             

            In addition, prescribers have few options for patients with MDD who have suicidal behaviors and ideation. Ketamine seems promising for patients at an elevated risk for self-harm. The Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression trial examined ketamine’s potential benefits for 80 suicidal patients with MDD. The results of this randomized controlled study showed that ketamine was superior to midazolam in improving the Scale for Suicidal Ideation (SCI). Patients’ SCI scores improved 4.96 points within 24 hours after a ketamine infusion of 0.5 mg/kg over 40 minutes.32 This suggests clinical use of ketamine as an adjuvant agent for acute episodes of suicide ideation in patients maintained on guideline recommended therapy for MDD may be appropriate. However, patient safety remains a concern (e.g., dissociative effects, abuse potential, respiratory, and cardiovascular effects).

             

            As mentioned earlier, esketamine (Spravato) is ketamine’s S-enantiomer and FDA-approved for treatment-resistant depression.33 In the TRANSFORM-1 randomized controlled trial, the antidepressant/esketamine groups did not have a statistically significant change in Montgomery-Asberg Depression Rating Scale (MADRS) total score (from baseline to study day 28) when compared to the antidepressant placebo group.34,35 However, the changes based on the MADRS were clinically meaningful and showed that esketamine has a beneficial role in treatment-resistant depression when used as an adjuvant agent.36,37 The combination of esketamine with an antidepressant produced desirable outcomes while minimizing adverse effects. Although adverse effects were low, several adverse effects are possible: vertigo, nausea, vomiting, anxiety, sedation, abuse potential, increased blood pressure, dissociation, and suicidal thoughts/behaviors.33

             

            CONCLUSION

            To paraphrase the father of toxicology, Paracelsus, it’s all about the dose. Ketamine is the poster child drug for this statement. Ketamine has the potential to be an important adjuvant therapy for the treatment of a range of conditions. Those listed in this CE—anesthesia, analgesia, and major depressive disorder—are currently the most studied disorders where ketamine and its derivatives may be useful. Due to ketamine’s dissociative and analgesic effects through NMDA antagonism, there may be additional future potential uses for ketamine in pain control and psychiatric disorders. Simply, ketamine treats not only the physical manifestations of these conditions but the emotional component that providers can easily overlook. However, the current data sets are small, many use rating scales instead of final health outcomes, and a larger and longer term series of trials are required to fully determine the place of ketamine in the treatment armamentarium for patients.

             

            Pharmacists and other healthcare providers will need to distinguish between therapeutic use and addiction. Often, these lines are muddled. Providing education is a first step to preventing abuse. Usually, addiction is a manifestation of an untreated, or undertreated, medical condition. Pharmacist intervention helps patients and healthcare providers to make the safest, most informed decisions possible to ensure the best possible outcomes.

             

            Pharmacist Post Test (for viewing only)

            Pharmacist Post-Test
            Objectives:
            1. Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
            2. Compare the different formulations of ketamine and its “kissing cousins”
            3. Describe potential risks associated with ketamine use

            1. Patient AV has a GCS score of 8 and requires intubation. He presents with volume depletion, hypotension, and sepsis. What drug would the anesthesiologist probably use for sedation?
            a. Fentanyl
            b. Etomidate
            c. Ketamine

            2. In which patients would you avoid recommending ketamine?
            a. Patients with reactive airway disease
            b. Patients with sepsis or hypotension
            c. Patients with traumatic brain injury

            3. Which formulation of esketamine is FDA-approved for treatment resistant depressive disorder?
            a. Injectable
            b. Nasal spray
            c. Infusion

            4. What is the most commonly used route of administration when using ketamine for agitation?
            a. IV
            b. IM
            c. PO

            5. A clinician asks you about ketamine’s adverse effects. What would you say to start?
            a. Ketamine can cause cardiac arrythmias.
            b. Ketamine can decrease blood pressure.
            c. Ketamine can worsen peptic ulcers.

            6. What is the correct order of administration for RSII medications?
            a. Premedication, sedative, paralytic
            b. Premedication, paralytic, sedative
            c. Sedative, premedication, paralytic

            7. When should prescribers monitor liver function in patients who receive repeated ketamine doses?
            a. At baseline and every 1 to 2 months
            b. At baseline and every 1 to 2 weeks
            c. At baseline and every 1 to 2 days

            8. What is a “K-hole?”
            a. A networking experience
            b. A near-death experience
            c. An extraterrestrial experience

            9. What is a limitation of using ketamine in MDD?
            a. Depressive symptoms improve slowly
            b. Requires an 8-week trial period first
            c. Effects last only a few days to weeks

            10. A police officer asks you to discuss ketamine and asks why you refer to similar drugs as “kissing cousins.” How would you explain it?
            a. They all have similar potency and antagonize NMDA receptor
            b. They are used in similar doses and act as a NMDA receptor agonist
            c. They are structurally similar and antagonize NMDA receptor

            Pharmacy Technician Post Test (for viewing only)

            Technician Post-Test
            Objectives:
            1. Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
            2. Compare the different formulations of ketamine and its “kissing cousins”
            3. Describe potential risks associated with ketamine use

            1. In which patient should prescribers avoid using ketamine?
            a. patient with serious peptic ulcer
            b. patient older than 3 months old
            c. patient with uncontrolled hypertension

            2. What ketamine dose results in dissociation?
            a. 0.1 to 0.5 mg/kg
            b. 0.5 to 2 mg/kg
            c. 2 to 3.5 mg/kg

            3. What is a risk associated with using ketamine in RSII?
            a. adrenal suppression
            b. increase ARDS incidence
            c. emergent reactions

            4. What ketamine formulation is currently available by prescription?
            a. sublingual tablet
            b. injectable solution
            c. 24-hour patch

            5. What risk is associated with ketamine use?
            a. exacerbates underlying schizophrenia
            b. lowers focal seizure threshold
            c. increases incidence of ARDS

            6. What is a key difference between PCP and ketamine?
            a. PCP has a shorter duration of action than ketamine
            b. PCP is 10 time more potent than ketamine
            c. PCP has less severe psychiatric effects than ketamine

            7. What is a benefit of using ketamine for agitation in comparison to haloperidol?
            a. faster onset
            b. more redosing
            c. fewer side effects

            8. What is ketamine’s FDA-approved indication?
            a. agitation
            b. analgesia
            c. anesthesia

            9. What can be expected when people use oral ketamine?
            a. high bioavailability
            b. high rate of adverse effects
            c. low plasma peak concentrations

            10. What is ketamine’s role in RSII?
            a. premedication
            b. sedative
            c. paralytic

            References

            Full List of References

            References

               
              1. Li L, Vlisides PE. Ketamine: 50 Years of modulating the mind. Front Hum Neurosci. 2016;10:612. Published 2016 Nov 29. doi:10.3389/fnhum.2016.00612

              2. Ketalar. Prescribing information. Par Pharmaceutical; 2022. Accessed July 25, 2022. https://www.parpharm.com/pdfs/catalog/sterile/Ketalar_PI_20220613.pdf

              3. Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary. Washington (DC): National Academies Press (US); 2011.

              4. Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. Journal of Psychiatry Neuroscience. 2017;42(4):222-229. DOI: 10.1503/jpn.160175.

              5. Vyklicky V, Korinek M, Smejkalova T, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(Suppl 1):S191-S203. doi:10.33549/physiolres.932678

              6. Godwin SA, Burton JH, Gerardo CJ, et al. American College of Emergency Physicians. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med. 2014;63(2):247-258.e18. doi:10.1016/j.annemergmed.2013.10.015[PubMed 24438649]

              7. Ellingson A, Haram K, Sagen N, Solheim E. Transplacental passage of ketamine after intravenous administration. Acta Anaesthesiol Scand. 1977;21(1):41-44.[PubMed 842268]

              8. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341-348. doi:10.1016/j.biopha.2006.06.021

              9. Zhu X, Kohan LR, Goldstein RB. substantial elevation of liver enzymes during ketamine infusion: a case report. A Pract. 2020;14(8):e01239. doi:10.1213/XAA.0000000000001239

              10. Wilkinson ST, Sanacora G. Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders. JAMA. 2017;318(9):793-794. doi:10.1001/jama.2017.10697

              11. Ho JH, Dargan PI. Arylcyclohexamines (Ketamine, Phencyclidine, and Analogues). In: Critical Care Toxicology. Brent J, Burkhart K, Dargan P, Hatten B, Megarbane B, Palmer R, eds. Springer; 2016. https://doi.org/10.1007/978-3-319-20790-2_124-1

              12. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacology. 2015;172(17):4254-4276. doi:10.1111/bph.13222

              13. Study of Wafermine™ for post-bunionectomy or abdominoplasty pain. ClinicalTrials.gov identifier: NCT03246971. Updated July 23, 2018. Accessed Jul 25, 2022. https://clinicaltrials.gov/ct2/show/study/NCT03246971

              14. Treating major depressive disorder: a quick reference guide. American Psychiatric Association. Published October 2010. Accessed July 25, 2022. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd-guide.pdf

              15. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341-348. doi:10.1016/j.biopha.2006.06.021

              16. Lankenau SE, Clatts MC. Patterns of polydrug use among ketamine injectors in New York City. Subst Use Misuse. 2005;40(9-10):1381-1397. doi:10.1081/JA-200066936

              17. Drug Fact Sheet: Ketamine. Department of Justice and Drug Enforcement Administration. Published April 2020. Accessed July 25, 2022. https://www.dea.gov/sites/default/files/2020-06/Ketamine-2020.pdf

              18. Lankenau SE, Sanders B, Bloom JJ, et al. First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug Alcohol Depend. 2007;87(2-3):183-193. doi:10.1016/j.drugalcdep.2006.08.015

              19. Average Cost of Illicit Street Drugs. AddictionResource.net. Updated June 21, 2021. Accessed July 25, 2022. https://www.addictionresource.net/cost-of-drugs/illicit/

              20. Świądro M, Stelmaszczyk P, Lenart I, Wietecha-Posłuszny R. The Double Face of Ketamine-The Possibility of Its Identification in Blood and Beverages. Molecules. 2021;26(4):813. Published 2021 Feb 4. doi:10.3390/molecules26040813

              21. Morris, H. Hamilton’s Pharmacopeia Ketamine: Realms and Realities. [Video]. Vice TV. December 26, 2017. Accessed July 25, 2022. https://www.vicetv.com/en_us/video/hamiltons-pharmacopeia-ketamine-realms-and-realities/59cd5d0b7752d1ac3e90aacf

              22. Kurdi MS, Theerth KA, Deva RS. Ketamine: Current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283-290. doi:10.4103/0259-1162.143110

              23. Scarponcini TR, Edwards CJ, Rudis MI, Jasiak KD, Hays DP. The role of the emergency pharmacist in trauma resuscitation. J Pharm Pract. 2011;24(2):146-159. doi:10.1177/0897190011400550

              24. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161.

              25. Johnstone-Petty, M. Ketamine use for complex pain in the palliative care population. J Hosp Palliat Nurs. 2018;20(6):561-567. doi: 10.1097/NJH.0000000000000488.

              26. Mercadante S, Caruselli A., Casuccio A. The use of ketamine in a palliative-supportive care unit: a retrospective analysis. Ann Palliat Med. 2018;7(2): 205-210. doi: 10.21037/apm.2018.01.01

              27. Bell RF, Kalso EA. Ketamine for pain management. Pain Rep. 2018;3(5):e674. Published 2018 Aug 9. doi:10.1097/PR9.0000000000000674

              28. Lalanne L, Nicot C, Lang JP, et al. Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report. BMC Psychiatry. 2016;16(1):395. doi:10.1186/s12888-016-1112-2

              29. Blonk MI, Koder BG, Van Den Bemt PMLA, Huygen FJPM. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2012;14(5): 466-472. https://doi-org.ezproxy.lib.uconn.edu/10.1016/j.ejpain.2009.09.005

              30. Linder LM, Ross CA, Weant KA. Ketamine for the acute management of excited delirium and agitation in the prehospital setting. Pharmacotherapy. 2018;38(1):139-151. doi:10.1002/phar.2060

              31. Lulla AA, Singh M. The Art of the ED Takedown. emDOCs.net - Emergency Medicine Education. Published March 4, 2015. Accessed July 25, 2022. http://www.emdocs.net/the-art-of-the-ed-takedown/

              32. Young R, McMahon S. Some States Allow Authorities to Use Ketamine to Subdue Suspects in The Field. But Is It Safe? Some States Allow Authorities to Use Ketamine to Subdue Suspects in The Field. But Is It Safe? | Here & Now. Published September 8, 2020. Accessed July 25, 2022. https://www.wbur.org/hereandnow/2020/09/08/ketamine-police-safety-elijah-mcclain

              33. Ketamine. In: Lexi-Drugs. Lexi-Comp, Inc. Updated July 20, 2022. Accessed July 25, 2022. http://usj-ezproxy.usj.edu:2099/lco/action/doc/retrieve/docid/patch_f/7135?cesid=a8n33eDrj1M&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dketamine%26t%3Dname%26acs%3Dfalse%26acq%3Dketamine#rfs

              34. Montgomery-Asperg Depression Rating Scale. Accessed July 27, 2022. https://www.mdcalc.com/calc/4058/montgomery-asberg-depression-rating-scale-madrs

              35. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. doi:10.1093/ijnp/pyz039

              36. Spravato. Prescribing information. Janssen Pharmaceutical Companies; 2019. Accessed July 25, 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf

              37. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. doi:10.1093/ijnp/pyz039

              Arthur E. Schwarting Symposium LIVE Event 2027 TBD

              Arthur E. Schwarting was an internationally recognized leader in the transformation of pharmacognosy from a plant-based discipline to a science based on the chemistry of natural products. He also was the preeminent pharmacognosist in the U.S. to engage in the study of medicinal agents from microorganisms, and he was a pioneer in the use of radio isotopes to elaborate the biochemical pathways by which plants and microorganisms make medicinally active products. The Arthur E. Schwarting Symposium is now an educational conference focused on pharmacy practice for pharmacists in many settings.

              Measure Twice, Cut Once: A Carpentry Approach to Pharmacy

              Five hours of live streaming CE including Law, Patient Safety, and Immunization

              2026 AGENDA

              11:00am-12:00 pm 

              Load-Bearing Walls: Getting Cardiovascular Therapy Right the First Time
              Katelyn Galli, PharmD, BCCP, UConn School of Pharmacy, Storrs, CT
              Type of Activity: Application
              ACPE UAN 0009-0000-26-009-L01-P
              Learning Objectives: At the end of this presentation the learner will:

              • Identify high-risk cardiovascular medications that are most commonly associated with preventable adverse drug events amid transitions of care
              • Describe evidence-based principles for precise cardiovascular medication dosing, including clinically relevant pharmacokinetic considerations that influence drug and dose selection
              • Explain the benefits and limitations of clinical decision support tools in cardiovascular pharmacotherapy
              • Recognize common system-level and cognitive factors contributing to cardiovascular medication near misses and adverse effects

               

              12:05-1:05 pm 

              LAW: The Legal Blueprint: Designing Error-Proof Pharmacy Policies
              Dylan DeCandia, PharmD, RPh, Franklyn’s Pharmacy in Ho-Ho-Kus, New Jersey
              Type of Activity: Application
              ACPE UAN 0009-0000-26-010-L03-P
              Learning Objectives: At the end of this presentation the learner will:

              • Describe the roles and responsibilities of each pharmacy staff member
              • Articulate when a pharmacist should seek legal clarification
              • Identify common pharmacy mistakes that may leave pharmacists liable
              • Construct policies and procedures that prevent future pharmacy errors

               

              1:10-2:10 pm 

              Patient Safety: Blueprints Before Builds: Patient Assessment in Clinical Decision-Making
              Devra Dang, PharmD, CDCES, FNAP, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT  
              Type of Activity: Application
              ACPE UAN 0009-0000-26-013-L05-P
              Learning Objectives:

              • Explain the Pharmacists’ Patient Care Process and strategies to optimize the “Collect” and “Assess” steps to improve assessment and clinical decision-making
              • Identify common pitfalls that affect optimal patient assessment across healthcare settings
              • List strategies to incorporate patient-centered approaches into patient assessment and clinical decision-making

               

              2:15-3:15 pm 

              Immunization: The Right Tool for the Job: Precision and Preparation in Immunization Practice
              Thomas E. Buckley, RPh, MPH, FNAP; Associate Clinical Professor Emeritus, UConn School of Pharmacy, Storrs, CT
              Type of Activity: Application
              ACPE UAN 0009-0000-26-011-L06-P
              Learning Objectives: At the end of this presentation the learner will:

              • Analyze contraindications as the “measurement” step
              • Determine the correct vaccine, dose, route, and needle length
              • Document and report finishing work
              • Detect administration errors and adverse events
              • Illustrate reliable vaccine information

               

              3:20-4:20 pm 

              Right Fit, Tight Seal: Building Better Cancer Care
              Thomas M Levay, PharmD, CSP, Yale New Haven Health, New Haven, CT
              Type of Activity: Application
              ACPE UAN 0009-0000-26-012-L01-P
              Learning Objectives: At the end of this presentation the learner will:

              • Recognize ways that general education and consultation contributes to better care
              • Identify crucial elements of a patient’s non-clinical care for patients with cancer
              • Demonstrate different ways to help patients at each phase of care

               

              Handouts will be posted 72 hours prior to the event  in 2 slides per page and 6 slides per page below:

              11:00am-12:00 pm Load-Bearing Walls: Getting Cardiovascular Therapy Right the First Time

              12:05-1:05 pm LAW: The Legal Blueprint: Designing Error-Proof Pharmacy Policies

              1:10-2:10 pm Patient Safety: Blueprints Before Builds: Patient Assessment in Clinical Decision-Making

              2:15-3:15 pm Immunization: The Right Tool for the Job: Precision and Preparation in Immunization Practice

              3:20-4:20 pm Right Fit, Tight Seal: Building Better Cancer Care

              ACPE Logo“The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.”

              Continuing Education Units

              The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations. Pharmacists can earn up to 5 contact hours (0.50 CEU) one of which is a law credit, one is an Immunization Credit, and one is a Patient Safety Credit.

              Please Note: Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (before February 1, 2026).  Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with Heather.Kleven@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to ensure that your credits have been properly uploaded.  Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.

              Registration Fees: 50% discount for UConn faculty/preceptors